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Abstract 
Chronic kidney disease (CKD) patients are at high risk of vascular calcification due to 
abnormal mineral metabolism, and potentially their treatment with vitamin D receptor 
activators (VDRAs; calcitriol, alfacalcidol and paricalcitol). The effect of VDRAs on 
calcification is not fully understood. This thesis compares physiological doses of 
VDRAs on vascular smooth muscle cell (VSMC) calcification in vessels from children 
and adults with CKD. 
The inferior epigastric artery was harvested during renal transplantation and vessel 
rings cultured in different calcium (Ca) and phosphorous (P) media with physiological 
doses of VDRAs. The Ca load and alkaline phosphatase (ALP) activity were quantified 
and histological analysis performed.  
In children’s vessel rings, calcitriol increased Ca load by 3.6 fold and ALP activity by 
2.2 fold compared to vehicle in high Ca and P medium, but two distinct groups of 
responders and non-responders to calcitriol were noted. Alfacalcidol increased Ca load 
by 3.4 fold but had no effect on ALP activity and paricalcitol had no effect on Ca load 
or ALP activity in any vessel rings. Patient variation was observed: this was 
independent of dialysis status and renal diagnosis. None of the VDRAs tested affected 
Ca load or ALP activity in adult vessel rings.  
VSMCs were explanted and their dose dependent responses to calcitriol (1, 10 and 
100nM) documented. 100nM calcitriol elicited the greatest upregulation in vitamin D 
dependent gene expression, including the vitamin D receptor (VDR) whose expression 
was greater in VSMCs explanted from dialysis patients than non-renal controls. 
Expression of two VDR isoforms (VDR-A and VDR-B) were shown by Western blot 
analysis. VDR-A expression as a percentage of total VDR was 30+6.5% in control 
VSMCs compared to 65+12% in dialysis VSMCs. VSMCs in which 100nM calcitriol 
activated the vitamin D response element (VDRE) luciferase, expressed 70+17% 
VDR-A compared to 6.8+2.5% in VSMCs with no VDRE luciferase activation. Patient 
variation in VDR isoform expression may contribute to the individual patient’s 
responses to VDRAs in both vessel rings and VSMCs.  
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Chapter 1 Introduction 
1.1 Chronic Kidney Disease is associated with increased cardiovascular risk. 
Chronic Kidney Disease (CKD) is a progressive disorder, characterised by a gradual 
decline in functional nephrons and a reduction in Glomerular Filtration Rate (GFR).  
CKD is defined by a GFR below 60ml/min (Levey et al., 2005). The incidence and 
prevalence of kidney failure is an increasing worldwide health problem (Eknoyan et 
al., 2004). As the GFR deteriorates below 60ml/min, there is a graded increase in the 
risk of cardiovascular morbidity (Go et al., 2004). CKD culminates in End Stage 
Kidney Disease (ESKD); by this stage, patients require renal replacement therapy in 
the form of dialysis.  
Cardiovascular disease is the most common cause of death in CKD patients receiving 
dialysis, the rate of cardiovascular mortality in dialysis patients in their 20s is 
comparable to octogenarians (Foley et al., 1998). In ESKD there are disturbances in 
mineral metabolism that lead to hypercalcaemia and hyperphosphatemia, predisposing 
patients to vascular calcification (Shroff et al., 2012). The high risk of cardiovascular 
mortality in CKD patients is largely due to vascular calcification. 
 
1.2 Mineral metabolism 
1.2.1 The role of the kidney, FGF23 and PTH in Ca and P homeostasis.   
The kidney is a major regulator of serum phosphorous (P); it is important for both P 
excretion and regulating the resorption of P and Calcium (Ca) to accommodate bone 
turnover. The kidney relies on autocrine signalling from fibroblast growth factor 23 
(FGF23) to maintain P homeostasis (Kuro-o, 2010b) (Shimada et al., 2004b). When 
serum P levels are high, FGF23 is synthesised by osteocytes and osteoblasts to raise 
circulating levels of FGF23. FGF23 binds to the fibroblast growth factor receptor 
(FGFR) on the basolateral membrane of the kidney tubules.  
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As shown in Figure 1-1 binding of FGF23 to the FGFR has 2 downstream effects to 
reduce serum P towards homeostatic levels (Mazzaferro et al., 2010):  
1. FGF23 blocks the synthesis of 1α hydroxylase (required for activation of 
vitamin D) and upregulates the synthesis of 24 hydroxylase (an enzyme that 
deactivates vitamin D). The combined effect is reduced levels of active vitamin 
D (Shimada et al., 2004a). This prevents further increase of serum P as vitamin 
D promotes bone turnover and resorption of Ca and P. 
2. FGF23 blocks the synthesis of, and increases endocytosis of the Na/P 
cotransporter on the apical membrane of the kidney tubule (Shimada et al., 
2004a). The reduced number of P transporters decreases P reabsorption from 
the filtrate therefore increasing P excretion.   
In order for FGF23 to bind to its receptor, the co-receptor klotho is required; in the 
presence of klotho the FGFR is conferred specific to FGF23 (Urakawa et al., 2006) 
(Kurosu et al., 2006). Klotho was originally identified in mice as a gene that was 
mutated in a premature aging phenotype, this included arteriosclerosis, growth 
retardation and skin atrophy (Kuro-o et al., 1997). Many studies have shown that 
defects in the FGF23-klotho axis cause premature aging syndrome due to increased P, 
Ca and vitamin D (Kuro-o, 2010c). A low P diet in FGF23 deficient mice, rescued 
many of the premature aging phenotypes despite further raising Ca and vitamin D 
levels. This suggests that P is primarily responsible for the premature aging phenotype 
(Kuro-o, 2010c). 
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Figure 1-1: Dual mechanism FGF23 to reduce serum P. 
Vitamin D increases the transcription of fibroblast growth factor 23 (FGF23) in 
osteocytes by binding to the vitamin D receptor (VDR) which interacts with the 
retinoid x receptor (RXR). Phosphorous (P) also increases transcription of FGF23, the 
mechanism of this has not yet been determined. Klotho confers the fibroblast growth 
factor receptor (FGFR) specific to FGF23 and the FGF23 secreted by osteocytes 
interacts with the klotho-FGFR complex on the basal membrane of kidney tubules. 
FGF23 blocks the synthesis of and increases endocytosis of the NaPi-2a cotransporter 
on the apical membrane of the kidney tubule. This decreases P reabsorption and 
increases P excretion via the urine to complete the negative feedback loop and 
maintain P homeostasis. FGF23 also maintains vitamin D homeostasis, it increases 
Cyp24 and decreases Cyp27b1 transcription to promote inactivation and suppress 
synthesis of 1,25 dihydroxyvitamin D. Thereby reducing serum vitamin D levels and 
the vitamin D induced resorption of Ca and P from bone (Kuro-o, 2010a).   
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Hyperphosphatemia also up-regulates parathyroid hormone (PTH) secretion. PTH 
promotes P and Ca resorption from bone raising serum levels further, however PTH 
also increases P excretion therefore its overall effect is to decrease serum P (Koeppen. 
B. M, 2010). Excessive PTH secretion is prevented by FGF23 which acts as a negative 
feedback mechanism and binds to the FGFRs in the parathyroid gland to downregulate 
PTH secretion. As in the kidney tubules, these FGFRs require klotho to confer them 
specific to FGF23 (Kurosu et al., 2006). 
The parathyroid gland is well known to contain Calcium Sensing Receptors (CaSR) 
and PTH is the primary regulator of serum Ca and is secreted when serum Ca levels 
are low (Souberbielle et al., 2010). PTH has 3 mechanisms of action to increase serum 
Ca as shown in Figure 1-2.  
1. PTH increases Ca reabsorption from the kidney tubule. 
2. PTH upregulates transcription of Cyp27b1 in the kidney to increase 1α 
hydroxylase activation of vitamin D. This leads to increased serum levels of 
1,25 dihydroxyvitamin D which increases Ca absorption from the small 
intestine. 
3. PTH and 1,25 dihydroxyvitamin D both increase bone turnover by 
upregulating the expression of RANKL in osteoblasts, RANKL drives the 
maturation of pre-osteoclasts to mature osteoclasts. Osteoclasts resorb the bone 
matrix and increase resorption of both Ca and P into the serum. 
Once normal serum Ca levels are restored the stimuli to upregulate PTH secretion is 
removed therefore acting as a negative feedback mechanism. 
Recent data has shown that the kidney itself also expresses CaSR predominantly in the 
thick ascending limb of the loop of Henle and has a role in the regulation of Ca 
homeostasis independent of PTH. This was shown in thyroparathyroidectomized, PTH 
supplemented rats where renal tubular Ca reabsorption was increased by chronic 
inhibition of CaSR independently of the PTH (Loupy et al., 2012). 
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Figure 1-2: Role of PTH in Ca homeostasis. 
Hypocalcaemia is detected by Ca sensing receptors (CaSRs) in the parathyroid gland 
and stimulates parathyroid hormone (PTH) secretion. PTH restores normal serum Ca 
by; increasing Ca reabsorption from the kidneys, upregulates Cyp27b1 transcription 
for the activation of vitamin D which increases Ca absorption in the intestine and 
increases Ca and P resorption from bone.  
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1.2.2 The impact of CKD on FGF-23, PTH and Ca and P homeostasis.   
In CKD, P excretion by the kidney is impaired therefore raised serum P is associated 
with CKD. In the early stages of CKD, impaired kidney function is compensated for 
by increased FGF23 production normalising serum P. As GFR declines further serum 
P is increased despite high serum FGF23 (John et al., 2011). CKD is associated with 
klotho deficiency, in the absence of klotho the FGFR is not conferred specific to 
FGF23 and FGF23 is unable to act on the kidney tubule to reduce serum P towards 
normal levels (Hu et al., 2012). This P retention leads to persistent hyperphosphatemia 
and stimulates a further increase in FGF23 levels however homeostatic mechanisms 
can no longer restore the P balance. 
Chronic hyperphosphatemia results in parathyroid cell proliferation, parathyroid gland 
hyperplasia and secondary hyperparathyroidism (Koizumi et al., 2013b). Excessive 
PTH secretion contributes to excessive bone turnover, reducing bone density and 
leading to CKD-Bone Mineral Disorder (CKD-BMD) (Moe et al., 2009), as well as 
chronic hypercalcemia and chronic hyperphosphatemia which is a direct stimulus for 
vascular calcification (Hruska et al., 2008).   
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1.3 Vascular Calcification 
1.3.1 What is vascular calcification? 
Vascular calcification is the deposition of hydroxyapatite crystals in the extracellular 
matrix of the vessel wall. Hydroxyapatite is formed from the crystallisation of Ca ions 
and inorganic P (Pi) ions, it has a mineral composition similar to that found in bone 
(Schlieper et al., 2010). At physiological pH of 7.4 Pi exists predominantly as H2PO4
- 
and HPO4
2- in a 1:4 ratio and is neutralised by Ca2+ ions to produce hydroxyapatite 
Ca10(PO4)6(OH)2 (Villa-Bellosta and Egido, 2015) 
Once considered a passive degenerative process that occurs in ageing, vascular 
calcification has now been recognised as a highly regulated, cell mediated process 
similar to bone ossification (Shroff et al., 2013). A nuclear magnetic resonance study 
showed that the molecular structure of Ca and P bio-minerals in ectopic calcified 
human plaque closely resembles that of bone, including a glycosaminoglycan scaffold, 
suggesting that similar mechanisms regulate physiological and pathological 
calcification (Duer et al., 2008). Both processes require a microenvironment that 
enables extracellular crystal growth; this is formed by the release of matrix vesicles 
into the extracellular matrix, where mineral nucleation and calcification can then 
occur.  To initiate ectopic vascular calcification several molecular processes must 
occur simultaneously, this includes; apoptosis, osteochondrogenic differentiation, 
down regulation of mineralisation inhibitors and the release of pro calcific matrix 
vesicles (Shanahan et al., 2011). 
 
1.3.2 Characteristics of arteriosclerosis are distinct from atherosclerosis. 
There are two distinct types of vascular calcification, atherosclerosis and 
arteriosclerosis. In atherosclerosis, calcification occurs in lipid rich plaques at 
damaged patches of the tunica intima. Atherosclerosis is associated with traditional 
cardiovascular risk factors including; age, obesity, dyslipidaemia and smoking (Shroff 
et al., 2013). Arteriosclerosis (also known as Monckeberg’s sclerosis) is associated 
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with CKD and diabetes, it is characterised by calcification of the vascular smooth 
muscle cells (VSMCs) in the tunica media. Sheet like calcification forms in the tunica 
media layer resulting in a concentric thickening of the vessel wall and increased 
vascular stiffness, that leads to systolic hypertension and left ventricular hypertrophy 
(Blacher et al., 1999). Although distinct diseases, atherosclerosis and arteriosclerosis 
can coexist in various combinations particularly in older diabetics and adults with 
CKD. These patients have been exposed to traditional cardiovascular risk factors for 
atherosclerosis and disease specific risk factors of arteriosclerosis (McIntyre, 2008). 
Coronary autopsy samples from renal patients had comparable tunica intima 
calcification to non-renal patients (atherosclerosis), but a higher proportion of tunica 
media calcification (arteriosclerosis) (Gross et al., 2007). In young dialysis patients 
and those without comorbidity, calcification is exclusively in the tunica media (Shroff 
et al., 2008b). From here onwards vascular calcification will refer to arteriosclerosis.  
 
 
 
 
Figure 1-3: Arteriosclerosis and atherosclerosis. 
Von kossa stained vessel rings showing calcified areas. A) Medial calcification 
observed in arteriosclerosis. B) Intimal calcification of intimal plaque observed in 
atherosclerosis. A – Adventitia. M – Tunica media. MC – Medial calcification. IP – 
Intimal plaque. IC – Intimal calcification. Histology accessed 28/03/2016 from 
http://library.med.utah.edu/WebPath/CVHTML/CV007.html and 
http://library.med.utah.edu/WebPath/CVHTML/CV168.html. 
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1.4 The highly regulated process of vascular calcification and its risk factors 
in CKD. 
Ectopic vascular calcification is a highly regulated process that occurs in the matrix 
surrounding VSMCs. Dysregulated mineral metabolism in CKD plays a key role in 
driving calcification, however, high levels of Ca and P alone do not result in the 
passive deposition of hydroxyapatite crystals in the vasculature (Shroff et al., 2012). 
Key processes involved in VSMC calcification include: apoptosis, osteo/chondrocytic 
differentiation, release of matrix vesicles and reduced expression of calcification 
inhibitors. A combination of risk factors found in the uremic milieu are required to 
enable this pathological calcification to develop (Shroff et al., 2012). 
 
1.4.1 Apoptosis of VSMCs 
Apoptosis of VSMCs is associated with and plays a key role in promoting vascular 
calcification. High intracellular Ca has been shown to drive apoptotic cell death, and 
the culture of either VSMCs or vessel rings in high Ca and P (as observed in CKD) 
reduced VSMC density by 30% (Proudfoot et al., 2000). Apoptotic bodies in the 
extracellular matrix provide a nidus for the accumulation of hydroxyapatite crystals 
and the initiation of calcification, it is in part accountable for the increased ectopic 
calcification observed in CKD as reviewed by (Shroff and Shanahan, 2007). VSMCs 
in culture undergo apoptosis, in these cells apoptosis has been shown to precede 
calcification. Inhibition of apoptosis reduced calcification by 40% demonstrating its 
importance in driving calcification (Proudfoot et al., 2000). 
 
1.4.2 Matrix vesicle release. 
The release of mineralisation competent matrix vesicles into the extracellular matrix 
provides a nucleation site for hydroxyapatite crystals to form, it is important in both 
physiological and ectopic calcification (Kapustin et al., 2011). Healthy VSMCs release 
small matrix vesicles into the extracellular matrix, however they do not support 
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mineralisation as they contain limited hydroxyapatite and are loaded with 
mineralisation inhibitors; matrix gla protein (MGP), osteopontin and fetuin A that 
prevent the spontaneous precipitation of Ca and P in the serum (Kapustin et al., 2011).  
High Ca and P conditions increased the rate of both vesicle release and apoptosis in 
human VSMCs (Reynolds et al., 2004). Initially, this may be a defence mechanism to 
extrude excess hydroxyapatite, however long term increased matrix vesicle release can 
be detrimental to calcification. VSMCs persistently exposed to the high Ca and P levels 
observed in CKD released matrix vesicles that contained preformed calcium phosphate 
Ca(H2PO4)2, were depleted of MGP and enabled hydroxyapatite crystal growth 
(Reynolds et al., 2004). It was later shown by (Kapustin et al., 2011) that raised 
extracellular Ca was required for release of calcifiable matrix vesicles, these vesicles 
shared properties with chondrocyte matrix vesicles. This includes expression of Ca 
binding annexins and exposed phosphatidylserine on the surface of matrix vesicles 
providing a site for hydroxyapatite nucleation therefore supporting the early stages of 
ectopic calcification. 
 
1.4.3 Perturbation in the level of physiological calcification inhibitors 
Expression of calcification inhibitors MGP, pyrophosphate, fetuin A and osteopontin 
prevent ectopic calcification in healthy soft tissue.  
MGP is endogenously expressed in both VSMCs and chondrocytes. Local expression 
of MGP in the vessel wall is required for inhibition of vascular calcification, this was 
shown in an experiment on MGP knockout mice where expression of MGP in VSMCs 
prevented calcification but high circulating levels of MGP did not (Krueger et al., 
2009). MGP is expressed in its inactive form as dephosphorylated uncarboxylated 
MGP (dp-ucMGP) and requires two post translational modifications, γ-carboxylation 
and serine phosphorylation to form fully active p-cMGP as reviewed by (Epstein, 
2016). Phosphorylation of 3 serum residues seem to be important for MGP secretion 
(Fusaro et al., 2011). UcMGP has 5 glutamic acid residues which require vitamin K 
for their γ-carboxylation to form 5 γ-carboxyglutamate (GLA) residues and produce 
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carboxylated MGP (cMGP). Defects in the vessel wall increase the local expression of 
ucMGP in VSMCs, however in a state of vitamin K deficiency which often occurs in 
CKD, ucMGP cannot be activated and accumulates at sites where vascular 
calcification is able to proceed (Cranenburg et al., 2008). The prevalence and severity 
of vitamin K deficiency is higher in CKD than the general population for 2 reasons. 
The first, dietary restrictions in CKD that limit P intake also reduce vitamin K 
consumption. The second, during γ-carboxylation vitamin K is oxidised and has to be 
recycled by reduction for subsequent carboxylase activity, CKD patients are often 
prescribed warfarin (a vitamin k antagonist) which blocks the reductase pathway and 
prevents vitamin K recycling (Wuyts and Dhondt, 2016). In addition, uremia was 
shown to reduce vitamin K γ-carboxylase activity in a rat model leading to 
accumulation of ucMGP and calcification that was reversed by vitamin K treatment 
(Kaesler et al., 2014). 
Pyrophosphate is a potent endogenous inhibitor of calcification, the main source of 
pyrophosphate in VSMCs is from the hydrolysis of adenosine triphosphate (ATP) to 
generate AMP and pyrophosphate (Villa-Bellosta and Egido, 2015). Pyrophosphate 
can be released into extracellular fluid and inhibit mineralisation as shown in Figure 
1-4, however it can also be dephosphorylated and inactivated by alkaline phosphatase 
(ALP). The inhibitory effect of pyrophosphate on calcification has been shown both 
in-vitro and in-vivo, physiological levels of 3-5µM pyrophosphate completely 
inhibited calcification in rat aortic VSMCs (Villa-Bellosta and Sorribas, 2011). 
Pyrophosphate treatment also inhibited vascular calcification in Hutchinson Guilford 
Progeria Syndrome (HGPS) mice. This phenotype was associated with increased ALP 
activity and reduced ATP synthesis therefore increased degradation and defective 
production of pyrophosphate resulting in calcification prone mice (Villa-Bellosta et 
al., 2013).   
Plasma levels of calcification inhibitor pyrophosphate were found to be lower in 
haemodialysis patients (2.26 + 0.19 uM) compared to healthy patients (3.26 + 0.17 
uM). In the haemodialysis patient’s pyrophosphate was reduced by a further 32% 
immediately post dialysis (Lomashvili et al., 2005). In addition, the upregulation of 
ALP observed in CKD (discussed below) would upregulate the de-phosphorylation 
and inactivation of pyrophosphate. 
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Fetuin A is a circulating calcification inhibitor that is taken up by VSMCs and 
concentrated in matrix vesicles, it reduces apoptosis and promotes phagocytosis of 
matrix vesicles by VSMCs therefore reducing their ability to nucleate P and Ca 
(Reynolds et al., 2005). Fetuin A levels are correlated with GFR and there was a graded 
decline in fetuin A from CKD stage 3-5 (Zhan et al., 2013). 
Osteopontin is normally expressed in mineralised tissue such as bone and teeth 
(Nemcsik et al., 2012). Post translational phosphorylation is required for osteopontin 
to have an inhibitory effect on calcification, this was shown in human VSMCs where 
only the phosphorylated osteopontin was able to dose dependently inhibit calcification 
(Jono et al., 2000). Osteopontin was also shown to accumulate in calcified vessels and 
reduce the extent of calcification in-vivo, as double knock out MGP/osteopontin mice 
had more extensive calcification than MGP only knockout mice (Speer et al., 2002), 
demonstrating the calcification inhibitory properties of osteopontin. As with 
pyrophosphate, the upregulated ALP activity observed in CKD leads to 
dephosphorylation and inactivation of osteopontin, reducing its effect on inhibiting 
calcification.  
 
1.4.4 Osteo / chondrocytic differentiation 
VSMCs, osteocytes, chondrocytes and adipocytes are all derived from mesenchymal 
stem cells. The terminal differentiation of these stem cells lines is dependent on the 
paracrine and autocrine factors in the microenvironment (Oreffo et al., 2005). 
VSMCs have great phenotypic plasticity and are able to dedifferentiate into 
mesenchymal-like stem cells this is important during cell stress and for vascular repair, 
they may either reach senescence or undergo an osteo/chondrocyte phenotypic change 
(Opitz et al., 2007). This is evidenced by changes in the expression of VSMC and osteo 
/ chondrocyte cell markers.  
A cell linage study in mice lacking the calcification inhibitor MGP, found that 97% of 
calcifiable cells in the tunica media were derived from VSMCs which had early up 
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regulation of Runx2 (an osteoblast transcription factor) and down regulation of 
myocardin (Speer et al., 2009). Notably the osteo/chondrocytic differentiation 
preceded calcification. 
In human arteries with Monckeberg’s sclerosis that undergo osteo/chondrocytic 
differentiation, up regulation of ALP has been observed in the vessel wall along with 
other osteogenic markers including bone gla protein (BGP), bone sialoprotein (BSP) 
and collagen II (Shanahan et al., 1999). There expression is regulated by osteogenic 
transcription factors, such as Runx2 and Sox9 which are also up-regulated in calcified 
vessels and in VSMCs that spontaneously calcify (Tyson et al., 2003).  
In-vitro co expression of ALP and collagen I was sufficient to induce mineralisation 
in high P medium (Murshed et al., 2005). This suggests that increased ALP activity 
alone would enable extracellular matrix mineralisation in the vasculature as the tunica 
media has a collagen rich matrix. ALP is a hydrolase enzyme normally expressed in 
bone but not normally expressed in VSMCs as shown in Figure 1-4. ALP 
dephosphorylates the calcification inhibitor pyrophosphate which renders it inactive 
and releases free inorganic phosphate (Pi) (Villa-Bellosta and Egido, 2015). Also, in 
an in-vitro study on human VSMCs ALP treatment dephosphorylated the calcification 
inhibitor osteopontin and promoted calcification (Jono et al., 2000). 
Excessive P levels observed in CKD is thought induce cellular stress and drive the 
oseto / chondrocytic differentiation of contractile VSMCs to a synthetic osteoblast like 
phenotype. High serum P results in the downregulation of VSMC markers, SMα actin, 
SM22α and myocardin along with upregulation of osteo/chondrocytic genes including; 
Runx2, osterix, ALP, osteopontin, type 1 collagen and osteocalcin (Shanahan et al., 
2011). Culture of human VSMCs in uremic conditions found in CKD changed the 
VSMC phenotype by decreasing expression of VSMC contractile marker genes by 50-
80% (Monroy et al., 2015). In addition, osteoblast marker ALP is thought to be 
upregulated in CKD, a circulating factor present in uremic serum increased ALP 
activity by two fold which in turn increased pyrophosphate hydrolysis enabling 
calcification (Lomashvili et al., 2008). 
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Figure 1-4: Schematic diagram showing effect of ALP activity on pyrophosphate 
in VSMCs and osteoblasts. 
In healthy VSMCs, pyrophosphate generated from the hydrolysis of ATP inhibits 
mineralization, there is no ALP activity. In osteoblasts, pyrophosphate is 
dephosphorylated and inactivated by ALP enabling mineralization. In uremia, 
pathological upregulation of ALP contributes to calcification. Image adapted from 
(Persy and McKee, 2011)  
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1.5 Vitamin D  
1.5.1 Vitamin D and the systemic regulation of Ca 
In the late 1800s and early 1900s, rickets was a disease of epidemic proportions, the 
healing properties of both cod liver oil and exposure of the skin to UV light led to the 
discovery of vitamin D between 1919 and 1924 as reviewed by (DeLuca, 1988). 
Vitamin D was produced as a pharmacologic treatment by the 1940s and used in the 
treatment of bone mineral disorders such as rickets. 
The role of vitamin D in bone mineralisation is through the elevation of plasma Ca and 
P via 3 key mechanisms. 
1. Increase Ca absorption from the small intestine. Vitamin D increases 
transcription of the Ca channel TRPV6 and calbindin in the small intestine to 
increase the efficiency of Ca absorption from 10 to 40% (Holick 2007). 
2. Increase resorption of Ca and P from bone. Vitamin D up regulates RANKL 
expression in osteoblasts and drives the maturation of pre-osteoclasts to 
osteoclasts which resorb Ca and P from bone and release it into the circulation 
(Turner, Hanrath et al. 2013). 
3. Reduce PTH secretion. Vitamin D increases expression of the vitamin D 
receptor (VDR) and the CaSR in the parathyroid glands to increase its 
sensitivity to both Ca and vitamin D. The effect of vitamin D on the parathyroid 
gland is to downregulate PTH expression in order to prevent excessive Ca and 
P resorption and extensive bone turnover (Brown, Dusso et al. 2002). 
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1.5.2 Vitamin D metabolism 
Vitamin D is a term used to describe several related compounds including calciferol, 
calcidiol and calcitriol. Calciferol is pre-vitamin D and can refer to either pre-vitamin 
D2 (ergocalciferol) or pre-vitamin D3 (colecalciferol), these are the 2 major forms of 
vitamin D in their biologically inactive forms. To be activated calciferol undergoes 2 
hydroxylation stages to produce calcidiol (25OHD) and then calcitriol (1,25(OH)2D).  
The majority (>90%) of the body’s required vitamin D is obtained from sunlight 
(Holick, 2007). Exposure to UV-B radiation converts the skin pigment 7-dehydro 
cholesterol to pre-vitamin D3. Low levels of pre-vitamin D2 and D3 can also be 
obtained from some foods such as oily fish. Both pre-vitamin D2 and D3 have to 
undergo two hydroxylation stages in order to activate them as shown in Figure 1-5. 
The first stage is catalysed by 25 hydroxylase and converts pre-vitamin D2 and D3 to 
25-hydroxylated vitamin D (25OHD). The 2nd stage is catalysed by 1α hydroxylase 
and converts 25OHD to the active form 1α, 25 dihydroxyvitamin D (1,25(OH)2D).  
The majority of 1α and 25 hydroxylases are expressed in the kidney and liver 
respectively, however both hydroxylase enzymes are expressed locally in VSMCs and 
other tissues enabling an autocrine/paracrine regulation of the cells vitamin D 
metabolism.  
The series of hydroxylation stages required for the metabolism of vitamin D are 
regulated by a group of cytochrome P450 enzymes (CYPs). CYPs capable of 25 
hydroxylation include the low affinity CYP27A1 and the high affinity CYP2R1 as well 
as potentially the less well defined CYP2J3 and CYP3A4 (Jones et al., 2014). The 
biological importance of CYP2R1 was confirmed by analysis of a patient with a 
homozygous Leu99Pro mutation in CYP2R1 which eliminated 25 hydroxylase 
enzyme activity and correlated with a form of hereditary rickets (Cheng et al., 2004). 
25 hydroxylation occurs in a substrate dependent manner therefore 25OHD is the main 
form of vitamin D found in circulation and clinically vitamin D status is determined 
by measuring 25OHD in the serum.  
The activation of 25OHD to 1,25(OH)2D is highly regulated, this is important as it has 
a key role in maintaining homeostatic levels of Ca and P in the serum as discussed on 
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page 31. So far only one gene has been identified encoding 1α-hydroxylase, that is 
CYP27B1 discovered by (St-Arnaud et al., 1997) who mapped it to the same locus as 
mutations that resulted in vitamin D dependency rickets. 1α-hydroxylase is expressed 
when serum Ca levels are low and 1,25(OH)2D exerts its biological effects via the 
VDR to increase serum Ca. In order to maintain homeostasis, 1α hydroxylation is 
highly regulated by multiple negative feedback mechanisms including raised serum 
levels of; Ca, FGF23 and 1,25(OH)2D itself, as well as positive feedback from PTH, 
these are all shown in Figure 1-5. Once in its active form, the half-life of 1,25(OH)2D 
is 10-20 hours (Levine et al., 1985) however it can be inactivated by  the 24 
hydroxylase enzyme.  
The CYP24A1 gene transcribes 24 hydroxylase which drives the  hydroxylation of 
1,25(OH)2D to calcitroic acid which is water soluble and easily excreted, CYP24A1 
also hydroxylates the precursor 25OHD to the inactive metabolite 24,25(OH)2D 
(Reddy and Tserng, 1989). The clinical importance of CYP24A1 in the 24 hydroxylase 
degradation of 1,25(OH)2D was shown by (Schlingmann et al., 2011) who identified 
recessive mutations in CYP24A1 in 6 children with idiopathic infantile hypercalcemia 
due to increased vitamin D sensitivity. 
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Figure 1-5: Vitamin D metabolism 
Activation of pre-vitamin D requires 25-hydroxylation to 25 hydroxyvitamin D (25-
OH-D3) and 1α hydroxylation to form active 1,25 dihydroxyvitamin D3 (1,25-
(OH)2D3). 1, 25-(OH)2D3 binds to the VDR to exert its biological effects, then it is 
catabolized by 24 hydroxylase to eventually form cacitroic acid which is water soluble. 
Activity of CYP27B1 and CYP24A1 are closely regulated by 1, 25-(OH)2D3, serum 
Ca ions (sCa2+) and parathyroid hormone (PTH). There is an additional negative 
feedback mechanism on CYP27B1 through the 1, 25-(OH)2D3, fibroblast growth factor 
23 (FGF23), klotho axis. sPO4 – serum phosphate. Figure from (Schlingmann et al., 
2011). 
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1.5.3  Vitamin D Receptor (VDR): Mechanism of action and different VDR 
isoforms 
1,25(OH)2D mediates its effects via the VDR which is expressed in almost all tissues 
throughout the body. The VDR is part of the Nuclear Hormone Receptor superfamily 
and shares a similar structure with them enabling it to regulate the transcription of 
multiple genes (Haussler et al., 1998). The VDR contains a zinc finger DNA binding 
domain at the N terminal (Haussler et al., 1995). The ligand binding domain is located 
at the C terminal along with 2 conserved retinoid x receptor (RXR) binding domains. 
At the extreme end of the C terminal there is also an activation function (AF2) which 
is a ligand dependent activation domain that is essential for transcriptional activation.   
Ligand binding to the VDR leads to a conformational change in the C terminal that 
facilitates strong dimerization with the RXR. As shown in Figure 1-6, the ligand bound 
VDR-RXR heterodimer trans-locates from the cytoplasm to the nucleus. Here it 
regulates transcription by interacting with a specific sequence in the promoter region 
of target genes, known as the vitamin D response element (VDRE) (Haussler et al., 
1998). Binding of the VDR to the VDRE triggers the recruitment of multiple protein 
cofactors and transcriptional machinery leading to either transactivation or repression 
of genes (Crofts et al., 1998). 
The human VDR gene is complex, 14 alternative 5’ variants of the VDR transcript 
have been identified by 5’ rapid amplification of cDNA ends (RACE). This gives rise 
to 3 different isoforms of the VDR protein shown in Figure 1-7, transcripts 1-5 
originate from exon 1a and are translated from the initiation codon in exon 2 and 
encode the 427 amino acid VDR-A protein (Crofts et al., 1998), this corresponds to 
the originally identified cDNA sequence for human VDR (Baker et al., 1988). 
Transcripts 6-10 originate from exon 1d where there is a second initiation codon, 
therefore have the potential to encode N terminal variant proteins. Transcript 6 was 
identified as transcribing VDR-B1 with a 50 amino acid extension and transcript 9 
encoded VDR-B2 with a 23 amino acid extension (Crofts et al., 1998). VDR transcripts 
1, 2 and 6 shown in Figure 1-7 are confirmed on the NCBI reference sequence database 
as transcript 1, 2 and 3 respectively (Pruitt et al., 2014).  
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VDR-B2 could not be detected in any tissue tested, however presence of the 54KDa 
VDR-B1 isoform was confirmed in human kidney tissue, 786 kidney cell line and three 
human intestine cell lines where it was expressed at comparable levels to VDR-A, as 
well as in MG63 osteosarcoma cells where VDR-B1 was detected at a third the level 
of VDR-A (Sunn et al., 2001). The additional 50 amino acids at the N terminal of 
VDR-B1 extends the A/B domain from 23 to 73 amino acids, this A/B region of 
nuclear receptors often contain a ligand independent activation function domain 
therefore the VDR-B1 isoform may have different functional properties to the VDR-
A. From here on VDR-B will refer to the 477 amino acid VDR-B1 isoform. 
Many genes contain a VDRE in their promoter and approximately 3% of the human 
genome is regulated either directly or indirectly by vitamin D (Bouillon et al., 2008). 
Vitamin D has a wide range of physiological functions, this includes both its role in 
the regulation of systemic Ca described in 1.5.1 and non-calcaemic effects to be 
discussed in 0. 
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Figure 1-6: Schematic diagram of vitamin D activation of the VDR 
The active form of vitamin D, 1,25(OH)2D binds to VDR and facilitates its 
dimerization with the RXR. This complex interacts with the VDRE in the promoter 
region of multiple genes and triggers the recruitment of coregulatory proteins which 
regulate histone acetylation and consequently transcription. VDR – Vitamin D 
Receptor. RXR – Retinoid X Receptor. VDRE – Vitamin D Response Element.  
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Figure 1-7: Human VDR gene 
Adapted from (Crofts et al., 1998). A) Exons in the human VDR gene. B) Structure of 
the human VDR transcripts, transcripts 1-5 originate from exon 1a, transcripts 6-10 
from 1d and transcripts 11-14 originate from exon 1f. Boxed numbers (1, 6 and 10) 
indicate transcripts with highest expression. All transcripts have a translation initiation 
codon in exon 2 and 1d transcripts have an additional upstream initiation codon. 
Starred transcripts encode different proteins, shown in C. C) Transcript 1 
(NM_000376) encodes the original 427 amino acid protein, the 23 amino acid of its 
A/B domain are shown in bold, transcript 6 and 9 encode proteins with a 50 amino 
acid and 23 amino acid N terminal extension respectively. Transcripts in green box are 
confirmed in the NCBI reference sequence database (Pruitt et al., 2014). 
 
  
  
 
39 
 
1.5.4 Vitamin D plethora!  
In recent years there has been a great scientific interest in the therapeutic benefits of 
vitamin D, outside its regulation of Ca homeostasis and bone mineralisation. There are 
many studies suggesting that vitamin D is associated with an array of beneficial health 
outcomes on; cardiovascular health, cancer, immune system, muscle function, chronic 
pain and other disorders. Despite the numerous association studies, an umbrella review 
that considered the relationship between vitamin D and 137 different health outcomes 
could not identify a clear role for vitamin D. In fact, the only consistently significant 
outcome was the relation between maternal vitamin D status and birth weight 
(Theodoratou et al., 2014). 
A negative relationship between low vitamin D levels and high plasma renin activity 
that leads to hypertension and cardiac hypertrophy has been observed clinically for 
over 2 decades (Burgess et al., 1990). A role for 1,25(OH)2D as a negative regulator 
of the renin – angiotensin – aldosterone system was supported in both VDR null mice 
which had increased renin expression, and in wild type mice injected with 1,25(OH)2D 
which had suppressed renin expression. Furthermore, in cell culture 1,25(OH)2D was 
shown to suppress renin transcription (Li et al., 2002). 1,25(OH)2D is thought to 
suppress renin in order to maintain cardiovascular health and reduce blood pressure, 
improving left ventricular function and decreasing the risk of left ventricular 
hypertrophy. However, patients with CKD given 2µg/day oral paricalcitol for 48 
weeks showed no difference in left ventricular mass index relative to the placebo group 
(Thadhani et al., 2012). 
Many observational or epidemiological studies have found a strong association 
between vitamin D and cancer prevention or survival for 15 different cancer types 
including colorectal, skin and breast cancers as reviewed by (Grant, 2016). In a study 
of 99 colorectal cancer patients which found that CYP24A1 (which inactivated 
1,25(OH)2D) expression was higher in cancer than adjacent regions and patients with 
high CYP24A1 mRNA expression had reduced overall survival (Sun et al., 2016). 
Despite these associations the mechanism has not been confirmed, 1,25(OH)2D is 
thought to inhibit tumour progression through the inhibition of cell proliferation, 
increased cell differentiation and induction of apoptosis.  
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Vitamin D deficiency is associated with increased risk of autoimmune diseases such 
as arthritis, multiple sclerosis and diabetes mellitus type 1 (Peelen et al., 2011). The 
VDR is expressed in resting monocytes and dendritic cells as well as in activated T 
and B lymphocytes (Provvedini et al., 1983), many immune cells also express enzymes 
involved in vitamin D metabolism. Following a pathogen challenge macrophages 
increased expression of VDR and CYP27A1 (vitamin D activating enzyme), 100s of 
1,25(OH)2D target genes have been identified in immune cells. The overall effect of 
these target genes is to suppress inflammation as reviewed by (Chun et al., 2014), 
therefore it is thought that vitamin D serves as an immune regulating agent to prevent 
autoimmune disorders. For example, there is a high incidence of vitamin D deficiency 
in patients with the autoimmune disorder systemic lupus erythematosus (SLE) 
(Mandal et al., 2014). SLE affects endothelial repair regulated by myeloid angiogenic 
cells (MACs).  It has been shown in SLE MACS in-vitro that calcitriol reduced their 
IL-6 secretion, as well as increasing SLE MACs angiogenic activity and normalising 
MAC phenotype (Reynolds et al., 2016).    
Several clinical studies have shown an association between vitamin D deficiency and 
chronic pain, for example in white middle aged British females (but not males) there 
was an association between 25(OH)D and reduced incidence of widespread chronic 
pain (Atherton et al., 2009). However, a review of 10 random double blind trials found 
that there was no consistent effect of vitamin D supplements in the relief of chronic 
pain compared to placebo (Straube et al., 2015). 
Many countries have a widespread deficiency in vitamin D. As vitamin D supplements 
are readily available over the counter and health care professionals are inundated with 
the benefits of vitamin D, it is not surprising that instances of overzealous vitamin D 
treatment leading to intoxication are increasingly common. Despite these risks, toxic 
doses of vitamin D have not yet been established.  
1.5.5 CKD patients are deficient in Vitamin D 
Vitamin D status is determined by measuring serum 25OHD, levels less than 50nM 
are considered as vitamin D deficiency by expert consensus (Norman et al., 2007) and 
up to 75nM 25OHD is insufficient for optimal Ca absorption (Heaney et al., 2003). 
  
 
41 
 
Patients with CKD are often deficient in 25OHD measured in the serum, there are 
multiple reasons for this:  
 CKD patients are less active therefore they have less exposure to sunlight. 
 The skins ability to synthesise pre-vitamin D in response to UV light may be 
impaired in CKD. Despite CKD patients having normal epidermal content of 
7-dehydrocholesterol, on exposure to UV-B irradiation their photo-production 
of cholecalciferol was less than in normal subjects (Jacob et al., 1984). 
 Reduced apatite and dietary restrictions to limit Na and K intake may reduce 
ingestion of natural sources of pre-vitamin D. A dietary assessment in which 
91 haemodialysis (HD) patients and 85 controls completed a 7-day food 
journal, found that total energy and nutrient intake was significantly lower in 
HD patients. This included pre-vitamin D intake which was on average 1.1µg 
per day in HD patients and 1.6µg per day in controls (Fusaro et al., 2016). 
 Proteinuria in CKD leads to loss of vitamin D binding protein hence increased 
loss of all vitamin D compounds, particularly 25OHD which has the highest 
binding affinity (Sato et al., 1982). 
 Patients on peritoneal dialysis were found to have reduced levels of vitamin D 
binding protein due to their loss, along with bound vitamin D compounds in 
the peritoneal dialysis fluid (Koenig et al., 1992). Vitamin D binding proteins 
are important for increasing the half-life of vitamin D compounds. 
In addition to 25OHD deficiency, CKD patients lose the ability to convert 25OHD to 
the active 1,25(OH)2D. There are numerous possible explanations for this.  
 As explained above CKD patients are likely to have chronic 
hyperphosphatemia and high levels of FGF-23, this increases CYP24A1 
expression and promotes 24 hydroxylation of 1,25(OH)2D to inactive 
metabolites (Koizumi et al., 2013a). 
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 Renal production of the 1α hydroxylase enzyme is reduced with the decline in 
renal mass (Pitts et al., 1988). 
 The activity of 1α hydroxylase may be suppressed in the acidic and uremic 
milieu found in CKD, furthermore the increased secretion of FGF-23 
suppresses CYP27B1 expression reducing 1α hydroxylase activity (Bouillon 
et al., 2014). 
 In health, 25OHD and D binding protein from the glomerular ultra-filtrate are 
taken up by endocytosis by the renal megalin and delivered to 1α hydroxylase 
in the proximal tubule. In CKD, expression of renal megalin is reduced 
therefore limiting the delivery of 25OHD to 1α hydroxylase (Nykjaer et al., 
1999). 
A combination of these factors lead to 25OHD and further 1,25(OH)2D deficiency in 
CKD patients, this has a detrimental effect on mineral metabolism and bone 
development particularly in children who could develop rickets. As discussed above 
1,25(OH)2D plays a key role in mineral homeostasis including the negative regulation 
of PTH. 
Vitamin D receptor activators (VDRAs) are often prescribed for control of secondary 
hyperparathyroidism in CKD patients who are deficient. Excessive use of VDRAs 
could have toxic effects due to its direct action on other tissues, a greater understanding 
of the risks involved is required.  
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Figure 1-8: Effect of vitamin D deficiency on mineral homeostasis in CKD 
Schematic diagram representing A) A state of vitamin D sufficiency, 7,8 
dehydrocholesterol is converted to active 1α,25(OH)2D3 for the systemic regulation of 
Ca and P homeostasis including the negative regulation of PTH secretion. B) A state 
of vitamin D deficiency in CKD. The increased circulating level of FGF-23 
upregulates 24 hydroxylase for inactivation of vitamin D compounds. 1α hydroxylase 
production in the kidney is reduced due to decreased renal mass and it is further down 
regulated by FGF-23, hence restricting the activation of 25OHD3. The reduced 
circulating level of 1α,25(OH)2D3 is unable to regulate PTH, leading to increased PTH 
secretion and secondary hyperparathyroidism. Excessive, unregulated PTH levels in 
the serum accelerate the resorption of bone, leading to a reduced bone density and 
increased systemic Ca and P levels increasing the risk of vascular calcification. 
Pharmacological intervention with VDRAs prevents secondary hyperparathyroidism, 
however the direct effect of VDRAs on VSMCs and vascular calcification is not 
known. 
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1.5.6 Vitamin D receptor activators 
CKD is a state of vitamin D deficiency, this exacerbates the disrupted mineral 
metabolism that occurs early in the progression of CKD, giving rise to 
hyperphosphatemia, secondary hyperparathyroidism and bone mineral disorder. In 
these patients VDRAs are often prescribed, particularly in children to prevent 
secondary hyperparathyroidism (Brown et al., 2002). There are numerous analogues 
of VDRA, this study will concentrate on 3 of them that are most commonly used: 
Alfacalcidol (1α hydroxyvitamin D3 (1OHD3)) 
Alfacalcidol is a synthetic prohormone that requires activation by 25 hydroxylase to 
produce the active form of 1,25(OH)2D3. 25 hydroxylase is mainly expressed in the 
liver but is also expressed locally in some cell types. Alfacalcidol is often prescribed 
to children with CKD who have vitamin D deficiency in order to treat secondary 
hyperparathyroidism.  
Calcitriol (1,25(OH)2D3) 
Calcitriol is the natural vitamin D hormone in its active form (Slatopolsky et al., 1995). 
It is a non-selective VDRA with a similar affinity for the VDR in the parathyroid 
glands as the VDRs in the bone and intestinal lumen (Christakos et al., 2003), therefore 
as well as suppressing PTH calcitriol can increase Ca and P resorption and absorption 
leading to hypercalcemia and hyperphosphatemia.    
Paricalcitol (19nor,1,25(OH)2D2) 
Paricalcitol is a synthetic analogue of vitamin D2 that lacks a carbon-19 methylene 
group found in all natural vitamin D metabolites (Slatopolsky et al., 1995). Paricalcitol 
is a selective VDRA that was developed to reduce the risk of hypercalcemia and 
hyperphosphatemia, it has a higher affinity for VDRs in the parathyroid gland than in 
the bone and intestinal mucosa. In a study on 20 haemodialysis patients, calcitriol and 
paricalcitol were equally efficient at reducing PTH but paricalcitol had a less calcemic 
effect (Veceric-Haler et al., 2016).  
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Figure 1-9: Chemical structure of VDRAs 
Chemical structure of the 3 different VDRAs studied. A) 1,25(OH)2D3 (Calcitriol) is 
the natural active form of vitamin D. B) 19-nor-1,25(OH)2D2 (Paricalcitol) is a 
synthetic analogue, it has the carbon 28 and double bond at carbon 22 characteristic of 
vitamin D2, however it lacks carbon 19 and the exocyclic double bond therefore differs 
from all natural forms of vitamin D. C) 1OHD3 (Alfacalcidol) is an inactive synthetic 
analogue of vitamin D that requires activation by the 25 hydroxylase enzyme. Adapted 
from (Slatopolsky et al., 1995). 
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1.6 Direct effects of 1,25(OH)2D on VSMCs 
1,25(OH)2D is able to have direct effects on VSMCs. VSMCs express both the 1α and 
25 hydroxylase enzymes as well as the VDR, therefore are able to act as an autocrine 
system (Somjen, Weisman et al. 2005). VDRAs may either reduce or promote ectopic 
calcification and there is controversial literature surrounding the benefits and 
detriments of VDRAs on vascular calcification. 
A review of the benefits of oral VDRA supplements in double-blind, placebo- and 
randomized-controlled trials found that VDRAs could have cardio protective effects 
however this was not consistent (Ku et al., 2013). In excess 1,25(OH)2D may increase 
the risk of hypercalcemia and vascular calcification. It is important to maintain levels 
of 1,25(OH)2D within the normal physiological range. Despite daily oral alfacalcidol 
supplements given to children on dialysis 36% had low levels and 11% had high 
1,25(OH)2D outside the normal range of 40-150pMol/litre (Shroff et al., 2008a). In 
this study both high and low levels were associated with increased carotid intima 
media thickness and coronary artery calcification. This suggests that there is a narrow 
physiological range where vitamin D is beneficial to vascular calcification in CKD 
patients, currently vitamin D is routinely prescribed to children with CKD therefore it 
is important to understand the pro and non-calcaemic mechanisms of different 
VDRAs. 
There is evidence that VDRAs have a bimodal effect on calcification with both high 
and low levels being associated with an increased risk. In a cross sectional study of 
126 haemodialysis patients, those with 25OHD deficiency had a higher incidence of 
vascular calcification than those with normal 25OHD levels (Wang et al., 2015). This 
bimodal effect of vitamin D on vascular calcification suggests that both the extreme 
low and high doses of vitamin D are causative of calcification. 
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There are a number of ways that vitamin D may impact on vascular calcification, either 
as a protective agent or by promoting vascular calcification. Some of these are 
discussed below. 
 
1.6.1 Vitamin D: Protective mechanisms against calcification 
1.6.1.1 Regulate calcification inhibitors 
Calcitriol has been shown to up-regulate the inhibitory proteins, osteopontin (Lau et 
al., 2012) and MGP. In rat VSMCs transiently transfected with luciferase constructs 
regulated by an MGP promoter, physiological concentrations of calcitriol were shown 
to upregulate transcription (Farzaneh-Far et al., 2001). These calcification inhibitors 
are important in the suppression of ectopic calcification. 
1.6.1.2 Upregulate CaSR expression 
Increased expression of the CaSR in VSMCs can increase their sensitivity to Ca 
exposure. At a narrow concentration range, calcitriol was shown to increase expression 
of CaSR and protect against calcification in human VSMCs (Mary et al., 2015). 
1.6.1.3 Anti – inflammatory effect 
The VDR is expressed in immune cells (Kassi, Adamopoulos et al. 2013) and vitamin 
D is known to suppress inflammatory cytokines including TNF-α, IL6 and IL 10 (Ku, 
Liu et al. 2013). Inflammation is a key component in atherosclerotic plaque 
calcification and also has a role in arteriosclerosis associated with CKD.  
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1.6.2 Vitamin D: Causative mechanisms of calcification 
1.6.2.1 Stimulate proliferation 
Vitamin D stimulates VSMC proliferation through upregulation of vascular 
endothelial growth factors (VEGF) (Cardus, Parisi et al. 2006) and increased VSMC 
migration (Rebsamen, Sun et al. 2002) which both promote calcification. 
1.6.2.2 Osteo/chondrocytic differentiation 
VDRAs also promote osteoblast differentiation of VSMCs including the up-regulation 
of Runx2 and osteocalcin which favours ectopic calcification in soft tissue (Shroff and 
Shanahan 2007).  
It is essential to understand the molecular mechanisms by which vitamin D effects 
vascular calcification in CKD. In recent years there has been numerous studies in this 
controversial area, they utilise different models, induce calcification by different 
mechanism and administer different doses of VDRAs. This has led to very varied 
outcomes in terms of the effect if VDRAs on vascular calcification. 
 
1.7 Models to study the effects of vitamin D on VSMC calcification in CKD 
1.7.1 In-vivo: Animal Models  
In-vivo studies enable the systemic effects of Vitamin D on mineral metabolism to be 
studied alongside the direct effects of vitamin D on VSMCs. The chronic nature of 
CKD cannot be modelled in animals, however the reduced kidney function can be 
mimicked in mice and rats by 5/6 nephrectomy to produce an in-vivo CKD model. To 
produce this CKD model, animals undergo right total nephrectomy and 1 week later 
2/3 left nephrectomy by ligation (Perez-Ruiz et al., 2006). These CKD animals have a 
good survival rate enabling mid to long term studies of several months. There is no 
animal model to replicate dialysis however to some extent the mid to long term 
physiological effects of VDRAs can be explored in this model. 
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Numerous groups have studied vascular calcification using this in-vivo CKD model, 
in these CKD animals a high P diet could induce vascular calcification. For example, 
in CKD DBA/2J mice fed a high, 1.5% P diet, calcified regions were observed in the 
aorta’s medial area and Ca load increased 8.5 fold compared to in mice fed a normal, 
0.5% P diet (Lau et al., 2012). In this model, both calcitriol (30ng/kg) and paricalcitol 
(100ng/kg or 300ng/kg) reduced vascular calcification, however even the highest 
doses were not able to lower PTH due to the excessively high P diet overstimulating 
PTH secretion (Lau et al., 2012). This did enable the study to reveal protective effects 
of VDRAs on calcification that are independent of PTH suppression; paricalcitol but 
not calcitriol increased expression of osteopontin in VSMCs, and  both of the VDRAs 
increased serum klotho (which was reduced by the CKD model), leading to increased 
P excretion to correct hyperphosphatemia, hence reduce the elevated level of FGF-23 
(Lau et al., 2012). The excessively raised P levels in this study do not reflect P levels 
observed in CKD and a more modest increase in P consumption would improve the 
physiological relevance. 
In contrast, a study on 5/6 nephrectomy Sprague Dawley rats found that a high, 1.2% 
P diet did not induce calcification but it did elevate PTH levels (Mizobuchi et al., 
2007). As there was no calcification in the control group any protective effects of the 
VDRAs in this model could not be observed. In the CKD Sprague Dawley rats, 
40ng/kg calcitriol suppressed PTH but caused extensive calcification whereas 
paricalcitol was able to suppress PTH without affecting Ca load in the aortic arch even 
thou administered at doses of 160ng/kg and 240ng/kg. Calcitriol increased serum Ca 
and P levels to a greater extent than paricalcitol, calcitriol but not paricalcitol also had 
a direct effect on VSMCs and increased their expression of osteoblast transcription 
factor Runx2 and upregulated its target gene osteocalcin (Mizobuchi et al., 2007). In a 
similar study also on CKD Sprague Dawley rats, in this instance fed a standard P diet 
showed that a clinically relevant dose of calcitriol (30ng/kg) increased vascular 
calcification, as shown by increased Ca deposits in the tunica media. Again, calcitriol 
had a direct effect on VSMCs and increased Runx2 expression, it also reduced MGP 
expression and increasing endothelial cell proliferation (Koleganova et al., 2009). It is 
not possible to determine from either of these in-vivo studies, if the increased 
calcification observed in response to calcitriol was due to the elevated levels of 
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systemic Ca and P or direct effects of calcitriol on VSMCs such as the upregulation of 
osteoblast genes.  
The CKD model in Wistar rats fed a high, 1.2% P diet showed that calcitriol (80ng/kg) 
increased aortic calcification, as did paricalcitol (240ng/kg) to a lesser extent. Both 
VDRAs partially reduced PTH levels, despite the high doses of calcitriol and 
paricalcitol neither were able to suppress PTH to normal levels, to do so would require 
even higher and less physiologically relevant doses (Lopez et al., 2008). 
In the studies discussed above the differential effects of calcitriol and paricalcitol on 
vascular calcification range between protective, null and causative as summarized in 
Table 1-1. This could be a consequence of differences in study design including; extent 
of high P diet, dose of VDRAs and species used. A high P diet was used in many 
studies to induce calcification however it is also important to maintain P levels within 
those physiologically relevant to CKD. 30ng/kg calcitriol and 100ng/kg paricalcitol 
reflect the current clinical doses (Lau et al., 2012), however many studies used much 
higher doses of VDRAs which could reduce the clinical relevance of their results. 
These studies all used the 5/6 nephrectomy CKD model however it was applied to 
different species (DBA/2J mice, Sprague Dawley rats and Wistar rats), this could 
contribute to the differential effects observed of calcitriol and paricalcitol on vascular 
calcification, it highlights the importance of using human tissue as a clinically relevant 
model to observe the effects of VDRAs on calcification. 
 
1.7.2 Ex-Vivo: Organ culture of aorta 
Culture of the thoracic aorta from mice in elevated inorganic P has been shown to 
induce vascular calcification of the tunica media (Akiyoshi et al., 2015). This enables 
the phenotypic changes that occur during calcification to be studied in an inducible 
model where the vessel architecture is still intact. Aging and diabetic mice are known 
to be at high risk of calcification, aortas from these groups cultured in high iP had more 
calcification than controls therefore this model reflects the calcification susceptibility 
observed in-vivo (Akiyoshi et al., 2015).  
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It would be of interest to study the effects of VDRAs on calcification in CKD vessels 
using this ex-vivo model, as it would enable the direct effects VDRAs on VSMCs 
within their whole vessel architecture to be studied independently of changes in 
systemic Ca and P levels. However, as discussed above an ideal animal model that 
reflects the chronic nature of CKD and the impact of dialysis treatment has not yet 
been developed.    
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Table 1-1: In-vivo studies on the effects of VDRAs on VSMC calcification. 
Comparison of in-vivo 5/6 nephrectomy CKD models including animal type and diet 
used to induce calcification or not. For each model the effect on calcification of the 
control condition (nil or vehicle) is shown. The effect on calcification of the VDRAs 
is in relation to the control condition. Red shading indicates increased calcification. 
Green shading indicates no or reduced calcification.  - Increased.  - Decreased. 
BGP – Bone gla protein. Ca – Calcium. FGF-23 – Fibroblast growth factor 23. MGP 
– Matric gla protein. P – Phosphate. PTH – Parathyroid hormone. 
 
In-Vivo Method 
5/6 nephrectomy 
VDRA Effect on Calcification 
DBA/2J Mice 
High P diet (1.5% P) 
Controls (0.5% P) 
(Lau et al., 2012) 
Nil 
Calcification, P, PTH, 
FGF-23, Klotho 
30ng/kg Calcitriol 
100ng/kg Paricalcitol 
Calcification 
Normalise P, FGF23 & klotho.     
PTH remains high 
Sprague Dawley Rats 
High P diet (1.2%) 
(Mizobuchi et al., 
2007) 
Vehicle No Calcification, PTH 
40ng/kg Calcitriol 
Calcification, serum Ca and P, 
PTH,  Runx2, BGP 
160ng/kg Paricalcitol 
No Calcification, serum Ca 
PTH 
Sprague Dawley Rats 
Normal diet 
(0.9% Ca and 0.8% P) 
(Cardus et al., 2007) 
Vehicle No Calcification, PTH 
100ng/kg Calcitriol 
Calcification,  serum Ca and P, 
PTH 
300ng/kg Paricalcitol 
No calcification,  serum Ca, 
PTH 
Wistar Rats 
High P (1.2%), low Ca 
(0.6%) diet 
(Lopez et al., 2008) 
Vehicle No Calcification, P 
80ng/kg Calcitriol   Calcification, P 
240ng/kg Paricalcitol  Calcification, No change P 
Sprague Dawley Rats 
Normal diet 
(Koleganova et al., 
2009) 
Nil No calcification 
30ng/kg Calcitriol 
 Calcification, Runx2,  
MGP 
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1.7.3 In -Vitro: VSMC explants 
VSMCs can be explanted from human vessels therefore have the benefit of being 
species specific. Furthermore, the Ca and P levels in the culture media can be 
controlled so that the direct effects of vitamin D on VSMCs can be studied 
independently of changes in systemic Ca and P levels. Vascular calcification can be 
studied in-vitro in explanted VSMCs by increasing the Ca and/or P content of the 
culture medium to induce VSMCs to calcify (Proudfoot et al., 2000).  
Calcification was induced in human VSMCs by increasing mineral content of the 
medium more than 3.5 fold from 0.9mM P to 3.3mM P. This dose of P did indeed 
increase Ca deposition in the VSMCs, it also increased expression of osteoblast genes; 
Runx2, Msx2 and bone morphogenetic protein 2 (BMP-2), a transforming growth 
factor involved in the regulation of bone development (Martinez-Moreno et al., 2012). 
In this study, 10nM calcitriol further increased expression of osteoblast genes BMP-2, 
Runx2, Msx2 and BGP, whereas 30nM paricalcitol reduced expression of BMP-2 in 
VSMCs. In the high P medium, calcitriol elevated Ca deposition whereas paricalcitol 
reduced Ca deposition. This suggests that both VDRAs have direct but opposing 
effects on VSMC calcification (Martinez-Moreno et al., 2012). A major limitation of 
this study is that there was no vehicle control for either of the VDRAs which are both 
only soluble in ethanol, ethanol is likely to be toxic to cells and could be influencing 
the observed responses. In addition, raising the P content of the medium to 3.3mM 
could be considered excessive, it is a toxic dose and does not reflect mineral levels 
observed physiologically. 
The causative effect of calcitriol on calcification is not consistent across all in-vitro 
studies on human VSMCs. In VSMCs induced to calcify with 2.5mM P and TNF-α 
(known to accelerate osteogenic processes), those treated with vehicle had extensive 
calcification and increased mRNA expression of Runx2 and BGP. Relative to vehicle, 
1nM and 10nM calcitriol had no effect on Ca deposition whereas, 100nM calcitriol 
significantly reduced; Ca deposition, expression of osteogenic BGP and expression 
and secretion of MMP-2 which promotes elastin degradation (Aoshima et al., 2012). 
This protective effect of calcitriol was only observed at the supra-physiological dose 
of 100nM, most studies use 10nM calcitriol to represent physiological doses. 
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Furthermore, the same study showed that in the absence of TNF-α, even 100nM 
calcitriol had no effect on Ca deposition in VSMCs (Aoshima et al., 2012). TNF-α is 
upregulated by chronic inflammation as observed in atherosclerosis therefore this 
study is of physiological relevance to atherosclerosis however has distinct 
characteristics from arteriosclerosis observed in CKD. 
In a different experimental set up, much lower doses of calcitriol were shown to have 
a protective effect on calcification in VSMCs. It was shown that 1nM calcitriol 
upregulated expression of total and cell surface CaSR via the VDR in both normal and 
high Ca media. VSMC calcification induced by high Ca (5mM) medium was 
prevented by 1nM calcitriol treatment (Mary et al., 2015). This response was observed 
at a narrow concentration range and neither 0.1 or 10nM calcitriol had a significant 
effect on calcification. The protective effect of calcitriol observed in this study through 
the upregulation of CaSR expression may only be effective in models induced to 
calcify in high Ca media. Although raised serum Ca is observed in CKD patients it is 
preceded by and accompanied with raised serum P. In addition, 5mM Ca is almost 3 
fold that observed in normal medium and would be a toxic dose not observed 
clinically, therefore the physiological significance of this model is questionable. 
As summarised in Table 1-2 a range of protective and calcification promoting effects 
of VDRAs were observed in different studies on VSMCs. Despite that each study was 
species specific and used VSMCs from humans, these VSMCs were not disease 
specific to CKD. They varied in their mode of inducing vascular calcification, with 
some using high mineral conditions that are not clinically relevant.  
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Table 1-2: In-vitro studies on the effects of VDRAs on VSMC calcification. 
Comparison of in-vitro studies in human VSMCs, tissue culture medium was 
supplemented to induce calcification as indicated for each study. For each study the 
effect on calcification of the control condition (nil or vehicle) is shown. The effect on 
calcification of the VDRAs is in relation to the control condition. Red shading 
indicates increased calcification. Green shading indicates no or reduced calcification. 
 - Increased.  - Decreased. BGP – Bone gla protein. BMP-2 – Bone morphogenic 
protein-2. Ca – Calcium. CaSR – Calcium sensing receptor. P – Phosphate.  
 
In-Vitro Method 
human VSMCs 
VDRA Effect on Calcification 
Control 0.9mM P or  
High P 3.3mM P 
(Martinez-Moreno et 
al., 2012) 
Nil 
Calcification, BMP-2, Runx2, 
Msx2 
10nM calcitriol 
 Calcification, BMP-2, 
Rumx2, Msx2 
30nM paricalcitol 
Calcification, BMP-2,  
No change Msx2 or Runx2 
Control 0.9mM P or  
High P 2.5mM P 
& TNF-α 
(Aoshima et al., 2012) 
Vehicle Calcification, Runx2, BGP 
1nM, 10nM, 
100nM calcitriol 
Calcification (dose dependently), 
BGP (100nM only) 
Control 0.9mM P or 
High P 3.3mM P 
& TNF-α 
(Guerrero et al., 2012) 
Nil Calcification,  BMP-2 
10nM calcitriol  Calcification,  Runx2, BMP-2 
30nM paricalcitol  Calcification, BMP-2 
Control 1.8mM Ca or 
High Ca 5mM Ca 
(Mary et al., 2015) 
Vehicle Calcification 
1.01nM, 0.1nM, 
10nM calcitriol 
No change in calcification 
1nM calcitriol Calcification, CaSR 
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1.7.4 Ex-Vivo: Intact human arterial vessel rings 
Ex-vivo studies of arterial rings from medium sized human muscular arteries enable the 
whole tissue architecture of the vessel wall to be studied including the lamellae, tunica 
intima, tunica media and adventitia. Vessel rings maintain their contractile phenotype for 
several weeks in culture enabling extended experiments to take place. This model was 
established to study calcification in vessels of children with CKD, (Shroff et al., 2008b) 
and enabled vessels from pre-dialysis and dialysis patients to be compared under 
experimental conditions. Vessels from children are particularly important to study 
vascular calcification as they have been exposed to minimal traditional cardiovascular risk 
factors such as dyslipidemia, hypertension, smoking and aging itself therefore the risk of 
atherosclerosis is low and effects of the uremic milieu and the impact of dialysis on the 
development of arteriosclerosis can be studied in isolation. This vessel ring model showed 
that culture of vessel rings in high Ca-P medium (2.7mM Ca and 2mM P) led to Ca 
deposition in the tunica-media of dialysis vessel rings and to a lesser extent in pre-dialysis 
vessel rings but not in control vessels (Shroff et al., 2010). In this model, many of the 
processes that occur in-vivo in calcification were observed in the calcified dialysis vessel 
rings, this included; apoptosis of VSMCs, increased number of matrix vesicles in the 
extracellular matrix and increased expression of osteoblast marker Runx2. ALP activity 
was also increased by high P media but not by high P and Ca media (Shroff et al., 2010)  
This ex-vivo model of human vessel rings from patients with CKD has not previously been 
used to test the effects of VDRAs on vascular calcification, this model formed the basis 
of this thesis. The effects of VDRAs on vascular calcification in explanted human VSMCs 
from both healthy control and CKD patients was also studied. In both models, calcification 
was induced by a modest increase in the media’s Ca and P content (1.5 and 2 fold 
respectively) to mimic raised mineral content observed in CKD. 
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1.8 Hypothesis and Project Strategy 
Cardiovascular disease, in particular vascular calcification is the leading cause of death in 
people with CKD. Children with CKD are routinely prescribed VDRAs to compensate for 
their vitamin D deficiency, prevent secondary hyperparathyroidism and to reduce the risk 
of bone disease. The direct effect of these VDRAs on VSMC calcification is not fully 
understood and current literature is confounding. 
The hypothesis examined in this PhD thesis was; VDRAs play a key role in driving 
vascular calcification in vessels from CKD patients and the differential expression pattern 
of the VDR can determine the extent of mineralisation in an in vitro and ex vivo model. 
Chapter 3: 
 Aim 1: To establish whether different VDRAs, calcitriol, alfacalcidol and 
paricalcitol accelerate the progression of vascular calcification in arterial rings 
isolated from children with CKD. 
The effects of three different VDRAs on vascular calcification in pre-dialysis and dialysis 
children were tested by treating intact paediatric arterial rings in pro calcaemic conditions 
with calcitriol, alfacalcidol or paricalcitol. The Ca content was quantified using a 
colourimetric cresolphthalein assay and the level of calcification was also visualised by 
histology.  
Chapter 4: 
 Aim 1: To determine whether VDRAs alfacalcidol and calcitriol act via 
different mechanisms to promote vascular calcification in vessel rings from 
children with CKD. 
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 Aim 2: To elucidate the different expression profiles in vessel rings that have 
an increased Ca load in response to calcitriol (responders) and vessel rings 
whose Ca load does not respond to calcitriol (non-responders). 
In order to examine the mechanistic effects of VDRAs on arterial rings, extensive 
histological analysis was performed to visualise any structural differences and changes in 
protein expression. In addition, activity of the osteoblast enzyme ALP in the arterial rings 
was determined by a colorimetric assay. 
Chapter 5: 
 Aim 1: To establish whether the effect of calcitriol on calcification in 
VSMCs is dose dependent. 
 Aim 2: To determine whether paricalcitol is less calcaemic than calcitriol 
in VSMCs. 
 Aim 3: To elucidate whether dialysis VSMCs are more susceptible to 
VDRA induced calcification than control VSMCs. 
For these studies VSMCs were explanted from the arteries of paediatric patients, both 
healthy controls and CKD dialysis patients. VSMCs were treated in pro calcaemic 
medium with either physiological dose calcitriol and paricalcitol or a range of calcitriol 
doses from a sub physiological to a supraphysiological dose. Ca content of treated VSMCs 
was quantified by colourimetric cresolphthalein assay. ALP activity was also determined 
by a colourimetric assay and changes in RNA or protein expression were analysed.  
Chapter 6: 
 Aim 1: To determine whether VDR expression in vessels varies between 
individuals giving rise to the different responses to calcitriol treatment in both 
arterial vessel rings and explanted VSMCs.  
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Arterial vessel rings were grouped dependent on calcification in response to calcitriol and 
their VDR expression was visualised by immunohistochemistry and quantified. In control 
and dialysis VSMCs treated with VDRAs, the total VDR mRNA expression was 
determined by qPCR and protein expression of VDR isoforms analysed by western blot. 
To investigate differences in VDR transactivation capacities, VSMCs were transfected 
with a luciferase construct under a VDRE promoter.       
 
Chapter 7: 
 Aim 1: To elucidate whether VDRAs accelerate the progression of vascular 
calcification in arterial rings isolated from adults with CKD. 
Arterial vessel rings from adults with CKD, either pre dialysis or on dialysis were treated 
in pro calcaemic conditions with VDRAs calcitriol and paricalcitol. Their Ca content was 
quantified by a colourimetric cresolphthalein assay and level of calcification visualised by 
histology. 
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Chapter 2 Methods 
2.1 Collection and processing of patient vessels 
2.1.1 Ethics and patient selection 
This study was approved by the NHS Health Research Authority, National Research 
Ethics Service (HRA NRES) committee London – Bloomsbury. Informed written consent 
was obtained from all patients or their parents/guardians and children if appropriate. For 
the children’s vessel study all patients were aged 1 to 17 years and for the adult vessel 
study the patient age range was 19 to 71 years. All patients were free from confounding 
pro-atherosclerotic risk factors. To ensure this, patients who had underlying inflammatory 
disorders, vasculitis, diabetes, or dyslipidaemia were excluded from the study. Patient 
details were recorded at the time of vessel collection including; age, gender, primary renal 
diagnosis, type of and time on dialysis (if applicable) and any vitamin D supplements 
prescribed. All vessels were allocated a unique vessel ID to fully anonymise all samples, 
this is shown in Table 2-1 along with the patient information. There were 3 categorise of 
vessels: 
• Controls: Non-renal patients undergoing routine abdominal surgery, who were 
free from inflammatory disease. 
• Pre-dialysis: CKD patients, normally CKD stage V (GFR < 15ml/min) who were 
undergoing renal transplant or catheter insertion prior to dialysis. 
• Dialysis: CKD patients at ESKD who were receiving renal replacement therapy in 
the form of peritoneal dialysis (PD) or haemodialysis (HD) prior to renal 
transplant. 
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Table 2-1: Patient information for children’s vessel rings. 
Vessel ID format: Year. Age and gender. Unique number. Vessel type.  
IE – Inferior epigastric artery. ME – Mesenteric artery. CAKUT – Congenital anomalies 
of the kidneys and urinary tract. ATN – Acute Tubular Necrosis. HD – Haemodialysis.  
PD – Peritoneal dialysis. 
Vessel ID 
Age 
(Years) 
Gender Primary renal Diagnosis 
Type of & time on 
dialysis (months) 
Alfacalcidol 
supplements 
07.6M.44.IE 6 Male CAKUT Pre-dialysis Yes 
07.16F.46.IE 16 Female Unknown  Pre-dialysis Not known 
07.10M.52.IE 10 Male Neonatal ischemia and ATN Pre-dialysis Not known 
07.9M.54.IE 9 Male Glomerulopathy Pre-dialysis Yes 
13.14M.105.IE 14 Male Cystic kidney disease Pre-dialysis Yes 
13.5M.110.IE 5 Male CAKUT Pre-dialysis Yes 
13.8F.111.IE 8 Female CAKUT Pre-dialysis Yes 
13.12F.113.IE 12 Female Glomerulopathy Pre-dialysis Yes 
14.15M.115.IE 15 Male CAKUT Pre-dialysis Yes 
14.11M.118.IE 11 Male CAKUT Pre-dialysis Yes 
14.8F.122.IE 8 Female Bilat Wilms Tumour Pre-dialysis Yes 
07.15F.45.IE 15 Female CAKUT 88 HD Yes 
07.2M.48.IE 2 Male CAKUT 0.25 PD Yes 
17.15F.49.IE 15 Female Cystic kidney disease 30 PD Yes 
07.2M.50.IE 2 Male CAKUT 21 HD Yes 
07.1M.51.IE 1 Male Glomerulopathy  0.02 PD Yes 
07.15F.53.IE 15 Female Glomerulopathy 0.6 PD Yes 
13.9M.104.IE 9 Male CAKUT 12  HD Yes 
14.8M.114.IE 8 Male CAKUT 14 HD Yes 
14.17M.116.IE 17 Male CAKUT 5 HD Yes 
14.13M.119.IE 13 Male CAKUT 8 HD Yes 
05.1.5M.04.IE 1.5 Male Glomerulopathy 17 HD Yes 
12.13M.16.IE 13 Male CAKUT 32 HD No 
13.15F.24.IE 15 Female CAKUT 23 PD Yes 
06.9M.34.IE 9 Male CAKUT 10 PD Not known 
06.8F.36.IE 8 Female Cystic kidney disease 13 HD Not known 
13.16M.101.IE 16 Male Cystic kidney disease 12 HD Yes 
13.15F.112.IE 15 Female Glomerulopathy 25 HD Yes 
14.8F.123.ME 8 Female N/A - Laparotomy Control No 
15.2F.127.ME 2 Female N/A – Closure of Stroma Control No 
15.5M.128.IE 5 Male N/A - Ileostomy Control No 
13.0.5F.109.ME 0.5 Female N/A – Anorectal reconstruction Control No 
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2.1.2 Vessel types 
All vessels used in these studies were medium sized muscular arteries, this included 
inferior epigastric, mesenteric and omental arteries.  
The inferior epigastric artery is a medium sized muscular artery that arises from the 
external iliac artery. It runs in the subcutaneous fat perpendicular to the surgical incision 
for a renal transplant. During a renal transplant the inferior epigastric is routinely dissected 
out and discarded to enable the surgeon deeper access into the abdomen. In this study the 
inferior epigastric arteries were collected during renal transplant from pre-dialysis and 
dialysis patients. They were utilised for ex-vivo studies of vessel rings and to explant 
VSMCs for in-vitro studies 
The omentum and the mesentery are folds of intra-abdominal tissue that are highly 
vascular. The omentum is a membrane layer that lines the abdominal cavity and organs 
within. The mesentery is a double layer of peritoneum that connects the small intestine to 
the wall of the abdominal cavity. A small piece of either omentum or mesentery is often 
removed from patients having abdominal surgery in order to access the viscera. For 
example, omentectomy is routinely performed when a catheter is inserted for peritoneal 
dialysis. Medium sized muscular arteries in the omentum or mesentery were dissected out 
of CKD and non-renal control patients for ex-vivo studies of vessel rings and VSMCs were 
explanted for in-vitro studies. 
 
2.1.3 Dissecting and cutting vessel rings. 
Vessels were collected and transported in M199 tissue culture medium (Sigma) and stored 
at 4˚C for a maximum of 24 hours before dissection in a sterile tissue culture hood. The 
surrounding fat and adventitia were gently stripped from the arteries. Vessels were 
dissected into 1mm-thick rings to enable perfusion in culture; between 12 and 20 rings 
were obtained from each vessel. 
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2.2 Ex-vivo methods 
2.2.1 Treatment of vessel rings 
Depending on the length of vessel available, up to three rings were cultured per condition 
for analysis of Ca content, ALP activity and for histology. Three baseline rings were also 
taken prior to culture. The vessel rings were cultured in FBS free M199 with PSG for 14 
days. FBS promotes VSMC growth therefore was not used in the culture of vessel rings. 
Rings were treated in either normal Ca-P medium as a control and high Ca-P medium to 
promote mineralisation. Normal Ca-P medium consisted of M199 alone which has 1mM 
phosphate (P) and 1.8mM calcium (Ca). In high Ca-P medium the mineral content was 
increased to a final concentration of 2mM P and 2.7mM Ca with the addition of NaH2PO4 
and CaCl2. Vitamin D treatment with either paricalcitol (Abbvie), calcitriol (Sigma 
D1530) or alfacalcidol (Selleckchem S1468) was added to a final concentration 10nM. In 
each case ethanol was used as the vehicle and its concentration was adjusted to 3.4mM in 
each condition (Figure 1). Medium was refreshed every three days.  
   
Figure 2-1: Schematic of treatment conditions for ex-vivo culture of vessel rings. For each 
condition a ring was analysed for Ca content, ALP activity and histology. 
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2.2.2 Vessel ring Ca load analysis 
Vessel rings were washed in HBSS (Ca free Hanks Balanced Saline Solution) and stored 
at -80°C until analysis. To extract Ca, vessel rings were placed in a Dounce Glass Tissue 
Homogenizer with 200μl 0.1M HCL and homogenised every 30 minutes for 2 hours. The 
tissue and solution were transferred to an Eppendorf and centrifuged at 13000g for 2 
minutes. The supernatant was removed and the Ca content of the supernatant was 
determined by ο-cresolphthalein assay. The pellet was washed in HBSS and homogenised 
every 30 minutes for an hour in 0.1M NaOH / 0.1% SDS. Again the tissue and solution 
were transferred to an Eppendorf and centrifuged at 13000g for 2 minutes, the supernatant 
was retained for BioRad protein assay. 
2.2.2.1 Ο-Cresolphthalein assay 
A colorimetric assay to determine Ca concentration, in which Ca reacts with ο-
cresolphthalein in an alkaline solution to form a violet complex that has maximum 
absorbance at 577nm. A standard curve was obtained by 1:2 serial dilutions of 55μl 
1mg/ml CaCl2 in 55μl 0.1M HCl in a 96 well plate. Samples were diluted in 0.1M HCl 
and a total of 55μl added to the plate for comparison to the standard. To each of the 
standard and samples, 25μl dH2O, 200μl ammonia buffer and 10μl ο-cresolphthalein 
solution were added and the absorbance was read immediately at 560nm by using a 
TECAS Genios Pro Multifunction Microplate Reader. Ca content was normalised to 
protein.  
2.2.2.2 BioRad Protein Assay 
Protein concentrations were measured to normalise Ca concentrations. 5μl supernatant in 
0.1M NaOH / 0.1% SDS was pipetted into a 96-well plate and the standard was prepared 
from 1:2 serial dilutions of 1mg/ml bovine serum albumin (BSA). BioRad DC protein 
assay kit was used according to the manufacturer’s instruction and absorbance was read 
at 710nm.  
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2.2.3 Vessel ring Alkaline Phosphatase activity 
Vessel rings were washed in HBSS and stored at -80°C for a maximum of 7 days before 
analysis. To extract ALP, vessel rings were homogenised in a Dounce Glass Tissue 
Homogenizer in 120μl 10% SDS every 10 minutes for an hour, during this process 
homogenisers were kept on ice to avoid enzyme degradation. The supernatant was 
retained for both a colorimetric ALP assay to determine enzyme activity and a protein 
assay for normalisation as above. 
2.2.3.1 Alkaline Phosphatase Assay 
 To determine ALP activity 100μl of 1mg/ml para-Nitrophenol phosphate (p-Npp) in ALP 
buffer was added to 50μl of sample (25μl supernatant diluted in 25μl 10% SDS) in a 96-
well plate and incubated at 37˚C in the dark for 30 minutes. P-Npp is an ALP substrate, 
and activity of ALP is determined by the decay of colourless p-Npp to yellow para-
nitrophenol (p-Np). A standard was prepared immediately prior to reading the absorbance. 
1:2 serial dilutions of 50μl p-Np in H2O were made and 100μl 1mg/ml p-Npp added to 
each well. The absorbance was read at 405nm using a TECAS Genios Pro Multifunction 
Microplate Reader and p-Np formation in samples calculated from the standard. ALP 
activity calculated as enzyme units (U, defined as product formed (μmol) over reaction 
time (min)) and standardised to protein content (mg), as determined by BioRad protein 
assay.  
 
2.2.4 Sample preparation for histology 
2.2.4.1 Embedding and sectioning of vessel rings 
Vessel rings were fixed in 4% paraformaldehyde (PFA) for 24 hours, then dehydrated in 
increasing concentrations of ethanol and then xylene in the Shandon Hypercenter XP 
processor and subsequently embedded in paraffin wax blocks using a Sakura Tissue-TEK 
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TEC tissue embedding console. Sections of 7μm were cut using a rotary microtome (Leica 
RM2125RTF).  
2.2.4.2 Dewax and rehydration 
Prior to staining, slides were dewaxed in xylene (2x 5 minutes) and rehydrated in graded 
concentrations of ethanol (1 minute 100% ethanol, 1 minute 100% ethanol, 1 minute 70% 
ethanol, 1 minute 50% ethanol) and washed in H2O (3 minutes). 
2.2.4.3 Dehydrate and mount 
After staining slides were dehydrated in graded concentrations of ethanol (1 minute 50% 
ethanol, 1 minute 70% ethanol, 1 minute 100% ethanol, 1 minute 100% ethanol) and 
cleared in xylene (2x 5 minutes). Then a coverslip was mounted with DPX mounting 
medium. Slides were visualised on a Zeiss Axioplan scope and images taken with a Zeiss 
colour camera using Axiovision software. 
 
2.2.5 Haematoxylin and eosin (H&E) staining  
Slides were dewaxed and rehydrated then stained in Harris haematoxylin (Sigma) for 5 
minutes and rinsed in H2O. Slides were differentiated in 0.3% acid alcohol (HCL in 70% 
ethanol) then rinsed in H2O again. Finally, slides were stained in stained in eosin (Sigma) 
for 3 minutes and then dehydrated as above. 
2.2.6 Von Kossa staining 
Slides were dewaxed and rehydrated then incubated in 2% silver nitrate in dH2O under a 
100-watt light for 2 hours. During this process Ca deposits are replaced by silver, which 
can be observed as metallic silver and is black in colour. To remove any unreacted silver, 
slides were washed 3x 2 minutes in H2O, 2x5 minutes in 3% sodium thiosulphate in dH2O 
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and a further 2x5 minutes in H2O. Slides were counterstained in haematoxylin and eosin 
as described above. 
 
2.2.7 Immunohistochemistry 
Slides were dewaxed and rehydrated then incubated in citrate buffer (Antigen unmasking 
solution, Vector laboratories) at sub-boiling temperatures for 15 minutes before being 
allowed to cool to room temperature. This step unmasks antigen binding sites in the tissue, 
as formalin fixing can induce molecular crosslinks in proteins changing the 3D structure 
of epitopes. Slides were washed (3x 5 minutes in phosphate buffer saline PBS) then 
incubated for 10 minutes in 3% hydrogen peroxide in methanol to block endogenous 
peroxidase activity. Slides were washed again and then non-specific antigen binding was 
blocked by incubating slides for 30 minutes in blocking serum diluted in PBS as per Table 
2-2. Blocking serum was made from a species that neither the primary nor secondary 
antibodies were raised in. Primary antibody was diluted in blocking serum as required 
(shown in Table 2-2) and sections were incubated in the primary antibody overnight at 
4˚C in a humidifying chamber. The next day they were washed (3x5 minutes in PBS-T) 
and incubated for 1 hour in biotinylated secondary antibody linked to horseradish 
peroxidase (1:200 in 1% blocking serum), then washed again (3x5 minutes in PBS-T). To 
amplify the secondary antibody signal, slides were incubated with the avidin/biotinylated 
enzyme complex (ABC reagent) for 30 minutes at room temperature, and then washed 
(3x5 minutes PBS). Depending on sensitivity of primary antibody, slides were incubated 
between 30 seconds and 4 minutes with DAB (3, 3- diaminobenzadine), a horseradish 
peroxidase substrate that produces a dark brown product. Slides were counterstained with 
haematoxylin, dehydrated and mounted as above. Blocking serum, DAB, secondary 
antibodies and ABC reagent were obtained from Vectastain ABC kit, Vector Laboratories. 
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Table 2-2: Immunohistochemistry antibodies. 
Primary Antibody Dilution Blocking solution Secondary 
Antibody 
DAB 
time 
mAb VDR (D-6) 
(Santa Cruz sc-13133) 
1:500 1% Horse serum  Mouse 1:200 3 min 
Smooth Muscle α actin 
(Sigma A2547) 
1:10 000 1% Horse serum Mouse 1:200 1 min 
CYP24A1 
(Abcam ab54594) 
1:100 1% Horse serum Mouse 1:200 50 sec 
Alkaline Phosphatase 
 (Abcam ab108337) 
1:500 1% Horse serum Rabbit 1:200 2-3 min 
Runx2 M70 
(Santa Cruz SC10758) 
1:200 10% Horse serum 
in 3% BSA 
Rabbit 1:100 3 min 
 
 
2.2.8 Cell counts in vessel rings 
The total numbers of VSMCs per unit area of the tunica media of vessel rings were 
calculated using H&E stained sections. For each vessel ring, 3 different frames were 
chosen at random and imaged at 40x magnification. An outline of the tunica media region 
was selected manually and its area was calculated using Image J software. This software 
was also used to keep a tally of the number of nuclei counted. The mean number of nuclei 
per area of tunica media was calculated using Microsoft Excel.  
The number of VSMCs in the tunica media that were expressing VDR were also counted 
by applying this method to sections that were positive for VDR expression after immuno-
staining.  
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2.3 In-Vitro Methods 
2.3.1 Explanting VSMCs from vessels 
To explant VSMCs, a vessel ring was cut into tiny pieces and cultured in a 6-well plate in 
M199 with 20% foetal bovine serum (FBS) as well as 100 U/ml penicillin, 100 U/ml 
streptomycin and 0.29 mg/ml glutamine (PSG). Plates were incubated in a 4% CO2 and 
37°C incubator (Thermo Haraeus HERAcell 150), to ensure tissue adhered to the plate 
they were not disturbed for the first 7 days, then the medium was refreshed every 3-4 days. 
Patient information for explanted control and dialysis VSMCs are shown in Table 2-3 and 
Table 2-4 respectively. 
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Table 2-3: Patient information for healthy control VSMC explants. 
VSMC ID format: Year. Age and gender. Unique number. Vessel type.  OM – Omental artery. ME – Mesenteric artery. 
VSMC ID Age (Years) Gender Operation vessel obtained from Vessel Type Vitamin D supplements 
13.0.1F.106.OM 0.1 Female Laparoscopy Omental Artery None 
13.10F.108.OM 10 Female Laparoscopy Omental Artery None 
06.1M.39.ME 1 Male Ileostomy Mesenteric artery None 
13.1F.28.OM 0.5 Female Anorectal reconstruction Omental Artery None 
13.3M.31.OM 3 Male Splenectomy Omental Artery None 
13.5F.32.OM 5 Female Lap ACE Omental Artery None 
13.5M.33.OM 5 Male LAP ACE Omental Artery None 
 
Table 2-4: Patient information for dialysis VSMCs. 
Vessel ID format: Year. Age and gender. Unique number. Vessel type. 
IE – Inferior epigastric artery. OM – Omental artery. HD – Haemodialysis. PD – Peritoneal dialysis. 
 VSMC ID 
Age 
(Years) 
Gender 
Primary renal 
Diagnosis 
Type of and time on 
dialysis (months) 
Vessel Type 
Vitamin D 
supplements 
05.1.5M.04.OM 1.5 Male Glomerulopathy 17 HD Omental Artery Alfacalcidol 
12.13M.16.IE 13 Male Dysplasia 32 HD Inferior Epigastric Alfacalcidol 
13.15F.24.IE 15 Female Dysplasia 23 PD Inferior Epigastric Alfacalcidol 
06.9M.34.IE 9 Male Dysplasia 10 PD Inferior Epigastric Alfacalcidol 
06.8F.36.IE 8 Female Cystic Kidneys 13 HD Inferior Epigastric Alfacalcidol 
13.16M.101.IE 16 Male Cystic Kidneys 12 HD Inferior Epigastric Alfacalcidol 
13.15F.112.IE 15 Female Glomerulopathy 25 HD Inferior Epigastric Alfacalcidol 
14.13M.119.IE 13 Male Unknown 8 PD Inferior Epigastric Alfacalcidol 
14.14M.124.IE 14 Male Dysplasia 10 HD Inferior Epigastric Alfacalcidol 
4.17M.125.IE 17 Male Dysplasia 18 PD Inferior Epigastric Alfacalcidol 
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2.3.2 Passaging and freezing VSMCs 
VSMCs were grown in M199 supplemented with 20% FBS and PSG. At 80% confluence 
VSMCs were passaged by splitting 1:2. Cells were washed with HBSS then incubated 
with 0.25% Trypsin-EDTA (Sigma) for 5 minutes at 37°C to dislodge the cells. Trypsin 
was neutralised with M199 with 20% FBS and PSG and cell split 1:2. 
For freezing, VSMCs were trypsinized as above and cells were centrifuged at 700g for 5 
minutes at 4°C. The pellet was re-suspended in freezing medium (FBS with 10% dimethyl 
sulfoxide (DMSO)), transferred to a cryo vial and frozen gradually in a Mr. Frosty 
Freezing Container (Thermo Scientific) containing isopropanol in a -80°C freezer. After 
24 hours frozen cells were transferred to liquid nitrogen. 
 
2.3.3 Calcification of VSMCs 
VSMCs were seeded in 6-well or 48-well plates with M199 supplemented with 20% FBS 
and PSG. At 80% confluence treatment began, cells were cultured in M199 with PSG and 
reduced serum (5% FBS). It is necessary to reduce serum content as FBS contains 
calcification inhibitors. 
Calcemic conditions were created by increasing the mineral content of M199 from 1mM 
P and 1.8mM Ca (normal Ca-P medium) to a final concentration of 2mM P and 2.7mM 
Ca (high Ca-P medium) by the addition of NaH2PO4 and CaCl2. Cells were treated with 
VDRAs, either 10nM paricalcitol (Abbot) or calcitriol (Sigma) at 1nM, 10nM or 100nM. 
In each case ethanol was used as the vehicle to a final concentration of 3.4mM and 3.4mM 
ethanol was included as a vehicle control. Experiments were performed in pairs with 
VSMCs explanted from one control and one dialysis patient treated simultaneously. 
Media was changed every 3 days and cells were cultured until the onset of calcification 
was observed by light microscopy (between 4 and 6 days). 
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Ca deposition in treated VSMCs was quantified by ο-cresolphthalein assay. In addition, 
also ALP activity was determined, RNA was isolated for qPCR analysis and protein was 
harvested for western blot analysis. 
 
2.3.4 VSMC Ca load analysis 
Cells were washed in HBSS and incubated at room temperature with 0.1M HCL for 2 
hours to dissolve the Ca deposits. The supernatant was analysed for Ca content using the 
ο-cresolphthalein assay described above. Ca content was analysed in triplicate wells of a 
48-well plate and normalised to protein content of triplicate neighbouring wells. Protein 
was harvested in 0.1M NaOH in 1% SDS and analysed with the BioRad protein assay 
described above.   
 
2.3.5 VSMC Alkaline Phosphatase Activity 
VSMCs in a 6well plate were washed in HBSS and each well was harvested in 100μl 1% 
Triton X-100 in PBS. Samples were kept on ice throughout as ALP is a heat labile enzyme. 
Samples were freeze-thawed twice from -80˚C to room temperature then centrifuged at 
13000g for 5 minutes at 4˚C. The supernatant was retained for the ALP activity assay and 
BioRad protein assay as described above.  
 
2.3.6 RNA isolation and Reverse Transcription 
Cells were lysed in RNA STAT-60 (Amsbio) and the RNA in the aqueous phase was 
separated out using chloroform, and then precipitated with isopropanol. The RNA pellet 
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was washed in 75% ethanol and re-suspended in Diethylpyrocarbonate (DEPC) treated 
H2O. 
Reverse transcription of RNA was carried out with Random primers (Promega), Oligo dT 
primers (Promega), dNTP mix (Eurogentec), RNAsin RNase inhibitor (Promega), 5x Mu-
MLV buffer (Eurogentec), Mu-MLV reverse transcriptase (Eurogentec) and DEPC H2O. 
The RNA and primers were incubated at 65˚C for 5 minutes prior to the reaction to 
denature the RNA. The reverse transcription reaction was carried out at 25˚C for 10 
minutes for primers to anneal and then 37˚C for 50 minutes for the reverse transcription 
to produce cDNA. A final incubation at 95°C for 5 minutes terminated the reaction and 
inactivated reverse transcriptase. The reaction was then cooled to 4˚C in an Applied 
Biosystems 2720 Thermal Cycler. The resulting cDNA was diluted to 2μg/100μl in DEPC 
H2O. 
 
2.3.7 Primer validation: Polymerase Chain Reaction 
Primers were validated to confirm that they were specific in only amplifying the expected 
product. PCR was carried out in 50μl reaction volume, with 2x PCR mastermix, 0.125μM 
of each forward and reverse (primer sequences shown in Table 2-5) and 0.1μg cDNA. 40 
cycles of 94˚C for 30 seconds, 60˚C for 30 seconds and 72° for 30 seconds were carried 
out in an Eppendorf vapo protect PCR machine 
PCR product was resolved on a 2% agarose gel (agarose in TAE) next to a Quick load 
purple 100 bp DNA ladder (New England Biolabs) at 120V for 30 minutes then visualised 
under ultraviolet light to estimate length of PCR products.  
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2.3.8 Quantitative real time PCR 
QPCR was carried out in 20μl reaction volume, with MESA GREEN qPCR Master Mix 
(Eurogentec) with 0.125μM of each forward and reverse primer Table 2-5 and 0.04μg 
cDNA. The cDNA was heated to 94°C to activate the polymerase. Then cDNA underwent 
45 cycles of 94˚C for 15seconds (denaturation) and 60˚C for 60 seconds (primer anneals 
to single strand and polymerase synthesises a complimentary sequence). This was carried 
out in a Corbette RotorGene 3000. A melt curve was also obtained by 1˚C inclines at 65-
99˚C. 
Ct (Cycle threshold) values were determined and gene expression was quantified using a 
standard curve. To obtain standards, PCR product was purified using the QIAquick PCR 
purification kit (Qiagen) and diluted to 0.05pM, 0.005pM, 0.0005pM and 0.00005pM. 
Gene expression was normalised to 18S rRNA expression. 
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Table 2-5: Primer sequences. 
Gene Primer sequence (5’ to 3’) 
Annealing 
temperature 
Amplicon 
length 
18S rRNA 
F: CCCAGTAAGTGCGGGTCATAA 
R: CCGAGGGCCTCACTAAACC 
60°C 101bp 
ALP 
F: ACGAGCTGAACAGGAACAACGT 
R: CACCAGCAAGAAGAAGCCTTTG 
55°C 104bp 
BSP 
F: AGTTTCGCAGACCTGACATCC 
R: TTCATAACTGTCCTTCCCACG 
55°C 161bp 
CYP24A1 
(24 hydroxylase) 
Qiagen QT00015428 60°C 119bp 
CYP27A1 
(25 hydroxylase) 
Qiagen QT00088536 60°C 105bp 
CYP27B1 
1α hydroxylase 
Qiagen QT01678012 57°C 184bp 
CYP2R1 
(25 hydroxylase) 
F: GAAAGCAGAGCCAGGTGTACG 
R: TCATGAATAAAGGAAGGCATGG 
58°C 150bp 
MGP Qiagen QT01004423 60°C 99bp 
Runx2 Qiagen QT00020517 60°C 102bp 
SM22 
F:TTGAAGGCAAAGACATGGCAGCAG 
R: TCCACGGTAGTGCCCATCATTCTT 
60°C 89bp 
SMA 
F: TGACAATGGCTCTGGGCTCTGTAA 
R: TTCGTCACCCACGTAGCTGTCTTT 
60°C 142bp 
SMMHC 
F: AGAAGCCAGGGAGAAGGAAACCAA 
R: TGGAGCTGACCAGGTCTTCCATTT 
60°C 131bp 
Total VDR 
F:GCCCACCATAAGACCTACGA 
R:AGATTGGAGAAGCTGGACGA 
60°C 203bp 
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2.3.9 Western Blotting 
Untreated cells in T25 flasks (baseline conditions) were harvested in 200µl of 
immunoprecipitation (IP) protein lysis buffer. The protein concentration was determined 
by BioRad protein assay. Protein lysates were mixed with 2x sample buffer. Protein from 
cells cultured and treated in 6-well plates were harvested directly into 100µl of 2x sample 
buffer per well, in order to avoid diluting samples. 
All samples were sonicated twice for 5 seconds and heated to 95°C for 5 minutes to 
denature the tertiary structure, enabling samples to be separated by electrophoresis in a 
size dependent manner.   
20µg of baseline protein or 20µl of protein harvested from treated cell lines were loaded 
onto a 10% polyacrylamide gel alongside a Precision Plus protein standard (Bio-Rad) and 
subject to sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) at 
120V for approx. 90 minutes in a Bio-Rad Mini-Protean Tetra System.  
Semi-dry transfer was used to transfer proteins onto a methanol charged PVDF 
Immobilon-P transfer membrane, proteins were transferred at 25V for 60 minutes in a 
Bio-Rad Trans-Blot Semi-Dry Transfer Cell. Membranes were blocked in 5% milk 
(Marvel) in TBS-T buffer for 60 minutes, then probed overnight at 4˚C with primary 
antibody in 5% milk in TBS-T (dilutions shown in Table 2-6). Membranes were washed 
3x 10 minutes in TBS-T, then probed with the corresponding horse radish peroxidase 
linked secondary antibody for 60 minutes and washed again 3x 10 minutes. An enhanced 
chemiluminescence (ECL) kit (ECL Prime Western Blotting Detection Reagent – GE 
Healthcare) and Fujifilm – Fuji Medical X-Ray Film were used to visualise proteins. 
Membranes were re-probed for β-actin as a gel loading control. The optical density of 
each band was quantified using Image J and normalised to the corresponding optical 
density of β-actin.      
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Table 2-6: Antibodies for western blot analysis. 
Primary Antibody Dilution Secondary Antibody Dilution 
mAb VDR (D-6), Santa Cruz sc-
13133 
1:500 Anti-Mouse IgG, 
GE Healthcare NA931V 
1:5000 
β-actin, Sigma A2228 1:10 000 Anti-Mouse IgG, 
GE Healthcare NA931V  
1:5000 
 
 
2.3.10 Luciferase assay – VDRE 
The Cignal Reporter Assay Kit VDRE (Qiagen CCS-2029L) was used to determine 
VDRE activation.  
VSMCs were seeded at a density of 20 000 cells per well in a 24-well plate in M199 with 
20% FBS. At 90% confluence cells were serum starved for 24 hours in M199 
supplemented with 0.5% BSA and PSG only. Transfection reagents were prepared using 
Lipofectamine LTX and Plus Reagent (Invitrogen). Lipofectamine LTX was diluted 1:9 
in OptiMEM (Gibco) and Plus reagent was diluted 1:18 in OptiMEM with 400ng construct 
per well. These transfection mixtures were combined (1:1) and incubated at room 
temperature for 5 minutes.  The transfection mixture was added 1:10 to serum free M199 
and cells were transfected for 6 hours with either VDRE reporter construct, positive 
control or negative control. The constructs specifications are shown in Table 2-7. 
After 6 hours, the transfection media was removed and replaced with serum free media 
containing treatment conditions. Triplicate wells of VSMCs were treated for 24 hours with 
either 100nM Calcitriol or 3.4mM ethanol as a vehicle control. Cells were washed in PBS 
and the Dual Glo Luciferase Assay system (Promega) was used to determine luciferase 
activity in each well, this was normalised to renilla activity as a control for transfection 
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efficiency. Luminescence was read using a Berthold Technologies, Mithras LB 940 
multimode microplate reader. 
A duplicate plate was seeded (80 000 cells/well in a 6-well plate), these cells were not 
transfected, however they were simultaneously treated with 100nM calcitriol or 3.4mM 
ethanol and harvested for either RNA or protein as described above. 
 
Table 2-7: Components of Cignal Reporter Assay Kit. 
Component Specification 
VDRE Reporter 
Inducible Vitamin D Responsive Firefly luciferase construct  
Constitutively expressing Renilla luciferase construct 
Positive Control 
Constitutively expressing GFP 
Constitutively expressing Firefly luciferase construct 
Constitutively expressing Renilla luciferase construct 
Negative Control 
Non inducible Firefly luciferase construct 
Constitutively expressing Renilla luciferase construct 
 
 
2.3.11 Immunocytochemistry 
VSMCs were seeded on coverslips in a 24-well plate at a density of 15 000 cells/well. 
Cells were fixed in 4% PFA and washed 3 x PBS. Cells were permeabilised in 0.5% NP40 
for 3 minutes and washed again 3x in PBS. To block non-specific antigen binding, cells 
were submerged in 3% BSA in PBS for 1 hour, then incubated at 4°C overnight in a 
humidifying chamber with primary antibody 1:500 mAb VDR (D-6) (Santa Cruz sc-
13133) in 3% BSA in PBS. Cells were washed 3x in PBS, then incubated with secondary 
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antibody (Donkey anti-Mouse Alexa Fluor 488, Invitrogen) diluted 1:500 in 3% BSA in 
PBS for 1 hour at room temperature in the dark. Cells were washed again in PBS and 
incubated for 5 seconds with DAPI (Sigma) 1:7000 in 3% BSA in PBS, then immediately 
washed again 3x in PBS. Coverslips were mounted onto slides using Mowiol mounting 
medium for imaging with an Olympus IX81 fluorescence microscope. 
 
 
2.4 Statistics 
2.4.1 Gaussian D’Agostino and Pearson Omnibus Normality Test 
Statistical analysis was performed in Graph Pad Prism 5. The Gaussian D'Agostino and 
Pearson omnibus normality test was performed as a guide to analyse the distribution of 
data. When P>0.05 samples were considered to have passed the normality test and it could 
be assumed that the sample was from a normally distributed population. P<0.05 indicated 
that the probability of that sample being chosen from a normally distributed population 
was less than 5%, therefore the sample distribution was considered to deviate significantly 
from the Gaussian ideal, the sample failed the normality test and the population was 
assumed not to be normally distributed. This normality test can generate false negatives 
and false positives, therefore it was used as a guide only and common sense was also 
applied. 
 
2.4.2 Parametric and Non-Parametric T-Tests 
Statistical tests were performed in Graph Pad Prism 5 to determine if two samples were 
significantly different from each other. The parametric, student’s t-test was applied when 
both sets of data were considered to be normally distributed. A non-parametric, Mann-
Whitney U test was applied when either or both of the samples were thought to be from a 
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population that did not follow Gaussian distribution, this test is based on rank and does 
not assume the population’s distribution. 
All tests were unpaired as each treatment condition was tested on individual vessel rings 
or populations of cells. Tests were always two-tailed to determine the significance of a 
change that could be either an increase or decrease.  
For both the unpaired two-tailed t-test and the two-tailed Mann-Whitney U test a P<0.05 
was considered statistically significant. This indicated that there was less than a 5% 
probability that the 2 samples were chosen at random from the same population, therefore 
the 2 populations were statistically different from each other.    
 
2.4.3 Correlation coefficient 
The correlation coefficient was calculated using Graph Pad Prism 5 to analyse the relation 
between two measured variables. Pearson correlation coefficient (R) assumes an 
approximate Gaussian distribution and was used as appropriate. When either or both of 
the variables did not follow Gaussian distribution the Spearman correlation coefficient 
(RS) was calculated, this is based on rank and does not assume Gaussian distribution.  The 
correlation coefficient (R or RS) has a range of -1 (perfect negative correlation) to 1 
(perfect positive correlation) with 0 representing no correlation.   
Two-tailed P values were calculated for both R and RS. The P value shows the probability 
that the correlation coefficient (R or RS) could have been calculated from random samples 
with no correlation. R (or RS) would be considered statistically significant if P<0.05, i.e. 
there was less than a 5% probability that R (or RS) was calculated from a random sample.  
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2.5 Buffers and solutions 
4% PFA (Paraformaldehyde) 
 4% PFA 
 PBS 
 pH 7.5 
 
ALP buffer 
 0.1M Glycine 
 1mM MgCl2 
 1mM ZnCl2 
 pH 10.4 
 
Ammonia buffer 
 0.24% NH4Cl 
 5% NH4OH 
 pH 10.5 
 
 
Immunoprecipitation (IP) protein lysis buffer  
 0.1M Tris-HCl pH 8.1 
 1% Triton X-100 
 0.15M NaCl 
 10µl protease inhibitor (Sigma) 
 
Mowiol mounting medium for immunocytochemistry 
 10% Mowiol 
 25% glycerol 
 0.1M Tris 
 pH 8.5 
 
 
Ο-Cresolphthalein solution 
 1mg/ml o-cresolphthalein 
 0.0672% NH4Cl 
 1.4% NH4OH 
 pH 10.5 
 
PBS-T 
 100ml H2O per PBS tablets 
 0.1% (v/v) Tween 20 
 
SDS-PAGE 2x sample buffer 
 62.5mM Tris pH6.8 
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 10% Glycerol 
 2% SDS    
 0.075% bromophenol blue 
 5% (v/v) β-mercaptoethanol (added fresh prior to use) 
 
SDS-PAGE resolving gel  
 10% acrylamide   
 375mM Tris pH 8.8   
 0.1% SDS    
 0.13% APS (stock 10% ammonium persulfate (Sigma) in H2O) 
 0.13% TEMED (N,N,N′,N′-Tetramethylethylenediamine, Sigma) 
 
SDS-PAGE stacking gel 
 5% acrylamide 
 125mM Tris pH 6.8 
 0.1% SDS  
 0.1% APS (10% ammonium persulfate (Sigma) in H2O) 
 0.2% TEMED (N,N,N′,N′-Tetramethylethylenediamine, Sigma) 
 
SDS-PAGE running buffer 
 25 mM Tris 
 250 mM glycine 
 0.1% SDS 
 pH 8.3 
 
TBS-T  
 150mM NaCl 
 10mM Tris 
 pH 8 
 0.2% (v/v) Tween 20 
 
TAE (Tris-acetic acid-EDTA) 
 40mM Tris 
 20mM acetic acid 
 1mM EDTA 
 
Western blot transfer buffer 
 20% (v/v) methanol 
 25mM Tris 
 0.2M glycine 
 1% SDS 
 pH 8.3 
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Chapter 3 The effects of VDRAs on vascular calcification in vessel 
rings isolated from children with CKD. 
3.1 Introduction 
Vessel rings from children with CKD enable the effects of VDRAs on arteriosclerosis to 
be studied without the confounding factors of atherosclerosis associated with aging and 
traditional cardiovascular risk factors. Data in this chapter were collected from paediatric 
patients with CKD who were undergoing renal transplant at Great Ormond Street 
Hospital. It is representative of the general paediatric CKD population including patients 
with different underlying renal diagnoses, varying ages, different genders, and patients on 
dialysis (including haemodialysis or peritoneal dialysis and with varying dialysis vintage) 
or in pre-dialysis CKD stage 5. To compensate for this patient variation, numerous rings 
were obtained from each patient’s vessel and the effects of different treatment conditions 
will be compared against the baseline vessel characteristics, such that each vessel can be 
its own internal control. Children’s vessels provide an ideal model to study uremic 
changes on the vessel wall as children are free of pre-existing cardiovascular risk factors 
like diabetes, dyslipidaemia or heart disease and patients are non-smokers.  
It has previously been demonstrated that these rings can remain viable for 2 weeks in 
serum free tissue culture medium (M199) supplemented with Ca and P (Shroff et al., 
2010), this method was used throughout this thesis.  
 
3.1.1 Aim 
1. To establish whether different VDRAs, calcitriol, alfacalcidol and paricalcitol, 
accelerate the progression of vascular calcification in arterial rings isolated from 
children with CKD. 
 
  
84 
 
This will be addressed using the following key questions; 
1. What effect do physiological doses of the VDRAs, calcitriol, alfacalcidol and 
paricalcitol, have on vascular calcification in vessels from children with CKD? 
2. Are there any differences in susceptibility to VDRA-induced vascular calcification 
between vessel rings from pre-dialysis and dialysis patients? 
3. Do any patient related factors affect the response of children’s vessel rings to 
VDRA-induced vascular calcification, including gender, age and primary renal 
diagnosis? 
 
3.2 Methods 
For this study, the inferior epigastric artery was collected from patients listed the methods. 
Vessel rings were cultured in either normal Ca-P medium (normal M199 tissue culture 
medium which contains 1mM P and 1.8mM Ca M199) or high Ca-P medium (M199 with 
added P and Ca to a final concentration of 2mM P and 2.7mM Ca) for 14 days, with the 
medium changed every 3 days. Vessels were exposed to physiological doses (10nM) of 
the different VDRAs, alfacalcidol, calcitriol or paricalcitol. Ethanol was used as the 
vehicle for each VDRA at a final concentration of 3.4mM; therefore 3.4mM ethanol was 
used as the vehicle control for vessels cultured without VDRAs. After 14 days of culture, 
vessel rings were either homogenised and their Ca content quantified by a colorimetric σ-
cresolphthalein assay, or they were fixed in formalin, paraffin embedded for sectioning 
and the Ca content visualised by von Kossa staining as described in the methods chapter. 
All data shown as mean + SE.
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Table 3-1: Vessel rings and the treatment conditions applied. 
Vessel ID format: Year. Age and gender. Unique number. Vessel type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Vessels collected and cultured by Rukshana Shroff in 2007. All analysis and 
histology for these vessels performed by myself, Joanne Laycock.  
 Vessel ID Calcitriol Alfacalcidol Paricalcitol 
P
re
-d
ia
ly
si
s 
07.6M.44.IE*    
07.16F.46.IE*    
07.10M.52.IE*    
07.9M.54.IE*    
13.14M.105.IE    
13.5M.110.IE    
13.8F.111.IE    
13.12F.113.IE    
14.15M.115.IE    
14.11M.118.IE    
14.8F.122.IE    
D
ia
ly
si
s 
07.15F.45.IE*    
07.2M.48.IE*    
07.15F.49.IE*    
07.2M.50.IE*    
07.1M.51.RA*    
07.15F.53.IE*    
13.9M.104.IE    
14.8M.114.IE    
14.17M.116.IE    
14.13M.119.IE    
C
o
n
tr
o
ls
 14.8F.123.ME    
15.2F.127.ME    
15.5M.128.IE    
13.0.5F.109.ME    
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3.3 Ca load in children’s CKD vessels. 
3.3.1 At baseline children’s CKD vessels showed no hydroxyapatite deposition. 
For this study it was important to consider the condition of each vessel prior to culture, 
therefore for each vessel, two rings were obtained on the day the vessel was harvested. 
One ring was analysed for its Ca content by σ-cresolphthalein assay and the other ring 
was formalin fixed for histology, von Kossa staining was performed to show the 
presence of hydroxyapatite deposition.  
The σ-cresolphthalein assay showed a wide range of baseline Ca load both in pre-
dialysis and dialysis vessels, this ranged from 16 to 243 ng/(ng/ul) and 9 to 318 
ng/(ng/ul) respectively. Individual values for vessel Ca load obtained from the σ-
cresolphthalein assay are shown in Table 3-2 and Table 3-3.  
Despite some vessel rings having a high σ-cresolphthalein score at baseline (shown in 
Table 3-2 and Table 3-3), none of the baseline vessel rings were positive for von 
Kossa, examples shown in Figure 3-3. This suggests that quantification of the vessel 
Ca load by σ-cresolphthalein assay is a more sensitive measure of vascular 
calcification than histology for visualising hydroxyapatite deposition.  
3.3.2 Culture of vessel rings in high Ca-P medium increased their Ca load.  
The effect of VDRAs on vascular calcification was considered in both normal Ca-P 
and high Ca-P media which is representative of the high circulating levels of Ca and P 
found in the serum of some CKD patients 
When vessel rings were cultured in normal Ca-P medium, there was no change in Ca 
load relative to baseline. Culture of vessel rings in high Ca-P medium significantly 
increased the Ca load from 134.3+27.3 in normal Ca-P medium to 495.1+73.0 in high 
Ca-P medium (p<0.0001), as shown in Figure 3-1. In some vessel rings from both pre-
dialysis and dialysis patients cultured in high Ca-P medium, calcified regions of the 
tunica media could be identified by von Kossa, examples of this are shown in Figure 
3-3.  
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Figure 3-1: High Ca-P medium induced calcification in CKD children's vessel 
rings.  
Vessel rings harvested from children with CKD were isolated at baseline or cultured 
for 14 days in either normal Ca-P medium (1mM P and 1.8mM Ca M199) or high Ca-
P medium (2mM P and 2.7mM Ca) to induce calcification. Both were in the presence 
of the vehicle 3.4mM ethanol. Ca load in the vessel wall analysed by σ-cresolphthalein 
assay. D'Agostino and Pearson omnibus normality test was performed as a guide to 
analyse the distribution and statistical significance was determined unpaired two-tailed 
t-test.  
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3.4 The effect of VDRAs on Ca load in vessel rings from children with CKD. 
3.4.1 Calcitriol and alfacalcidol, but not paricalcitol, promoted vascular 
calcification in vessel rings isolated from children with CKD.  
The previous section showed that culture of CKD vessel rings in normal Ca-P did not 
affect Ca load, however culture in high Ca-P medium increased their Ca load. The next 
section will show that the three different VDRAs studied affect Ca load to different 
extents. 
The effects of calcitriol, paricalcitol and alfacalcidol on vascular calcification in 
vessels from children with CKD were assessed using this ex-vivo model. Each VDRA 
was used at a final concentration of 10nM, this dose represents normal physiological 
levels of vitamin D in healthy individuals. Vessel rings were cultured for 14 days with 
one of the VDRAs in either normal Ca-P medium or with high Ca-P medium.  
Either with or without any of the VDRAs, increasing the mineral content in the 
medium significantly increased the Ca load in the vessel wall as represented in Figure 
3-2.   
In normal Ca-P medium 10nM calcitriol did not affect Ca load, however in high Ca-P 
medium 10nM calcitriol further increased mean Ca load in the vessel wall (Figure 
3-2A). Despite the increase in mean Ca load observed between high Ca-P medium and 
high Ca-P medium with calcitriol, there was a subset of vessel rings that did not 
respond to calcitriol and showed no change in Ca load relative to high Ca-P only. 
Responders and non-responders to calcitriol were investigated further in Chapter 4. 
10nM Alfacalcidol significantly increased Ca load in the vessel rings cultured in high 
Ca-P medium, however alfacalcidol had no effect on Ca load in normal Ca-P medium; 
Figure 3-2B. The effect of paricalcitol, (a synthetic analogue of calcitriol that is 
thought to be less calcaemic), on calcification in the ex-vivo vessel rings was also 
tested. Paricalcitol had no effect on Ca load in either normal or high Ca-P media 
(Figure 3-2C). 
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Figure 3-2: Ca load in vessel rings from CKD children cultured with VDRAs. 
Vessel rings isolated from children with CKD were cultured in either normal Ca-P 
medium (1mM P and 1.8mM Ca) or high Ca-P medium (2mM P and 2.7mM Ca), as 
well as either the vehicle of 3.4mM ethanol or A) 10nM calcitriol, B) 10nM 
alfacalcidol or C) 10nM paricalcitol. The different y-axis on all 3 graphs accommodate 
the different calcification potentials of the 3 VDRAs. D'Agostino and Pearson omnibus 
normality test was performed as a guide to analyse the distribution and statistical 
significance was determined by A&C) two-tailed Mann Whitney test and B) unpaired 
two-tailed t-test.  
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3.4.2 Ca deposition was specific to the tunica media. 
The data shown above was determined by σ-cresolphthalein assay which quantifies Ca 
load in the vessel wall. Ca deposition in each vessel ring was also visualised by von 
Kossa stain. This demonstrated that Ca deposition was localised to the tunica media, 
as shown in Figure 3-3 E and F. At baseline, all vessel rings were negative for von 
Kossa staining, examples of von Kossa positive and negative rings are shown in Figure 
3-3. 
The von Kossa staining was semi-quantitatively scored as 0, +, ++, +++ or ++++ 
(whilst blinded to the σ-cresolphthalein score) dependent on the estimated percentage 
of tunica media positive for von Kossa, and therefore Ca deposition. Each score was 
assigned a colour and this gives rise to the key in Figure 3-4. 
The Ca load determined by σ-cresolphthalein assay, and its corresponding colour for 
von Kossa positive areas are represented graphically in Figure 3-4. After culture in 
normal Ca-P medium all vessel rings were negative for von Kossa. There was a wide 
range of von Kossa positive densities in vessel rings cultured in high Ca-P medium as 
demonstrated in Figure 3-3. Figure 3-4A shows that, for vessel rings cultured in high 
Ca-P with or without calcitriol, the rings with a higher Ca load tended to have a higher 
von Kossa density and be grouped as ++, +++ or ++++. However, some vessel rings 
with a high Ca load determined by the σ-cresolphthalein assay were negative for von 
Kossa, this suggests that histological analysis of Ca load is not as sensitive as the 
quantitative σ-cresolphthalein assay.   
A summary of all von Kossa scores and Ca load in high Ca-P medium for pre-dialysis 
and dialysis vessels are shown in Table 3-2 and Table 3-3 respectively. 
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Figure 3-3: Von Kossa. 
Vessel rings harvested from children with CKD were isolated at baseline (A&D) or 
cultured for 14 days in high Ca-P medium (2mM P and 2.7mM Ca) to induce 
calcification, in the presence of 3.4mM ethanol (B&E) or calcitriol (C&F). Vessel 
rings were fixed in PFA and paraffin sections von Kossa stained for hydroxyapatite 
deposition (brown) and counterstained by methyl green. A,B,C) Vessel 13.8F.111.IE 
(8 year old female, pre-dialysis). D,E,F) Vessel 14.17M.116.IE (17 year old male, 5 
months haemodialysis). Images taken at 20 x magnification  
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Figure 3-4: Ca load and von Kossa density in vessel rings. 
Vessel rings isolated from children with CKD were cultured for 14 days with either 
3.4mM ethanol or 10nM calcitriol, in either normal Ca-P medium (1mM P and 1.8mM 
Ca) or high Ca-P medium (2mM P and 2.7mM Ca). Vessel rings were harvested and their 
Ca load analysed by σ-cresolphthalein assay and the density of Ca deposition visualised 
by von Kossa stain.  Ca loads were colour coded dependent on the density of the vessels 
von Kossa positive area (black), a representative key is shown above. D'Agostino and 
Pearson omnibus normality test was performed as a guide to analyse the distribution of 
Ca load scores and statistical significance was determined by two-tailed Mann Whitney 
test.  
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Table 3-2: Summary of pre-dialysis children’s Ca load 
Vessel IDs with their corresponding Ca load and von Kossa score in each treatment condition. Ca load (Ca (µg) / protein (µg/µl)) as 
determined by the σ-cresolphthalein assay and von Kossa score determined by the density of von Kossa positive area as shown in the 
key.  
P
re
-d
ia
ly
si
s 
Vessel ID Method  1mM P and 1.8mM Ca 2mM P and 2.7mM Ca 
  Baseline Ethanol Calcitriol Alfacal Parical Ethanol Calcitriol Alfacal Parical 
14.11M.118.IE 
Von kossa 0 0 0   +++ +++   
Ca load 12 25 17   455 430   
14.8F.122.IE 
Von Kossa 0 0 0  0 ++++ +++  ++++ 
Ca load 13 13 87  18 1445 322  2669 
13.12F.113.IE 
Von Kossa 0 0    ++ 0  0 
Ca load 15     556 140  43 
13.14M.105.IE 
Von Kossa 0 0 0  0 0 0  0 
Ca load 16 31 21  23 32 60  61 
14.15M.115.IE 
Von Kossa 0 0    +++ +++  +++ 
Ca load 22 28   39 195 1102  716 
07.16F.46.IE 
Von Kossa 0 0 0 0   0 0  
Ca load 69 147 221 183  756 2197 1184  
07.10M.52.IE 
Von Kossa 0 0 0 0  0 0 0  
Ca load 71 98 301 129  189 1645 679  
07.6M.44.IE 
Von Kossa 0 0 0 0  0 0 0  
Ca load 82 104 487 122  302 2443 977  
13.8F.111.IE 
Von Kossa 0 0 0   0 0  0 
Ca load 106 225 111   666 887  1054 
07.9M.54.IE 
Von Kossa          
Ca load 138 126 273 220  231 1388 704  
13.5M.110.IE 
Von Kossa 0 0    0 0  0 
Ca load 243     711 1191  226 
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Table 3-3: Summary of dialysis children’s Ca load. 
Vessel IDs with their corresponding Ca load and von Kossa score in each treatment condition. Ca load (Ca (µg) / protein (µg/µl)) as 
determined by the σ-cresolphthalein assay and von Kossa score determined by the density of von Kossa positive area as shown in the 
key.  
 
 
 
D
ia
ly
si
s 
Vessel ID Method  1mM P and 1.8mM Ca 2mM P and 2.7mM Ca 
  Baseline Ethanol Calcitriol Alfacal Parical Ethanol Calcitriol Alfacal Parical 
14.17M.116.IE 
Von Kossa 0 0 0  0 +++ +++  +++ 
Ca load 9 15 7  13 517 420  478 
14.13M.119.IE 
Von Kossa 0 0 0  0 ++ ++  ++ 
Ca load 10 28 29  21 571 209  96 
13.9M.104.IE 
Von Kossa 0 0 0  0 + 0  0 
Ca load 21 14 17  21 97 165  175 
14.8M.114.IE 
Von Kossa 0 0 0  0 +++ ++  0 
Ca load 77 130 145  164 1151 198  144 
07.2M.48.IE 
Von kossa 0 0 0 0   0 0  
Ca load 104 168 174 166  289 2984 1308  
07.2M.50.IE 
Von Kossa          
Ca load 113 142 486 164  337 4138 496  
07.1M.51.RA 
Von Kossa 0 0 0 0   0   
Ca load 184 202 223 274  407 2396 1484  
07.15F.53.IE 
Von Kossa 0 0 0       
Ca load 254 416 523 390  567 5794 3622  
07.15F.45.IE 
Von Kossa 0 0 0 0   0 0  
Ca load 312 308 413 389  501 5380 1262  
07.15F.49.IE 
Von Kossa   + 0  +  +  
Ca load 318 332 633 547  423 3582 2017  
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3.4.3 Calcitriol increased Ca load more so than alfacalcidol in CKD children’s 
vessel rings. 
Having established that calcitriol and alfacalcidol, but not paricalcitol significantly 
increased Ca load in ex-vivo vessel rings from CKD children cultured in high Ca-P media. 
The length of vessels obtained was insufficient to study all 3 VDRAs in the same patient, 
however in the next section the relative effects of either alfacalcidol or paricalcitol were 
compared to the effect of calcitriol on Ca load in vessel rings from the same patients. 
Figure 3-5 compares the Ca load between vessel rings from the same patient treated with 
calcitriol and either alfacalcidol or paricalcitol. In normal Ca-P medium there was no 
difference in the Ca load between vessel rings treated with alfacalcidol and calcitriol. In 
high Ca-P medium calcitriol induced significantly more calcification than alfacalcidol. 
The Ca load in vessel rings treated with paricalcitol was not significantly different to 
calcitriol in either normal or high Ca-P media. Variable responses to paricalcitol were 
observed in high Ca-P medium with paricalcitol increasing Ca load in 4/10 vessels and 
decreasing or not effecting Ca load in 6/10 vessels. 
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Figure 3-5: Comparison of Ca load in CKD children’s vessel rings treated with 
different VDRAs. 
Vessel rings isolated from children with CKD were cultured in both normal Ca-P medium 
(1mM P and 1.8mM Ca) and high Ca-P medium (2mM P and 2.7mM Ca), as well as either 
A) 10nM calcitriol and 10nM alfacalcidol, or B) 10nM calcitriol and 10nM paricalcitol. 
After 14 days vessel rings were harvested and analysed by σ-cresolphthalein assay for Ca 
load. Ca load in vessel rings from the same patient treated in different conditions are linked 
by lines. D'Agostino and Pearson omnibus normality test was performed as a guide to 
analyse the distribution and statistical significance was determined by A) unpaired two-
tailed t-test. 
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3.4.4 There was positive correlation between the vessel’s Ca load at baseline and 
after culture in high Ca-P medium with calcitriol. 
There was a wide range of baseline Ca load in the vessel rings from 9 to 318 µg/ (µg/µl), 
this suggests a high variance in susceptibility to calcification between patients. To 
determine if baseline Ca load could be used as a predictor of the patient’s Ca load after 
treatment with any of the VDRAs in high Ca-P their correlation was considered. 
As shown in Figure 3-6A there was a strong positive correlation between Ca load at 
baseline and after treatment in high Ca-P medium with calcitriol (Spearman r = 0.76, 
P<0.0001). There was no significant correlation between baseline Ca load and the Ca load 
in vessel rings cultured in high Ca-P medium only, with alfacalcidol or with paricalcitol. 
Therefore, in the presence of pre-existing vessel calcification calcitriol, but not the other 
VDRAs, induces significantly greater calcification. 
There was no correlation between Ca load in vessel rings cultured in high Ca-P medium 
only to Ca load after culture in high Ca-P medium with calcitriol, alfacalcidol or 
paricalcitol (data not shown). Therefore, high Ca load in response to high Ca-P medium 
does not indicate that there will be a greater Ca load in that vessel in response to any of 
the VDRAs. This suggests that increase in Ca load in response to VDRAs may be driven 
by mechanisms other than Ca-P deposition alone.  
It was considered whether vessel ring Ca load in response to treatment with calcitriol in 
high Ca-P was a predictor of Ca load in response to treatment with other VDRAs. Figure 
3-7 shows that there was no significant correlation in Ca load after treatment in high Ca-
P medium with calcitriol and alfacalcidol. The Spearman correlation coefficient showed 
that there was significant positive correlation (RS=0.72 P=0.02) between the Ca load in 
vessel rings after treatment with calcitriol and paricalcitol in high Ca-P. This suggests that 
paricalcitol affects calcification via a similar mechanism as calcitriol whereas alfacalcidol 
acts via a different mechanism.  
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Figure 3-6: Correlation between Ca load in vessel rings at baseline and cultured in 
high Ca-P medium with different VDRAs.  
Vessel rings isolated from children with CKD were taken at baseline and cultured in high 
Ca-P medium (M199 with 2mM P and 2.7mM Ca) with A) vehicle ethanol, B) calcitriol, 
C) alfacalcidol or D) paricalcitol. After 14 days Ca load was analysed by σ-cresolphthalein 
assay and correlation to Ca load at baseline determined. D'Agostino and Pearson omnibus 
normality test was performed as a guide to analyse the distribution. The correlation was 
determined by calculating A, C and D) the Pearson correlation coefficient or B) the 
Spearman correlation coefficient and their statistical significance determined by two-
tailed P values. 
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Figure 3-7: Correlation between Ca load in vessel rings cultured in high Ca-P 
medium with different VDRAs. 
Vessel rings isolated from children with CKD were cultured in high Ca-P medium (M199 
with 2mM P and 2.7mM Ca), as well as calcitriol and either A) alfacalcidol or B) 
paricalcitol. After 14 days vessel rings were harvested and their Ca load analysed by σ-
cresolphthalein assay. D'Agostino and Pearson omnibus normality test was performed as 
a guide to analyse the distribution. The correlation and its statistical significance were 
determined by calculating the Spearman correlation coefficient and two-tailed P values. 
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3.5 There was no difference in Ca load between vessel rings from pre-dialysis and 
dialysis patients. 
Vessels were collected at the time of renal transplant from patients who were either in pre-
dialysis CKD or on dialysis. Pre-dialysis patients were in CKD stage 5 and do not require 
renal replacement therapy. Dialysis patients received renal replacement therapy in the 
form of either heamodialysis or peritoneal dialysis. Dialysis is thought to have detrimental 
effects on the vasculature, as it can replace only a fraction of normal renal function, and 
may per se induce inflammation and haemodynamic stresses. Therefore, it was important 
to consider whether vessel rings from dialysis patients differed to pre-dialysis patients in 
their Ca load at baseline, in response to high Ca-P conditions and in response to different 
VDRAs.  
 
3.5.1 There was no difference in Ca load in pre-dialysis and dialysis vessels at 
baseline or after culture. 
Initially Ca load in pre-dialysis and dialysis vessel rings were compared at baseline and 
after culture in normal Ca-P as well as in high Ca-P media. As shown in Figure 3-8, there 
was no difference in the vessel Ca load between pre-dialysis and dialysis vessel rings at 
baseline or after culture in normal or high Ca-P medium.  
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Figure 3-8: Ca load in pre-dialysis and dialysis vessel rings. 
Vessel rings were isolated from either pre-dialysis or dialysis CKD children, rings were 
either taken at baseline or cultured for 14 days in either normal Ca-P medium (M199 with 
1mM P and 1.8mM Ca) or high Ca-P medium (M199 with 2mM P and 2.7mM Ca) to 
induce calcification. Both were in the presence of 3.4mM ethanol, which will be used as 
the vehicle in this project. Ca load in the vessel wall analysed by σ-cresolphthalein assay. 
D'Agostino and Pearson omnibus normality test was performed as a guide to analyse the 
distribution and statistical significance was determined by unpaired two-tailed t-test. 
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3.5.2 VDRAs affected Ca load in pre-dialysis and dialysis vessel rings to the same 
extent. 
The previous section described experiments that showed that calcitriol and alfacalcidol 
both increase Ca load in CKD vessel rings. 
Next, it was considered whether any of the VDRAs had a greater effect on the Ca load in 
vessel rings from dialysis than pre-dialysis patients. In vessel rings treated with calcitriol 
and alfacalcidol (Figure 3-9 A and B), there was a trend for a higher Ca load in dialysis 
than pre-dialysis vessel rings in both normal Ca-P as well as high Ca-P media. There was 
a significant increase in Ca load in both pre-dialysis and dialysis vessel rings treated with 
either calcitriol or alfacalcidol when the mineral content was increased from normal to 
high Ca-P media (Figure 3-9A and B). Vessel rings from dialysis patients treated with 
paricalcitol in high Ca-P medium tended to have a lower Ca load (not significant) than 
pre-dialysis vessel rings; shown in Figure 3-9 C. In both pre-dialysis and dialysis vessel 
rings treated with calcitriol in high Ca-P medium each had a group of vessel rings that 
responded to calcitriol with an increased Ca load and a group that showed no response to 
change in Ca load with calcitriol treatment, possible causes for these differences are 
discussed in Chapter 4.  
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Figure 3-9: Comparison of the effect of VDRAs on Ca load in vessel rings from pre-
dialysis and dialysis patients.  
Vessel rings were isolated from either pre-dialysis or dialysis CKD children and cultured 
for 14 days in either normal Ca-P medium (M199 with 1mM P and 1.8mM Ca) or high 
Ca-P medium (M199 with 2mM P and 2.7mM Ca) to induce calcification. Vessel rings 
were treated with A) 10nM calcitriol, B) 10nM alfacalcidol or C) 10nM paricalcitol. Ca 
load in the vessel wall analysed by σ-cresolphthalein assay. D'Agostino and Pearson 
omnibus normality test was performed as a guide to analyse the distribution and statistical 
significance was determined by; A) two-tailed Mann Whitney test and B and C) two-tailed 
t-test. 
  
104 
 
3.5.3 The type of and length of time on dialysis did not affect Ca load in vessel 
rings. 
Both pre-dialysis and the dialysis patient groups had a large variation in Ca load with in 
each condition. The effect of dialysis on Ca load in each treatment condition was analysed 
further taking into consideration type of and time on dialysis. There was no significant 
difference between the Ca load in vessel rings from patients on haemodialysis and 
peritoneal dialysis at baseline or cultured in any of the treatment conditions with different 
VDRAs (data not shown). 
There was no significant correlation between baseline Ca and time on dialysis, as 
determined by Pearsons correlation coefficient R=0.60 and P=0.065. In addition, there 
was no significant correlation between time on dialysis and Ca load; after treatment in 
high Ca-P medium only, with calcitriol, alfacalcidol or paricalcitol. 
The type of and time on dialysis did not affect Ca load in response to VDRAs. As there 
were two distinct groups; those that responded and those that did not respond to calcitriol 
treatment with an increased Ca load, it were investigated whether other patient variables 
including gender, age and underlying renal diagnosis affected the Ca load in response to 
treatment.  
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3.6 The effect of other patient related factors on Ca load. 
3.6.1 Ca load was higher in vessel rings from females than males. 
This study included vessel rings from both male and female CKD patients therefore it was 
important to consider whether gender affects Ca load in the vessel wall. In this group of 
patient’s, females tended to have a higher Ca load than males at baseline. As shown in 
Figure 3-10A, mean Ca load was significantly higher in females than males after 2 weeks 
of culture in either normal or high Ca-P media.  
Next, the effect of different VDRAs in males and females were considered. Figure 3-10B, 
C and D show that the trend for a higher Ca load in females compared to males persisted 
after treatment with each of the VDRAs, calcitriol, paricalcitol and alfacalcidol. Ca load 
in females was significantly greater than males after culture for 14 days in normal medium 
with alfacalcidol. 
There was no difference between the male and female groups in their underlying kidney 
disease or dialysis status including length of time on and type of dialysis, however there 
was a trend for females to be older than males, data shown in the appendix Figure-10-1 
(NS p=0.07). Males ranged from 1 to 17 years with a mean of 8.6+1.4 years whereas 
females ranged from 8 to 16 years with a mean of 12.7+1.3 years. 
The females in this study tended to be older and had a higher Ca load in each treatment 
condition than males; therefore, it was tested whether age was a predictor of Ca load in 
the vessels from children with CKD. Linear regression analysis showed that age was not 
a predictor of baseline Ca load or Ca load in vessel rings cultured in high Ca-P medium 
only, with calcitriol, alfacalcidol or paricalcitol (data not shown). 
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Figure 3-10: Ca load in vessel rings from male and female CKD patients. 
Vessel rings were isolated from male and female CKD children and the Ca load in the 
vessel walls were analysed by σ-cresolphthalein assay. A) At baseline and after culture 
for 14 days in either normal Ca-P medium (M199 with 1mM P and 1.8mM Ca) or high 
Ca-P medium (M199 with 2mM P and 2.7mM Ca) to induce calcification. In addition, 
rings were cultured in normal and high Ca-P media with B) calcitriol, C) alfacalcidol and 
D) paricalcitol. D'Agostino and Pearson omnibus normality test was performed as a guide 
to analyse the distribution and statistical significance was determined by; A, C, D) two-
tailed t-test, and B) Mann Whitney test. 
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3.6.2 Primary renal diagnosis did not affect Ca load in the vessel rings. 
All children with CKD were eligible for this study, CKD includes many forms of renal 
disease that lead to a chronic loss in renal function, and therefore it was important to 
consider the effect of primary renal diagnosis on Ca load in the vessel rings. Patients were 
grouped as having CAKUT (congenital anomalies of the kidney and urinary tract), 
glomerulopathy or other. One-way ANOVA tests showed that there was no significant 
difference between the groups in the Ca load at baseline or after culture in high Ca-P 
medium with any of the VDRAs (data shown in appendix Figure -10-2).  
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3.7 Control vessels 
3.7.1 Harvesting control vessels 
It was important to compare Ca load in CKD vessels to healthy non-renal control patients 
both at baseline and in response to culture in high Ca-P with and without different VDRAs. 
Age matched control vessels were obtained from non-renal patients who had no 
inflammatory complications and were undergoing routine abdominal surgery at Great 
Ormond Street Hospital. The inferior epigastric artery obtained from CKD patients is a 
medium sized muscular artery, ideally this same vessel would be obtained from control 
vessels for comparison, however, vessel collection is limited to those that can be easily 
accessed during surgery and are dispensable without any risk to the child. The inferior 
epigastric artery can be accessed only via some surgical approaches, so for this study only 
one inferior epigastric artery was harvested from a control patient for ex-vivo analysis. As 
alternative, medium sized muscular arteries from a different vascular bed were obtained. 
The mesentery, which is easily accessible during routine abdominal surgery, were 
harvested and the mesenteric arteries dissected out. Control vessels used in this study are 
shown in Table 3-1 and the patient information is shown in the methods. 
 
3.7.2 Ca load in control vessel rings 
Similar to CKD vessels, in control vessel rings increasing mineral content from normal to 
high Ca-P significantly increased Ca load as shown in Figure 3-11. Calcitriol had no effect 
on Ca load in control vessels in either normal or high Ca-P media, this differs to CKD 
vessel rings that had an increased Ca load in response to calcitriol.  
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Figure 3-11: Ca load in control vessel rings. 
Vessel rings isolated from healthy control children were cultured in either normal Ca-P 
medium (1mM P and 1.8mM Ca) or high Ca-P medium (2mM P and 2.7mM Ca), as well 
as either the vehicle of 3.4mM ethanol or 10nM calcitriol. Statistical significance was 
determined by unpaired two-tailed t-test.  
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3.8 Discussion 
3.8.1 Summary 
Data in this chapter established that the different VDRAs, calcitriol, alfacalcidol and 
paricalcitol, have different effects on accelerating the progression of vascular calcification 
in arterial rings isolated from children with CKD. 
The key findings of this chapter were: 
1. Calcitriol, and to a lesser extent alfacalcidol increased Ca load in vessel rings from 
children with CKD. Whereas paricalcitol had no effect on Ca load in vessel rings. 
Vessel rings treated with calcitriol formed two groups, responders whose Ca load 
increased and non-responders whose Ca load did not change.  
2. Vessel rings from pre-dialysis and dialysis patients were equally susceptible to 
VDRA-induced vascular calcification. 
3. Susceptibility to VDRA-induced vascular calcification in children’s vessel rings 
was independent of age, gender, dialysis vintage and primary renal diagnosis. Ca 
load was higher in females then males in both normal and high Ca-P without 
VDRA treatment. 
 
3.8.2 Vessel Histology 
Histological analysis by haematoxylin and eosin of each arterial vessel ring at baseline 
showed that the paediatric vessels studied here were free from atherosclerosis, furthermore 
von Kossa staining showed no evidence of intimal calcification. Calcification in cultured 
vessel rings occurred in the tunica media layer, indicative of Monckberg’s sclerosis which 
is associated with CKD. However, von Kossa staining showed that there was no evidence 
  
111 
 
of Ca or hydroxyapatite deposition at baseline in any of the vessel rings despite some 
having high Ca loads quantified by the σ-cresolphthalein assay. This coincides with data 
collected previously in our group where vessels from children with CKD had high Ca 
loads at baseline, yet 0% of the pre-dialysis and only 25% of the dialysis vessels had 
diffuse speckled calcification in the tunica-media detected by von Kossa. Both data 
suggest that Ca accumulation occurs before calcification can be detected by von Kossa. 
 
3.8.3 Von Kossa Vs σ-cresolphthalein assay 
The summarised Ca loads in pre-dialysis (Table 3-2) and dialysis vessel rings (Table 3-3) 
show the Ca load in arterial rings after treatment. Rings with the highest Ca load quantified 
by σ-cresolphthalein tended to have von Kossa positive areas within the tunica media, 
with no evidence of intimal calcification in any vessels. However, some arterial rings 
showed no von Kossa positivity in any treatment condition regardless of the high Ca load 
determined by σ-cresolphthalein assay. Discrepancies between Ca load determined by σ-
cresolphthalein assay and by von Kossa analysis are likely to arise as analysis is performed 
on a single neighbouring ring for each methodology, unfortunately it is not possible to 
apply both techniques to the same ring and there was insufficient tissue for repeated 
analysis. Furthermore, there is the technical limitation of von Kossa positivity being 
determined from a single 7µm vessel ring section, the lateral or central location of this 
section within the 1mm vessel ring may affect its degree of exposure to treatment 
conditions. 
Both methods have their advantages, von Kossa staining enables the regional deposition 
of Ca to be analysed whereas the σ-cresolphthalein assay is unable to distinguish between 
medial and intimal calcification.  However, von Kossa staining is not a sensitive method 
to identify or quantify calcium load, our previous work showed that von Kossa positivity 
in only 25% of vessels that exhibited the highest Ca load (Shroff et al., 2008b). The σ-
cresolphthalein assay is a sensitive assay that is highly accurate, as described by (Zak et 
al., 1975) it involves a direct reaction between Ca and the σ-cresolphthalein complex 
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therefore there is minimal risk of contamination. The data in this chapter focuses on 
quantification of the Ca load from each arterial ring by the σ-cresolphthalein assay. The 
accompanied histological analysis of Ca deposition in the vessel rings was important to 
show the localisation of hydroxyapatite deposition, in each case this was specific to the 
tunica media and is representative of Monckberg’s sclerosis associated with CKD (Lanzer 
et al., 2014).  
 
3.8.4 VDRAs had differential effects on vascular calcification in children’s vessel 
rings. 
The effect of 10nM calcitriol on the Ca load in vessel rings split the vessel rings into two 
populations; responders and non-responders, this is observed in Figure 3-2A. Responders 
to calcitriol showed an increase in Ca load in high Ca-P with calcitriol, whereas the Ca 
load in non-responders remained below 600 µg/(µg/µl) and was comparable to that of 
rings cultured in high Ca-P. Previous literature is confounding, for example (Guerrero et 
al., 2012) showed that 10nM calcitriol had no effect on calcification in either the thoracic 
aorta from Westar rats or in human VSMCs, whereas (Martinez-Moreno et al., 2012) 
found that 10nM calcitriol increased Ca load in human VSMCs.    
The data in this chapter suggests that there is variation between individual vessels in their 
susceptibility to calcitriol induced calcification, this could account for the varied results 
observed in the current literature. Experiments to determine the possible mechanisms for 
this differential response between individuals were described in Chapter 4. This will 
include the effect of calcitriol on responder and non-responder vessel ALP activity, 
expression of proteins involved in osteoblast conversion and expression of the vitamin D 
inactivating enzyme 24 hydroxylase. To further investigate individual patient responses 
to vitamin D, Chapter 6 examines the expression of the vitamin D receptor in both vessel 
rings and explanted VSMCs.  
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Paricalcitol had no effect on Ca load in the vessel rings whereas calcitriol increased Ca 
load as shown in Figure 3-2. Never the less comparison of vessels treated with both 
calcitriol and paricalcitol as shown in Figure 3-5B found that there was no difference in 
the effect of calcitriol and paricalcitol in high Ca-P medium on Ca load in the vessel rings. 
In addition, there was a positive correlation (RS=0.73, P=0.02) between the Ca loads in 
vessel rings subject to these treatment conditions (Figure 3-7B). In contrast current 
literature showed that in-vitro 30nM paricalcitol but not calcitriol had a protective effect 
on calcification in rat aortic rings and human VSMCs by reducing inflammatory cytokines 
(Guerrero et al., 2012). Paricalcitol also reduced expression of BMP2 and other osteoblast 
markers in human VSMCs in high P medium whereas calcitriol further increased their 
expression (Martinez-Moreno et al., 2012). 
The Ca load after treatment with alfacalcidol in high Ca-P medium did not correlate 
significantly to the Ca load after treatment with calcitriol (Figure 3-7A). In addition, the 
Ca load was significantly lower with alfalcalcidol than with calcitriol in high Ca-P 
medium as shown in Figure 3-5A. Alfacalcidol is thought to be less calcaemic than other 
VDRAs, for example in a randomised crossover study (Hansen et al., 2014) found that 
alfacalcidol but not paricalcitol significantly increased the expression of the calcification 
inhibitor Fetuin A, this is a circulating inhibitor therefore its expression would not affect 
calcification in the isolated vessel ring model. All children were treated with alfacalcidol, 
therefore all vessels would have had exposure to alfacalcidol in-vivo. 
The data presented here suggests that calcitriol and paricalcitol may be acting on vascular 
calcification via similar mechanisms, whereas alfacalcidol could be acting via an 
alternative mechanism. The mechanism of action of different VDRAs on calcification, for 
example their effect on the activity of the osteoblast related enzyme ALP will be explored 
further in both the arterial vessel rings (Chapter 4) and in VSMCs (Chapter 5).  
Calcitriol and paricalcitol are both active forms of vitamin D3, respectively they are the 
naturally occurring 1α, 25 dihydroxyvitamin D3 and the synthetic analogue 19 nor 1α, 25 
dihydroxyvitamin D2 developed for its reduced calcaemic effect on the intestine. 
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Alfacalcidol on the other hand, is an inactive form of vitamin D, 1α hydroxyvitamin D3 
as discussed in the introduction. 
Alfacalcidol requires autocrine activation by 25 hydroxylase in the isolated vessel rings. 
In Chapter 4 it was shown that 25 hydroxylase is locally expressed in VSMCs therefore 
alfacalcidol can be activated in isolated vessel rings, however the expression and activity 
of the 25 hydroxylase enzyme may be a regulatory, limiting factor for alfacalcidol. 
Alfacalcidol is routinely prescribed to children with CKD in Europe, and therefore its 
effect on calcification in cultured ex-vivo vessel rings from this cohort is of great interest. 
The mechanisms of action by which different VDRAs affect vascular calcification in 
vessel rings and the distinctly different effects of calcitriol on vessel rings are explored in 
chapter 4. 
 
3.8.5 There was no difference in susceptibility to VDRA-induced vascular 
calcification between vessel rings from pre-dialysis and dialysis patients. 
Data collected here suggests that there is no difference between the Ca load in vessel rings 
from pre-dialysis CKD stage 5 and dialysis patients, neither at baseline, after culture in 
normal or high Ca-P media (Figure 3-8). In addition, there was no significant difference 
between the Ca load in dialysis and pre-dialysis vessel rings after treatment with any of 
the VDRAs. This differs from previous findings where dialysis vessels had a higher 
baseline Ca load than pre-dialysis vessels (Shroff et al., 2008b) (Todd et al., 2015). In this 
chapter, a trend was observed of a higher Ca load in dialysis vessels than pre-dialysis after 
treatment with calcitriol or alfacalcidol however this was not significant. Interestingly, 
both pre-dialysis and dialysis vessel rings treated with calcitriol have responders and non-
responders shown in Figure 3-9. 
In addition, the data presented here showed no difference between susceptibility to 
calcification between haemodialysis and peritoneal dialysis patients. This differs to 
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(Srivaths et al., 2014) who found in a cohort of paediatric patient’s cardiac calcifications 
were more prevalent in haemodialysis (9/21) than peritoneal dialysis (2/17) patients. This 
study’s focus is cardiac rather than vascular calcification, which could account for the 
differences observed. Both studies have low patient numbers and a higher sample number 
is required to determine any difference in calcification prevalence between the modes of 
dialysis. 
Interestingly the average age in females (12.7+1.3) tended to be greater than males 
(8.6+1.4) (NS), this coincided with a tendency for a greater Ca load in females than males 
in each of the conditions. The Ca load was significantly greater in vessel rings from 
females than males cultured in normal or high Ca-P media as well as normal Ca-P medium 
with alfacalcidol. A Doppler ultrasound was used to analyse vascular compliance in 600 
volunteers aged 3 days to 65 years, they found vascular compliance increased rapidly in 
the first decade and declined rapidly in the 2nd decade before reaching a steady decline 
into later life (Laogun and Gosling, 1982). Vascular compliance therefore susceptibility 
to calcification may decline in the first decade and increase again in the 2nd decade 
(Toussaint and Kerr, 2007). Similarly, in the male cohort (IQR 4.3–13.3 years), a 
significant negative correlation between age and Ca load was observed, whereas in the 
older female cohort (IQR 8-15 years) there was a trend (NS) for a positive correlation 
between age and Ca load. Together this suggests the possibility that the changes in 
vascular compliance with age during the paediatric years could be closely linked to their 
susceptibility to vascular calcification observed here in ex-vivo culture (Doyon et al., 
2013). To confirm whether the different trends observed between Ca loads in males and 
females are a consequence of gender difference or the staggered age range within these 
cohorts it would be of interest to study vessels from more male and female children of 
closely matched age.  
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3.8.6 Control Vessels 
Previous data from our lab showed that dialysis vessels but not control vessels calcified 
after exposure to either high P or high Ca-P media (Shroff et al., 2010) (Todd et al., 2015), 
whereas the data presented here indicates that both control and dialysis vessels calcify on 
exposure to high Ca-P medium. A number of factors may have contributed to calcification 
of the control vessels in this study including the toxicity of the vehicle ethanol and the 
vascular bed from which controls were obtained. 
A key difference between this study and previous ones is that in this study, the high Ca-P 
medium which increased Ca load, also contained 3.4mM ethanol. Ethanol is known to be 
toxic to cells, for example in Saos -2 cells, doses of ethanol from 1mM to 300mM reduced 
cell proliferation and affected mineralisation (Vignesh et al., 2006). 
There are a limited number of control vessels available from routine abdominal surgery, 
unfortunately these tend to be from a different vascular bed to the CKD vessels. The 
mesenteric arteries dissected from control patients may have different susceptibility to 
calcification than the inferior epigastric. Arterial calcification was induced in a rat model, 
interestingly the mesenteric arteries had more calcification than any other vascular bed 
identified by a striking uptake of 3 different radiotracers used to identify calcification by 
CT scan (Bordoloi et al., 2015). This suggests that mesenteric vessels may have increased 
susceptibility to calcification relative to other vascular beds and demonstrates the 
importance of obtaining inferior epigastric arteries from the non-renal controls for 
comparison. Furthermore, at least one control child (13.0.5F.109.ME) is known to have 
had previous operations in the same abdominal area, their vessels may have been 
structurally damaged during this process predisposing the vessel to calcification when 
exposed to the high Ca-P ex-vivo. 
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3.8.7 Limitations 
The work in this chapter was conducted on whole vessel rings from children with CKD, 
as discussed in the introduction, this is an extremely valuable and clinically relevant model 
for studying the effects of VDRAs. Human vessels are a scarce resource, therefore the 
vessel numbers in this chapter are limited by the number of transplant operations 
performed and the number of consenting patients that fit the eligibility criteria. The length 
of the vessel obtained determined how many 1mm vessel rings were dissected from it for 
treatment in different conditions. It was not possible to obtain enough rings from the same 
vessel to compare all three VDRAs (calcitriol, alfacalcidol and paricalcitol) at the same 
time, therefore the effects of alfacalcidol and paricalcitol were not compared. In each 
vessel the effects of calcitriol were compared to the vehicle control (ethanol) and where 
possible either alfacalcidol or paricalcitol. Calcitriol is the natural active form of vitamin 
D3 therefore an important reference point with which to compare other VDRAs. 
The experiments in this chapter consider the effects of different VDRAs at a concentration 
of 10nM, this is equivalent to the physiological level therefore is the most clinically 
relevant concentration. In previous literature the effect of VDRAs on calcification, has 
been shown to be dose dependent therefore the ideal would be to compare a range of 
concentrations, for example from a sub physiological dose of 1nM to a supra physiological 
dose of 100nM. The limited vessel availability restricted the study to consider the effects 
of physiological dose VDRAs only in the vessel rings. 
Ideally, multiple experimental repeats would be performed on each vessel to show that the 
data was reproducible for each patient’s vessel rings, unfortunately this was not possible 
with the limited length of the vessels obtained. In addition, the tissue size was insufficient 
to extract RNA, as vitamin D is a known transcriptional regulator of multiple genes it is 
important to investigate its effect on mRNA expression of genes contributing to 
mineralisation. As there were many more avenues to explore and human vessels are a very 
valuable but limited resource it was essential to maximise their utilisation, therefore 
VSMCs were explanted from the human vessels. This enabled a wider range of 
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experimental conditions and techniques to be applied and is discussed in chapters 5 and 
6.     
All children were treated with alfacalcidol at the time of harvesting their vessels. This may 
have some influence on their response to ex-vivo exposure to VDRAs, such as by 
upregulating the VDR after prolonged exposure to vitamin D therapy. Effects of VDRAs 
on expression of the VDR in vessel rings and VSMCs is discussed in chapter 6. 
Throughout these studies ethanol was used as a vehicle, this was necessary as VDRAs are 
only partly soluble in some alcohols. All 3 VDRAs were solubilised in ethanol to the same 
final concentration of 3.4mM regardless of the final VDRA concentration. For cell culture, 
ethanol is recommended as the vehicle. In human VSMCs cultured in high inorganic P, 
only concentrations of ethanol ≥60mM significantly increased expression of Runx2 and 
osteocalcin as well as upregulating ALP activity (Oros et al., 2012). These mechanisms 
contributed to an increased calcium deposition in VSMCs exposed to ≥60mM ethanol 
(Oros et al., 2012).  In this study, it was important to use ethanol as a vehicle for the 
VDRAs at a concentration that would not influence calcification, and therefore the final 
concentration of ethanol was 3.4mM, considerably below the range shown to affect 
calcium deposition. Culture of vessel rings in normal Ca-P medium with 3.4mM ethanol 
as a vehicle control had no effect on Ca load relative to baseline, the mean + SE was 134.3 
+ 27.3 in comparison to 104.3 + 22.1 at baseline. However, the effect of ethanol on Ca 
load in high Ca-P medium has not been studied relative to high Ca-P medium only, in 
future studies an important additional control would be high Ca-P only.  
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Chapter 4 By what mechanisms do VDRAs induce vascular 
calcification in children’s vessel rings? 
4.1 Introduction 
The previous chapter showed that each of the VDRAs, calcitriol, paricalcitol and 
alfacalcidol elicited a different pattern of effects on calcification in the vessel rings. This 
indicates that each VDRA may act on vascular calcification via a different mechanism or 
combination of mechanisms. 
Paricalcitol had no significant effect on Ca load in the vessel rings therefore its mechanism 
of action on calcification will not be investigated further. 
Alfacalcidol consistently increased Ca load in the vessel rings, however to a lesser extent 
than calcitriol. To understand the causative mechanisms of both calcitriol and alfacalcidol 
on calcification, here I compare the effect of both these VDRAs in two of the highly 
regulated processes of calcification discussed in the introduction, cell viability and the 
activity of osteoblast enzyme ALP which is a marker of osteogenic conversion.  
In Chapter 3, the Ca load of children’s vessels treated with calcitriol separated them into 
two distinct populations, non-responders and responders. In high Ca-P medium, calcitriol 
had no effect on Ca load in 8 children’s vessels (non-responders), whereas it considerably 
increased calcification in the other 13 children’s vessels (responders). The mechanistic 
basis of these two different responses is not yet understood. This chapter will explore the 
expression profiles of SMC and osteoblast markers in non-responder and responder 
vessels to determine any differences in osteogenic conversion. In addition, the expression 
of 24 hydroxylase, a downstream target of vitamin D that is also involved in vitamin D 
inactivation will be investigated to determine any difference between non-responders and 
responders’ ability to upregulate the expression of vitamin D target genes. 
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4.1.1 Aims 
1. To determine whether VDRAs alfacalcidol and calcitriol act via different 
mechanisms to promote vascular calcification in vessel rings from children with 
CKD.  
2. To elucidate the different expression profiles in vessel rings that have an increased 
Ca load in response to calcitriol (responders) and vessel rings whose Ca load does 
not respond to calcitriol (non-responders). 
These will be addressed using the following key questions; 
1. Can alfacalcidol be activated locally in VSMCs? 
2. Do alfacalcidol or calcitriol affect ALP activity in vessel rings? 
3. Do alfacalcidol or calcitriol affect the cell viability of VSMCs in vessel rings? 
4. Are markers of osteogenic conversion at baseline or after calcitriol treatment 
different in responders and non-responders? 
5. Do responders and non-responders differ in their expression of 24 hydroxylase, a 
downstream target of vitamin D? 
 
4.2 Method 
To determine the expression of vitamin D activation enzymes in VSMCs, VSMCs were 
explanted from children’s vessel rings. RNA was harvested from the VSMCs and 
expression of CYP27A1 and CYP27B1 determined by qPCR analysis. In this experiment 
VSMCs explanted from both dialysis patients and control patients were used, the VSMC 
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ID for explants utilised are shown on the axis and the relevant patient information is in 
the Methods. 
To investigate the mechanistic effects of calcitriol and alfacalcidol on vascular 
calcification in vessels of children with CKD, vessel rings were taken at baseline and 
cultured in both normal Ca-P medium (1mM Ca and 1.8mM P) and high Ca-P media 
(2mM Ca and 2.7mM P) with either the vehicle of 3.4mM ethanol, 10nM calcitriol or 
10nM alfacalcidol. After 14 days of culture, 1 vessel ring per condition was homogenised 
and their ALP activity quantified by a colorimetric assay. All data shown as mean + SE. 
The other vessel ring was fixed in formalin, paraffin embedded for sectioning and stained. 
Staining included haematoxylin and eosin (H and E) for VSMC cell counts and 
immunostaining of SMA, Runx2, ALP as well as 24 hydroxylase. Vessels utilised in each 
experiment are shown in Table 4-1 and the corresponding patient information is shown in 
Methods. 
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Table 4-1: Vessels utilised in each experiment.  
Patients’ vessels utilised in the viability assay, ALP activity assay and comparison of 
responder and non-responder vessel rings including immunohistochemistry staining of 
SMA, Runx2, ALP and 24 hydroxylase. R – Responder. NR – Non-responder. 
Vessel ID format: Year. Age and gender. Unique number. Vessel type. 
 
 Vessel ID Viability ALP 
Responders Vs 
Non-Responders 
P
re
-d
ia
ly
si
s 
07.6M.44.IE*    (R) 
07.16F.46.IE*    (R) 
07.10M.52.IE*    
07.9M.54.IE*    
13.14M.105.IE    (N-R) 
13.5M.110.IE    (R) 
14.15M.115.IE    
14.8F.122.IE    
D
ia
ly
si
s 
07.15F.45.IE*    
07.2M.48.IE*    
07.15F.49.IE*    
07.2M.50.IE*    
07.1M.51.RA    
14.8M.114.IE    (N-R) 
14.13M.119.IE    (N-R) 
 
*Vessels collected and cultured by Rukshana Shroff in 2007. All analysis and histology 
for these vessels performed by myself, Joanne Laycock. 
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4.3 Differential effects of calcitriol and alfacalcidol on vascular calcification. 
It was shown in Chapter 3, using a model of intact vessel rings from children with CKD 
cultured in high Ca-P medium that both alfacalcidol and calcitriol increased Ca load. The 
Ca load was significantly higher in vessel rings treated with calcitriol than with 
alfacalcidol. In this section the potential mechanisms for the differential effects of 
calcitriol and alfacalcidol were explored, this included expression of alfacalcidol 
activation enzymes, effects on cell viability and effects on ALP expression.   
 
 
4.3.1 VSMCs express 25 hydroxylase for the activation of alfacalcidol. 
As discussed in the introduction inactive vitamin D requires 2 hydroxylation enzymes for 
its activation. 1α hydroxylase which is mainly expressed in the kidney and is encoded by 
the CYP27B1 gene, and 25 hydroxylase which is encoded by both the CYP2R1 and the 
CYP27A1 genes and is mainly produced by the liver. However, many organ systems in 
the body produce low levels of both of the activation enzymes for autocrine / paracrine 
function. 
VDRAs can either be administered in their active di-hydroxylated form (1,25(OH)2D) or 
in their inactive form requiring hydroxylation to activate them. Calcitriol is the natural 
active form of vitamin D, whereas alfacalcidol (1α-OHD) is inactive and requires 25 
hydroxylase for its activation as described in the introduction. 
It was important to determine if 25 hydroxylase was expressed in the vessel rings to enable 
alfacalcidol to be activated hence function in its active form. MRNA expression of the 
vitamin D activation genes CYP27B1, CYP2R1 and CYP27A1 could not be determined 
in the vessel rings as there was insufficient tissue to extract RNA. Alternatively, VSMCs 
were explanted from the vessel rings and the mRNA expression of the vitamin D 
activation enzymes in explanted VSMCs from both healthy controls and dialysis patients 
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was examined. As shown in Figure 4-1, all control (n=4) and dialysis (n=6) VSMC 
explants expressed both CYP27A1 and CYP27B1 enabling autocrine activation of 
vitamin D in VSMCs. Interestingly, mRNA expression of CYP2R1 was not detectable in 
any of the VSMCs. 
This data shows that the 25 hydroxylase enzyme required to activate alfacalcidol and 
encoded by CYP27A1 is expressed in VSMCs from control and dialysis vessels, therefore 
it can be assumed that the VSMCs in ex-vivo vessel rings were also able to express 25 
hydroxylase for the local activation of alfacalcidol. There was no significant difference 
between control and dialysis VSMCs in their expression of either CYP27A1 or CYP27B1, 
there was some variation in expression of up to 3 fold between different VSMCs within 
each group. 
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Figure 4-1: Expression of vitamin D activation enzymes in explanted VSMCs. 
VSMCs were explanted from control (A and D) or dialysis (B and E) vessel rings. The 
mRNA expression of vitamin D hydroxylation enzymes was determined by qPCR for A, 
B, C) CYP27A1 and D, E, F) CYP27B1. 
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4.3.2 Calcitriol but not alfacalcidol increased ALP activity in vessel rings from 
children with CKD. 
The previous section showed that alfacalcidol can be activated locally in VSMCs, it was 
shown in Chapter 3 that both alfacalcidol and to a greater extent calcitriol increased Ca 
load in the vessel rings. In this section, I consider the effect of both alfacalcidol and 
calcitriol on ALP activity in the vessel rings to determine if this mechanism contributed 
to the increased calcification observed.  
Culture of vessel rings in either normal Ca-P or high Ca-P medium did not affect ALP 
activity relative to baseline as shown in Figure 4-2A. ALP activity in the vessel wall was 
increased by calcitriol in both normal Ca-P medium (from 9.6+1.0 to 13.0+1.1 U/mg 
(p=0.043)) and even more so in high Ca-P medium (from 11.4+1.3 to 24.5+2.5 U/mg 
(p=0.0004)) as shown in Figure 4-2B. There was also a trend for alfacalcidol to increase 
ALP activity in high Ca-P medium only however this was not significant.  
In the presence of either calcitriol or alfacalcidol, raising the mineral content from normal 
to high Ca-P medium increased the ALP activity in vessel walls, whereas in the absence 
of a VDRA high Ca-P medium had no effect on ALP activity; as shown in Figure 4-2A, 
B and C. 
In order to confirm if the VDRAs have differential effects on ALP activity, a direct 
comparison was made between the ALP activities in vessel rings from the same patients 
treated with different VDRAs. As shown in Figure 4-2D calcitriol increased ALP activity 
significantly more than alfacalcidol in both normal Ca-P and high Ca-P media.  
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Figure 4-2: Calcitriol increased ALP activity in CKD children’s vessel rings. 
Vessel rings were isolated from children with CKD. A) A ring was taken at baseline and 
others cultured for 14 days in either normal Ca-P medium (1mM P and 1.8mM Ca) or 
high Ca-P (2mM P and 2.7mM Ca) to induce calcification. In addition, rings were cultured 
with B) calcitriol, C) alfacalcidol or D) a comparison of calcitriol and alfacalcidol. Vessel 
rings were homogenised and the ALP activity in the vessel wall was determined by a 
colourimetric assay. Statistical significance was analysed by unpaired two-tailed t-test. 
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4.3.3 Calcitriol increased ALP activity to a greater level in dialysis than pre-
dialysis vessel rings. 
As demonstrated in chapter 3, there was a trend (NS) for vessel rings from dialysis patients 
cultured in high Ca-P medium with either calcitriol or alfacalcidol to have a higher Ca 
load than vessel rings from pre-dialysis patients cultured in the same conditions. Here I 
compare the ALP activity in vessel rings from pre-dialysis and dialysis patients. ALP 
activity was analysed in vessels which were of sufficient length to culture an additional 
ring per treatment condition. ALP activity was determined by a colorimetric assay and 
normalised to protein content. Some treatment conditions have lower n numbers due to, 
limited tissue availability or insufficient protein extracted for accurate protein 
measurement.  
There was no difference in ALP activity between pre-dialysis and dialysis vessel rings at 
baseline or after culture in normal Ca-P or high Ca-P media. As shown in Figure 4-3 in 
vessel rings treated with calcitriol in high Ca-P medium, ALP activity was greater in 
dialysis (29.6+1.9 U/mg) than pre-dialysis (18.5+3.6 U/mg) vessel rings (p=0.019). In 
vessel rings treated with alfacalcidol there was no significant difference in ALP activity 
between pre-dialysis and dialysis vessel rings. 
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Figure 4-3: Comparison of ALP activity in pre-dialysis and dialysis vessel rings. 
Vessel rings were isolated from children with CKD who were either pre-dialysis or 
receiving dialysis. A) A ring was taken at baseline and others cultured for 14 days in either 
normal Ca-P (1mM P and 1.8mM Ca) or high Ca-P (2mM P and 2.7mM Ca) to induce 
calcification. In addition, rings were cultured with B) calcitriol or C) alfacalcidol. Vessel 
rings were homogenised and the ALP activity in the vessel wall was determined by a 
colorimetric assay. Statistical significance was analysed by unpaired two-tailed t-test. 
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4.3.4 ALP activity was not a significant predictor of Ca load in children’s vessel 
rings in the presence of calcitriol or alfacalcidol. 
It was shown in Chapter 3 that alfacalcidol and to a greater extent calcitriol increased Ca 
load in vessel rings cultured in high Ca-P medium. A similar pattern was observed with 
ALP activity in this chapter where there was a trend for alfacalcidol to increase ALP 
activity in high Ca-P medium and calcitriol significantly increased ALP activity in the 
vessel rings in high Ca-P medium. Next, I considered whether ALP activity was a 
significant predictor of Ca load in vessel rings from the same patient treated in high Ca-P 
alone, with alfacalcidol or calcitriol. 
In high Ca-P only, ALP activity was a significant predictor of Ca load (R2 = 0.5386, 
P=0.0244) as shown in Figure 4-4A. Despite that in high Ca-P medium calcitriol increased 
both Ca load and ALP activity in the vessel rings, ALP activity was not a significant 
predictor of Ca load in the presence of calcitriol, nor was it with alfacalcidol (Figure 4-4B 
and C). Although increased ALP activity may contribute to calcification, the extent to 
which these VDRAs upregulate ALP activity is independent of their effects on VSMC 
calcification. 
This suggests that in vessel rings from CKD patients treated with calcitriol or alfacalcidol 
the Ca load may be affected by other mechanisms in addition to changes in ALP activity.  
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Figure 4-4: Is ALP activity a predictor of Ca load in vessel rings? 
Vessel rings were isolated from CKD children and cultured for 14 days in high Ca-P 
medium (2mM P and 2.7mM Ca) to induce calcification. Vessel rings were treated with 
A) Ethanol, B) Calcitriol or C) Alfacalcidol Ca load and ALP activity in the vessel walls 
were determined by colourimetric assays and linear regression analysis was performed to 
determine if ALP activity was a significant predictor of Ca load. 
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4.3.5 Calcitriol but not alfacalcidol reduced VSMC viability in children’s vessel 
rings. 
The previous section showed that calcitriol but not alfacalcidol increased ALP activity in 
vessel rings cultured in high Ca-P medium. However, ALP activity was not a significant 
predictor of Ca load in vessel rings treated with either calcitriol or alfacalcidol, therefore 
they may be acting by additional mechanisms contributing to vascular calcification. In 
this next section I consider whether changes in VSMC viability could be a mechanism 
that contributes to the increased Ca load (as observed in Chapter 3) in children’s vessel 
rings after treatment with alfacalcidol or calcitriol. 
The effect of calcitriol and alfacalcidol on cell viability in the vessel rings from children 
with CKD, was determined by counting the smooth muscle cell density in the tunica media 
layer in sections stained with H and E. A representative example of a vessel ring in each 
treatment condition is shown in Figure 4-5. The structural components of the vessel rings 
remained intact including the tunica adventitia consisting of connective tissue, the tunica 
media containing VSMCs and the internal elastic lamella making up the tunica intima. 
Cystic areas in the tunica media were observed in some vessel rings cultured in high Ca-
P with alfacalcidol, artificial damage can occur during processing and sectioning of the 
vessel rings, however the central location of these damaged regions indicates that they are 
cystic areas with VSMC cell death.      
VSMC cell counts showed that alfacalcidol did not affect cell viability in either normal 
Ca-P or high Ca-P medium. High Ca-P medium did not affect cell number, however in 
high Ca-P medium, calcitriol reduced cell number from 26.5+2.4 to 15.5+3.2 cells per 
100µm2 (p=0.02) as shown in Figure 4-6. 
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Figure 4-5 Cell viability shown by Haematoxylin and Eosin of treated vessel. 
Haematoxylin and Eosin stain of pre dialysis vessel 07.6M.44.IE after 14 days culture in 
either normal Ca-P medium (1mM P and 1.8mM Ca) or high Ca-P M199 medium (2mM 
P and 2.7mM Ca). With the addition of either the vehicle (3.4mM ethanol), alfacalcidol 
or calcitriol. Images taken at 20x magnification. A- Adventitia. M – Tunica Media. L – 
Lumen. I – Internal elastic lamella. N – VSMC Nuclei. C – Cystic area. 
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Figure 4-6: Calcitriol reduced cell number in high Ca-P medium. 
Vessel rings were isolated from children with CKD. Vessel rings were cultured for 14 
days in either normal Ca-P medium (1mM P and 1.8mM Ca) or high Ca-P medium (2mM 
P and 2.7mM Ca). With the addition of either the vehicle (3.4mM ethanol), alfacalcidol 
or calcitriol. Vessel rings were stained with H and E and the number of cells per 100µm2 
of tunica media were counted in 3 different areas per vessel, the mean of these is shown 
for n = 4-6 patients’ vessels per condition. Statistical significance was analysed by 
unpaired two-tailed t-test. 
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4.4 Comparison between children’s vessel rings that responded and did not 
respond to calcitriol. 
In chapter 3 it was shown that the mean effect of calcitriol in high Ca-P medium was to 
significantly increase Ca load. It was also observed that the vessel rings’ Ca loads 
separated into 2 groups, responders whose Ca load had increased in response to calcitriol 
and non-responders whose Ca loads remained low. In this next section non-responder and 
responder vessel rings were compared for their expression of osteogenic markers as well 
as their expression of 24 hydroxylase a sensitively regulated downstream gene of vitamin 
D.    
 
4.4.1 There was no difference between responders and non-responders to 
calcitriol in their expression of osteogenic markers. 
During VSMC calcification, smooth muscle cells undergo osteogenic conversion and 
develop an osteoblast like phenotype as discussed in the introduction. This is characterised 
by a downregulation of smooth muscle cell markers and an upregulation of osteogenic 
markers. It was considered whether non-responders and responders to calcitriol had 
differential expression of either smooth muscle or osteogenic markers at baseline and after 
culture in high Ca-P with or without calcitriol treatment. The expression of SMA, Runx2, 
and ALP were compared in 3 non responder and 3 responder vessel rings. 
There was no observed difference between responders and non-responder vessel rings in 
their expression of SMA, Runx2 or ALP. SMA was expressed consistently throughout the 
tunica media in both non-responder and responder vessels an example is shown in Figure 
4-7. There were no Runx2 positive nuclei in baseline vessel rings, however they could be 
observed in both non-responder and responder vessel rings cultured in high Ca-P with or 
without calcitriol, and example of this is shown in Figure 4-8 B and C. ALP was expressed 
in large areas throughout the media of vessel rings both at baseline and after culture, an 
example of this is shown in Figure 4-9.  
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Figure 4-7: SMA expression in vessel rings. 
Vessel rings that were harvested from children with CKD were isolated at baseline (A) or 
cultured for 14 days in high Ca-P medium (2mM P and 2.7mM Ca) to induce calcification, 
in the presence of 3.4mM ethanol (B) or calcitriol (C). Vessel rings were immune-stained 
for SMA (Brown) and counter stained with haematoxylin. D) Negative control with no 
primary antibody. Example shown: Non responder vessel 14.134M.119.IE. Images taken 
at 20 x magnification. A- Adventitia. M – Tunica Media. L – Lumen.  
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Figure 4-8: Runx2 expression in vessel rings. 
Vessel rings that were harvested from children with CKD were isolated at baseline (A) or 
cultured for 14 days in high Ca-P medium (2mM P and 2.7mM Ca) to induce calcification, 
in the presence of 3.4mM ethanol (B) or calcitriol (C). D) negative control with no primary 
antibody. Vessel rings were immune-stained (Brown) for Runx2 and counter stained with 
haematoxylin. Example vessel ring 14.134M.119.IE is shown. Images taken at 40 x 
magnification. A- Adventitia. M – Tunica Media. L – Lumen. R- Runx2 positive nuclei.  
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Figure 4-9: ALP expression in vessel rings 
Vessel rings that were harvested from children with CKD were isolated at baseline (A) or 
cultured for 14 days in high Ca-P medium (2mM P and 2.7mM Ca) to induce calcification, 
in the presence of 3.4mM ethanol (B) or calcitriol (C). D) Negative control with no 
primary antibody. Vessel rings were immune-stained (Brown) for ALP and counter 
stained with haematoxylin. Example vessel ring 14.8M.114.IE. Images taken at 40x 
magnification. A- Adventitia. M – Tunica Media. L – Lumen.  
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4.4.2 Vessel rings that responded and did not respond to calcitriol differ in their 
expression profile of 24 hydroxylase. 
It was shown in the previous section that there was no difference in osteogenic conversion 
between non-responder and responder vessel rings before or after culture. In the next 
section the expression of 24 hydroxylase, which is sensitively upregulated by VDRAs was 
compared between responder and non-responder vessel rings. The CYP24A1 gene 
transcribes the 24 hydroxylase enzyme for the inactivation and degradation of vitamin D, 
as discussed in the introduction its expression is regulated by VDRAs forming a negative 
feedback loop. 
24 hydroxylase was highly expressed in the tunica media of both non-responder and 
responder vessel rings at baseline. After 14-day culture in high Ca-P medium only or high 
Ca-P with calcitriol, 24 hydroxylase was consistently expressed in the responder vessel 
rings tunica media at similar levels to baseline as shown in the example in Figure 4-10 D, 
E, F. 24 hydroxylase expression was reduced in non-responder vessel rings cultured in 
high Ca-P only. Whereas its expression was greatly increased in the tunica media of non-
responder vessel rings cultured in high Ca-P media with calcitriol, as shown in Figure 
4-10 B and C. This differential 24 hydroxylase expression in the high Ca-P medium only 
was observed in 3 responder and 3 non-responder vessel rings, the semi quantitative 
summary is shown in Table 4-2. 
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Figure 4-10: 24 hydroxylase expression in non-responder and responder vessels. 
Vessel rings that were harvested from children with CKD were isolated at baseline (A and 
D) or cultured for 14 days in high Ca-P medium (2mM P and 2.7mM Ca) to induce 
calcification, in the presence of 3.4mM ethanol (B and E) or calcitriol (C and F). Vessel 
rings were immune-stained for 24 hydroxylase (Brown) and counter stained with 
haematoxylin. A,B,C,G) Non responder vessel 14.8M.114.IE. D,E,F) Responder vessel 
07.16F.46.IE. G) negative control with no primary antibody. Images taken at 40x 
magnification. A- Adventitia. M – Tunica Media. L – Lumen.  
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Table 4-2: Summary of 24 hydroxylase expression in responder and non-responder 
vessel rings. 
Vessel rings that were harvested from children with CKD were isolated at baseline or 
cultured for 14 days in high Ca-P medium to induce calcification, in the presence of 
3.4mM ethanol as vehicle or calcitriol. Vessel rings from 3 responder and 3 non-responder 
vessels were immune-stained for 24 hydroxylase. The area of tunica media positive for 24 
hydroxylase was semi-quantitatively quantified. 
0 0% positive 
+ 1-25% positive 
++ 26-50% positive 
+++ 51-75% positive 
++++ 76%-100% positive   
 
  Baseline 
High Ca-P 
Ethanol 
High Ca-P 
Calcitriol 
Responders 
07.16F.46.IE + + + + + + + + + + + + 
07.6M.44.IE + + + + + + + + + + + + 
13.5M.110.IE + + + + + + + + + + + + 
Non-
responders 
14.8M.114.IE + + + + 0 + + + + 
13.14M.105.IE + + + + + + + + + 
14.13M.119.IE + + + + + + + + 
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4.5 Discussion 
4.5.1 Summary 
Data presented in this chapter showed that calcitriol and alfacalcidol act via different 
mechanisms to promote vascular calcification in vessel rings from children with CKD. 
Furthermore, it was determined that non-responder and responder vessel rings differ in 
their expression profiles of the vitamin D target 24 hydroxylase. 
The key findings were: 
1. Alfacalcidol can be activated locally in VSMCs as demonstrated by the expression 
of 25 hydroxylase (CYP27A1) as well as 1α hydroxylase (CYP27B1) in explanted 
VSMCs.  
2. Calcitriol but not alfacalcidol increased ALP activity in vessel rings cultured in 
either normal Ca-P or high Ca-P media. 
3. Calcitriol, but not alfacalcidol reduced VSMC viability in vessel rings cultured in 
high Ca-P media, this is known to precede VSMC calcification and was 
demonstrated by a reduction in VSMC number. 
4. Non responder and responder vessel rings expressed comparable levels of markers 
of osteogenic conversion (SMA, Runx2 and ALP). 
5. Responder vessel rings had persistently high expression of 24 hydroxylase in all 
conditions, where as non-responders had reduced 24 hydroxylase expression after 
culture with high Ca-P medium only. 
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4.5.2 Expression of vitamin D activation enzymes 
When comparing the mechanistic actions of calcitriol and alfacalcidol in vessel rings it 
was essential to determine if alfacalcidol was functioning in its active or inactive form. 
Autocrine activation of alfacalcidol would require expression of the 25 hydroxylase 
enzyme. 
Expression of CYP27B1 encoding the 1α-hydroxylase was evident in each of the 
explanted VSMCs from both control and dialysis vessels as shown in Figure 4-1. This 
agrees with previous literature showing 1α-hydroxylase expression and activity in human 
VSMCs (Somjen et al., 2005). CYP27B1 expression in dialysis VSMCs was 
approximately 150% that of control VSMCs (NS), this increased expression in CKD 
coincides with findings that human inferior epigastric arteries from CKD patients had 
approximately 200% of the 1α hydroxylase protein expression found in control vessels 
(Torremade et al., 2016). 
CYP2R1 could not be detected in explanted VSMCs from either control or dialysis 
patients, however each VSMC explant expressed CYP27A1 gene encoding 25 
hydroxylase. Hence, it can be assumed that VSMCs in the vessel rings also expressed the 
25 hydroxylase enzyme, enabling alfacalcidol to be locally activated in this ex-vivo model 
and to mimic the effect it would have on vessels in-vivo. CYP27A1 and CYP2R1 are less 
well studied than CYP27B1, both are expressed in the human endometrium and in thyroid 
cells (Bergada et al., 2014) and (Bennett et al., 2012), there is also evidence for the 
expression of CYP2R1 in human brain pericytes (El-Atifi et al., 2015) and in renal cells 
(Urbschat et al., 2013) indicating the ability of 25 hydroxylase to have autocrine function 
in specific tissue types. There is no literature to suggest that CYP2R1 nor CYP27A1 are 
expressed in VSMCs and this is the first time CYP27A1 expression in human VSMCs has 
been shown. 
Due to the small amount of human tissue harvested from patients, expression of vitamin 
D activation enzymes, 1α hydroxylase and 25 hydroxylase were not investigated in vessel 
rings. Given the expression in VSMCs, it may be suggested that vessel rings also express 
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vitamin D activation enzymes. In future studies it would be of interest to confirm 
expression of vitamin D activation enzymes in the vessel rings. 
 
4.5.3 Calcitriol but not alfacalcidol increased ALP activity in children’s vessel 
rings. 
In Chapter 3 it was shown that high Ca-P medium increased Ca load in vessel rings from 
children with CKD, this was further increased by alfacalcidol and to a greater extent by 
calcitriol. Here I considered if calcitriol or alfacalcidol had an effect on ALP activity that 
could contribute to increased calcification in the vessel rings. 
ALP is an osteogenic enzyme normally expressed in bone and not in healthy VSMCs 
therefore an increase in its expression or activity is a marker of osteo / chondrocytic 
differentiation. ALP is known to dephosphorylate and inactivate the calcification inhibitor 
pyrophosphate (Villa-Bellosta and Sorribas, 2011), as discussed in the introduction. 
Therefore, as well as being an osteoblast marker, an increase in ALP activity further 
promotes vascular calcification. 
Previous findings from our group showed that high P only medium increased ALP activity 
in CKD vessel rings by approximately 2 fold whereas high Ca-P medium reduced ALP 
activity (Shroff et al., 2010). This differed from findings in this thesis, high Ca-P medium 
had no effect on ALP activity in the children’s CKD vessel rings despite the increase in 
Ca load observed in the vessel rings cultured with high Ca-P in Chapter 3. In this study, 
ALP activity was investigated in a small number of vessels only (n=3-6) and more n 
numbers are required to confirm the null effect of high Ca-P on ALP activity. Furthermore, 
in this study each of the vessel rings were cultured in the presence of 3.4mM ethanol as 
the vehicle control, ethanol may interfere with ALP activity and it would be of interest to 
include a nil control along with a vehicle control in future studies. Interestingly data 
presented here showed that in the presence of either alfacalcidol or calcitriol, increasing 
the mineral content to high Ca-P medium did increase ALP activity by approximately 1.5 
and 2 fold respectively.  
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In this study, 10nM calcitriol significantly increased ALP activity in children’s CKD 
vessel rings both in normal Ca-P medium and by a greater extent in high Ca-P medium.  
Previously, it was shown that 1nM calcitriol increased ALP activity by 301% in bovine 
VSMCs (Wang et al., 2002). In human aortic SMCs, both 10nM and 100nM calcitriol 
dose dependently increased ALP activity. Furthermore, patients’ serum collected directly 
after the administration of calcitriol and applied to VSMCs for 5 days led to a significant 
increase in ALP activity (Becs et al., 2016).  
Vessel rings cultured in high Ca-P medium with calcitriol had both the highest Ca load 
shown in Chapter 3 and the highest ALP activity shown in this chapter. However, ALP 
activity was not a significant predictor of Ca load in vessel rings treated with either 
calcitriol or alfacalcidol. This suggests calcitriol and alfacalcidol triggered other pro - 
calcification mechanisms. 
 
4.5.4 Calcitriol but not alfacalcidol reduced cell viability in children’s vessel rings. 
Previous studies have shown that reduced cell viability caused by high P levels precedes 
calcification, for example incremental increases in P concentration from 1mM to 10mM 
dose dependently reduced cell viability in a rat aortic cell line cultured for 10 days, this 
was consistent with and may have caused increased Ca and P deposition (Shin and Kwun, 
2013). Therefore, the effect of calcitriol and alfacalcidol on cell viability were studied. 
In this chapter high Ca-P alone did not affect cell viability, this may be explained as the 
2mM P was a modest increase in P relative to the study above. However, in previous work 
by our group the same high Ca-P medium reduced VSMC density in CKD vessel rings 
(Shroff et al., 2010). Interestingly, in high Ca-P medium calcitriol but not alfacalcidol did 
reduce cell viability as shown in Figure 4-6. This agrees with previous literature as 
calcitriol has previously been shown to reduce cell viability, 0.1 and 1nM calcitriol 
increased apoptosis and reduced proliferation in human VSMCs treated for 24 hours (Sato 
et al., 2016). 
  
146 
 
It can be concluded that alfacalcidol and calcitriol act on vascular calcification by different 
mechanisms. In high Ca-P medium calcitriol both increased ALP activity and reduced cell 
viability leading to a significant increase in Ca load. Alfacalcidol also increased Ca load 
in high Ca-P medium, however it did not increase ALP activity or reduce cell viability 
therefore the mechanism by which alfacalcidol increased calcification has yet to be 
defined.  
 
4.5.5 Comparable expression of, SMA, Runx2 and ALP in vessel rings that 
responded and did not respond to calcitriol. 
As discussed in the introduction, past literature shows contradictory responses to calcitriol 
in different experimental set ups, in some models calcitriol increased Ca load where as in 
others it reduced Ca load. Therefore, it is understandable that calcitriol had different 
effects on calcification in vessel rings from different individuals. I observed in Chapter 3 
that the Ca load after treatment with high Ca-P separated vessel rings into ‘responders’ 
whose Ca load increased in response to calcitriol, and ‘non-responders’ whose Ca load 
was not effected by calcitriol. Here I compared the expression level of osteogenic markers 
in responder and non-responder vessel rings to explore any differences in osteogenic 
conversion. 
A previous study in our group observed that SMA expression was patchy in dialysis 
relative to control vessel rings which may be an early indication of osteogenic conversion 
(Shroff et al., 2010). In this chapter I compared SMA expression at baseline and after 
culture in high Ca-P medium with or without calcitriol in CKD vessel rings. There was no 
downregulation of SMA protein expression in either the non-responder or responder 
vessel rings to indicate osteogenic conversion.  
Vascular calcification is associated with the transition of VSMCs to an osteogenic 
phenotype, in fact Runx2 expression in VSMCs was found to be essential to precede 
arterial medial calcification in mice, as SMC specific Runx2 knock out mice did not 
develop vascular calcification (Lin et al., 2015). There was no baseline expression of 
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Runx2 in vessel rings, these baseline rings did not show evidence of calcification as shown 
by von Kossa staining in Chapter 3. Therefore, this agrees with previous literature 
showing that Runx2 was only expressed in calcified and not healthy inferior epigastric 
arteries from dialysis patients (Moe et al., 2003). This chapter showed that Runx2 was 
expressed in vessel rings cultured in high Ca-P medium this agrees with previous work in 
our group which also showed that high Ca-P medium increased expression of Runx2 in 
children’s dialysis vessel rings (Shroff et al., 2010). The addition of calcitriol to high Ca-
P did not further increase the expression of Runx2 in either responder or non-responder 
vessel rings. Previous literature shows mixed evidence for the effects of calcitriol on 
Runx2 expression in human VSMCs, when induced to calcify with high P and TNFα, 
1nM, 10nM and 100nM calcitriol had a trend to reduce Runx2 mRNA expression with no 
significant effect (Aoshima et al., 2012). Whereas in human VSMCs induced to calcify in 
high P only, 10nM calcitriol increased Runx2 mRNA expression (Martinez-Moreno et al., 
2012). 
In the CKD vessel rings shown here, ALP was expressed at baseline as well as after culture 
in high Ca-P medium. This agrees with previous literature as CKD is associated with the 
upregulation of tissue nonspecific ALP in the vasculature, for example rats made uremic 
by either 5/6 nephrectomy or by feeding adenine showed increased ALP protein 
expression and activity (Lomashvili et al., 2008). A circulating factor in uremic serum is 
thought to increase ALP activity, aortic rings from normal rats cultured in uremic serum 
also had increased ALP activity (Lomashvili et al., 2008). As discussed above multiple 
studies have shown that calcitriol increased ALP activity, however there is little evidence 
for the effect of calcitriol on ALP protein expression. In this study calcitriol had no effect 
on ALP expression in either responder or non-responder vessels. Ideally ALP activity 
rather than expression would be compared as this represents the functional form of ALP. 
Only 2 of the non-responder vessel rings had sufficient tissue in order to analyse ALP 
activity therefore it was not possible to compare ALP activity between non-responder and 
responder vessel rings in this study.  
Expression levels of SMA, Runx2 and ALP were comparable between non-responder and 
responder vessel rings in each treatment condition. High Ca-P medium with or without 
  
148 
 
calcitriol did not affect expression of SMA or ALP, however Runx2 expression was 
increased by high Ca-P medium. 
 
4.5.6 Differential expression of 24 hydroxylase in vessel rings that responded and 
did not respond to calcitriol. 
To further explore the mechanistic differences between calcitriol responder and non-
responder vessel rings, expression of 24 hydroxylase was compared. 24 hydroxylase is 
transcribed by the CYP24A1 gene which is strongly induced by calcitriol, when bound to 
the VDR it interacts with the 2 VDRE in the promoter region of CYP24A1 (Jones et al., 
1998). CYP24A1 expression is highly regulated by vitamin D, at the time of vessel 
collection all CKD patients were receiving alfacalcidol supplements, therefore the 
expression of 24 hydroxylase evident in baseline vessel rings is likely to be in response to 
these in-vivo supplements. 
CYP24A1 mRNA is downregulated by PTH (Shinki et al., 1992). In culture most cells 
lose the expression of their PTH receptors, in AOK B50 cells which are stably transfected 
with PTH receptors, PTH was shown to destabilise CYP24A1 mRNA and reduced its half-
life by 4.2 fold from 5.7+0.7 hours to 1.4+0.4 hours (Zierold et al., 2003). In this study of 
ex-vivo vessel rings, expression of the PTH receptor is unknown and PTH was not present 
in the culture medium therefore a CYP24A1 mRNA half-life of approximately 6 hours 
can be assumed. After 14 days in culture in the absence of a VDRA it was anticipated that 
24 hydroxylase would not be expressed at detectable levels. As expected 24 hydroxylase 
was not expressed in non-responder vessel rings cultured in high Ca-P only and the 
addition of calcitriol increased expression of 24 hydroxylase. Interestingly the high levels 
of 24 hydroxylase did persist in responder vessel rings after 2 weeks in culture without 
exposure to a VDRA. Consequently, when these vessel rings were exposed to calcitriol 
expression of 24 hydroxylase remained persistently high and there was no upregulation of 
24 hydroxylase expression when exposed to calcitriol. 
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The ability of non-responder vessel rings to upregulate 24 hydroxylase expression in 
response to calcitriol, leading to the inactivation of calcitriol may have prevented calcitriol 
from causing an increase in Ca load. Vessel rings that expressed 24 hydroxylase after 
culture in high Ca-P medium only, were unable to further upregulate their already high 24 
hydroxylase expression in response to calcitriol treatment. Vessel rings inability to 
regulate 24 hydroxylase for the inactivation of calcitriol may have contributed to the 
increased Ca load by calcitriol observed in the responder but not in the non-responder 
vessel rings.   
 
4.5.7 Limitations 
As discussed in Chapter 3, experiments on whole vessel rings from patients were limited 
by tissue availability. In the following chapter, work on VSMCs explanted from both 
healthy control and dialysis patients enable wider analysis of the effects of VDRAs on 
vascular calcification. This includes analysis of the dose dependent effect of calcitriol on 
calcification as well as extracting RNA to determine the response to VDRAs at the 
transcriptional level. 
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Chapter 5 The effects of VDRAs on calcification in VSMCs explanted 
from children with CKD.  
5.1 Introduction 
The effect of vitamin D on vascular calcification is thought to be dose dependent with 
both high and low doses leading to an increased risk, as described in the introduction. It 
would be of great interest to compare the effect of different doses of calcitriol on vascular 
calcification in CKD. Studies on whole vessel rings shown in Chapter 3 and 4, were 
limited by tissue availability and size of the vessels obtained. To overcome these 
limitations VSMCs were explanted from the vessels and this chapter explores the dose 
dependent effect of calcitriol on calcification in explanted VSMCs from control and 
dialysis patients. 
In the vessel rings no effect of paricalcitol on vascular calcification was observed, which 
differs from previous literature as discussed in the introduction and chapter 3. This chapter 
compares the effects of physiological dose paricalcitol to calcitriol in explanted VSMCs. 
Due to the small size of vessel rings, there was insufficient tissue from which to extract 
RNA and to examine the mechanistic effects of VDRAs at the transcriptional level. This 
is an important aspect as ligand bound VDR acts as a transcriptional regulator for many 
genes. Experiments on explanted VSMCs discussed in this chapter enabled the expression 
of vitamin D target genes to be examined at the transcriptional level. 
Patients receiving dialysis represent the extreme cases with end stage kidney disease, 
therefore, VSMCs from these patients were compared to those from healthy control, non-
renal patients. 
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5.1.1 Aims  
1. To establish whether the effect of calcitriol on calcification in VSMCs is dose 
dependent. 
2. To determine whether paricalcitol is less calcaemic than calcitriol in VSMCs. 
3. To elucidate whether dialysis VSMCs are more susceptible to VDRA induced 
calcification than control VSMCs. 
These will be addressed using the following key questions; 
1. Do control and dialysis VSMCs express different levels of smooth muscle and 
osteogenic markers at baseline? 
2. What effects do physiological dose paricalcitol and calcitriol at a range of doses 
have on calcification? Does this differ between VSMCs from control and dialysis 
patients? 
3.  Does calcitriol increase CYP24A1 expression in a dose dependant manner? Are 
10nM calcitriol and 10nM paricalcitol equally effective at upregulating CYP24A1 
expression?  
4. Do physiological dose paricalcitol or calcitriol at a range of doses effect 
calcification of VSMCs by regulating the expression or activity of osteoblast 
enzyme ALP? Does this differ between VSMCs from control and dialysis patients? 
5. Do physiological dose paricalcitol or calcitriol at a range of doses protect against 
VSMC calcification by regulating expression of the calcification inhibitor MGP 
or the osteoblast transcription factor Runx2? Does this differ between VSMCs 
from control and dialysis patients? 
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5.2 Method 
For this study the omental or mesenteric artery was collected from healthy control patients 
and either the inferior epigastric or omental artery was collected from dialysis patients, all 
patient information is shown in the Methods. The VSMCs used in each experiment are 
shown in Table 5-1. VSMCs were explanted from these vessels and used for all 
experiments in this chapter. 
VSMCs were cultured in either normal Ca-P medium (normal M199 tissue culture 
medium which contains 1mM P and 1.8mM Ca M199) or high Ca-P medium (M199 with 
added P and Ca to a final concentration of 2mM P and 2.7mM Ca) to induce calcification. 
VSMCs were cultured for between 4 and 6 days until the onset of calcification, with the 
medium replaced every 3 days. 
VSMCs were cultured with either the vehicle as 3.4mM ethanol or VDRA calcitriol at one 
of three doses from sub physiological (1nM) to physiological (10nM) and supra 
physiological (100nM), as well as with a physiological dose of paricalcitol (10nM). 
VSMCs from each patient were analysed in triplicate for their Ca content, the Ca load in 
VSMCs was determined by ο-cresolphthalein assay and was normalised to protein 
content. Experiments with insufficient calcification (Ca load < 5µg/ µg in all treatment 
groups) were excluded from analysis. 
Treated VSMCs were also analysed for their ALP activity and their mRNA extracted for 
qPCR analysis. All data is shown as mean + SE. 
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Table 5-1: VSMCs utilised in each experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*VSMCs explanted by Alex Todd. ** VSMCs explanted by Rukshana Shroff. All other 
VSMCs explanted by myself, and experiments on all explants performed by myself, 
Joanne Laycock unless indicated by #. 
# Experimental repeat on this VSMC isolate performed under my supervision by Annelies 
DeMare, a master’s student that I, Joanne Laycock trained, planned experiments for and 
assisted in the lab. All data interpretation and analysis was performed by myself.  
VSMC ID format: 
Year. 
Age and gender. 
Unique number. 
Vessel type. 
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Controls VSMC ID 
13.0.1F.106.OM        
13.10F.108.OM        
13.1F.28.OM*        
13.5M.33.OM*     #   
13.3M.31.OM*     #   
13.5F.32.OM*        
Dialysis VSMC ID 
13.16M.101.IE        
12.13M.16.IE*        
13.15F.24.IE*        
14.17M.125.IE  #   #   
13.15F.112.IE     #   
14.13M.119.IE     #   
14.14M.124.IE     #   
06.8F.36.IE**        
06.9M.34.IE**        
05.1.5M.04.OM**        
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5.3 Control VSMCs have higher expression of smooth muscle cell markers at 
baseline than dialysis VSMCs. 
All experiments in this chapter were performed on VSMCs that were explanted from 
vessels from children who were either CKD patients on dialysis or healthy control 
patients. It was important to characterise the phenotype of these explanted cells to confirm 
they were of VSMC origin. VSMCs are contractile cells that regulate vascular tone, as 
such fully differentiated VSMCs express a unique repertoire of contractile proteins 
including smooth muscle α-actin (SMA), smooth muscle myosin heavy chain (SMMHC), 
h1 calponin, SM22α and smoothelin (Gomez and Owens, 2012). These VSMC markers 
may also be expressed in other cell types therefore expression of only one of these cell 
markers is not sufficient. 
The phenotype of explanted control and dialysis cells was confirmed by qPCR. MRNA 
expression of smooth muscle cell markers SMA, SM22α and SMMHC were confirmed in 
each cell type (Figure 5-2 A-I). 
As an early indication of calcification, VSMCs dedifferentiate towards their mesenteric 
stem cell origin and they develop an osteoblast like phenotype, including the expression 
of some osteogenic markers. Therefore, the mRNA expression at baseline of osteogenic 
markers Runx2 and BSP were determined in each of the isolated control and dialysis 
VSMCs. 
Each of the cell lines isolated from both control and dialysis patients expressed SMA, 
SMMHC, SM22 alpha, BSP and Runx2 at varying levels. As shown in Figure 5-2, control 
cell lines expressed higher levels of SMA than dialysis cell lines. The dialysis cell line, 
05.1.5M.04.OM showed particularly high levels of both BSP and Runx2 mRNA 
expression as shown in Figure 5-2 K and N. Across all cell lines tested there was no 
significant difference in Runx2 and BSP expression between control and dialysis VSMCs 
as shown in Figure 5-2 L and M.  
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Figure 5-1: Baseline mRNA expression of SMC markers. 
QPCR analysis was performed to determine the mRNA expression of SMC markers in 
VSMCs explanted from children’s vessels, expression was normalised to that of reference 
gene 18s. VSMCs were from 6 non-renal control patients (A, C and E) and 10 dialysis 
patients (B, D, F). Cell marker expression between these 2 groups was compared (G, H, 
I), data is shown as mean + SE and statistical significance determined by an unpaired two-
tailed t-test. 
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Figure 5-2: Baseline mRNA expression of osteoblast cell markers. 
QPCR analysis was performed to determine the mRNA expression of osteoblast markers 
in VSMCs explanted from children’s vessels, expression was normalised to that of 
reference gene 18s. VSMCs were from 6 non-renal control patients (A and C) and 10 
dialysis patients (B and D). Cell marker expression between these 2 groups was compared 
(E and F) data is shown as mean + SE and statistical significance determined by an 
unpaired two-tailed t-test. 
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5.4 Ca load in VSMCs explanted from control and dialysis children.  
5.4.1 VDRAs reduced Ca load in VSMCs explanted from children. 
The previous section showed that the explanted cells expressed several VSMC markers 
therefore could be identified as such. Next I considered the effect of VDRAs on 
calcification in these VSMCs.  
Initially VSMCs were cultured in normal Ca-P medium as control, or high Ca-P medium 
to induce calcification. As shown in Figure 5-3A, high Ca-P medium significantly 
increased Ca load in VSMCs from 0.59+0.17µg/µg to 10.16+0.49µg/µg (p<0.0001). The 
addition of a vehicle did not affect the Ca load of VSMCs in high Ca-P medium 
(9.29+0.69µg/µg). 
The physiological dose of 10nM calcitriol reduced Ca load from 9.29+0.69µg/µg to 
5.57+0.85µg/µg (p=0.007), whereas 1nM and 100nM calcitriol had no effect on Ca load 
(Figure 5-3B). Similarly10nM paricalcitol reduced Ca load in children’s VSMCs to 
4.28+0.83 (p=0.001) as shown in Figure 5-3C. 
These data consider the effect of high Ca-P medium and VDRAs on VSMCs from children 
regardless of their CKD status. Following this it was important to consider whether 
VSMCs from CKD patients on dialysis were more susceptible to calcification than those 
from healthy controls, and whether they responded differently to VDRA treatment. For 
this, VSMCs from patients on dialysis were compared to VSMCs from healthy controls.    
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Figure 5-3: Ca load in VSMCs: 
VSMCs (P9 or P10) explanted from 7 children were cultured for between 4 and 6 days, 
until the onset of calcification. Each experiment was done in triplicate and the mean for 
each VSMC type is shown. Experiments with insufficient calcification (Ca load < 5µg/µg 
in all treatment groups) were excluded from analysis: VSMCs were treated with: A) 
Normal Ca-P medium (1mM P and 1.8mM Ca) or high Ca-P medium (2mM P and 2.7mM 
Ca) with and without the vehicle control of 3.4mM ethanol. B) High Ca-P medium with 
the vehicle, 1nM, 10nM or 100nM calcitriol. C) High Ca-P medium with the vehicle, 
10nM calcitriol or 10nM paricalcitol. Data is shown as mean + SE and statistical 
significance determined by an unpaired two-tailed t-test. 
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5.4.2 There was no difference between control and dialysis VSMCs in their 
susceptibility to calcification. 
The cultured VSMCs were explanted from 2 healthy control and 4 dialysis children. A 
comparison of control and dialysis VSMCs showed that culture in high Ca-P medium 
increased calcification comparably in both cell types, as shown in Figure 5-4A. The 
addition of the vehicle to high Ca-P medium had no effect on Ca load in either control or 
dialysis VSMCs.  
In dialysis VSMCs treated in high Ca-P medium, the physiological dose of calcitriol 
(10nM) significantly reduced Ca load from 9.17+0.25µg/µg to 5.41+1.33µg/µg (p=0.032) 
whereas the extreme doses had no effect, as shown in Figure 5-4B. A similar pattern was 
observed in control VSMCs in high Ca-P medium, 10nM calcitriol reduced Ca load from 
9.53+2.58µg/µg to 5.87+0.16µg/µg, (n=2 therefore the statistical significance was not 
calculated).  
The physiological dose of paricalcitol (10nM) significantly reduced Ca load in dialysis 
VSMCs from 9.17+0.25µg/µg to 3.01+0.54µg/µg (p<0.001), as shown in Figure 5-4C. 
Again a similar effect was observed in control VSMCs where Ca load was reduced 
9.53+2.58µg/µg to 5.86+1.36µg/µg (n=2) with 10nM paricalcitol. 
Large variations were observed within both control and dialysis VSMCs in their 
susceptibility to calcify in the high Ca-P medium alone or with any of the treatment 
conditions observed. These experiments were performed on VSMCs explanted from 
different patients; cells from different individuals may calcify to different extents in 
response to the treatment conditions and give rise to the observed variations, for this 
reason it is important to consider the effect of VDRA treatment on individual cell lines.  
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Figure 5-4: Ca load in control and dialysis children's VSMCs. 
VSMCs (P9-P10) explanted from 2 healthy control and 4 dialysis children were cultured 
for between 4 and 6 days, until the onset of calcification. Each experiment was done in 
triplicate and the mean for each VSMC type is shown. Experiments with insufficient 
calcification (Ca load < 5µg/µg in all treatment groups) were excluded from analysis: 
VSMCs were treated with: A) Normal Ca-P medium (1mM P and 1.8mM Ca) or high Ca-
P medium (2mM P and 2.7mM Ca) with and without the vehicle of 3.4mM ethanol. B) 
High Ca-P medium with the vehicle, 1nM, 10nM or 100nM calcitriol. C) High Ca-P 
medium with the vehicle, 10mM calcitriol or 10nM paricalcitol. Data is shown as mean + 
SE, statistical significance between treatments in dialysis VSMCs was determined by an 
unpaired two-tailed t-test. 
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5.4.3 The effect of calcitriol on Ca load formed a U-shaped dose response curve, 
the ‘U’s troth shifted in VSMCs from different individuals. 
The mean VSMC Ca loads presented in Figure 5-4B showed that 10nM calcitriol reduced 
Ca load in VSMCs, whereas both 1nM and 100nM calcitriol had no effect on Ca load in 
either control or dialysis VSMCs. 
The large standard errors suggest that there was wide variation between VSMCs from 
individual patients in their level of Ca deposition in response to different VDRA treatment 
conditions. The extreme doses of calcitriol may have had an effect on Ca load in VSMCs 
from some individuals, however this information was lost when only the mean response 
of all control or dialysis VSMCs was presented, therefore it is important to consider the 
effect of VDRA treatment on VSMCs from each individual.  
In the 2 different control VSMCs, both 1nM and 10nM calcitriol significantly reduced 
calcification in high Ca-P medium (Figure 5-5A and B), 100nM calcitriol also reduced 
calcium deposition in one of these control VSMCs but had no effect in the other. The 
effect of 1nM and 10nM calcitriol on reducing Ca load was most noticeable in control 
VSMCs 13.10F.108.OM (Figure 5-5A). In these cells, Ca deposition was reduced from 
7.54+0.21µg/µg to 1.27+0.04 µg/µg and 1.43+0.21µg/µg with 1nM and 10nM calcitriol 
respectively; 100nM calcitriol had no effect on Ca load in these VSMCs. In control 
VSMCs 13.0.1F.106.OM, 1nM, 10nM and 100nM calcitriol all significantly reduced Ca 
deposition. The greatest reduction in Ca deposition was observed by 10nM calcitriol 
which reduced Ca load from 19.35+0.59µg/µg to 9.11+0.22µg/µg, this was significantly 
lower than after treatment with either 1nM or 100nM calcitriol, as shown in Figure 5-5B. 
Unlike in control VSMCs, 1nM calcitriol had no significant effect on Ca load in any of 
the 4 dialysis VSMCs. Both 10nM and 100nM calcitriol significantly reduced Ca load in 
some of the dialysis VSMCs. In the dialysis VSMCs 13.16M.101.IE, there was a trend for 
1nM calcitriol to reduce Ca load in high Ca-P medium from 9.87+1.65µg/µg to 
5.37+1.66µg/µg (NS). In these VSMCs 10nM calcitriol significantly reduced Ca load 
from 9.87+1.65µg/µg to 2.85+0.71µg/µg (p=0.003) whereas 100nM calcitriol had no 
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effect on Ca load, as shown in Figure 5-5C. This differed from dialysis VSMCs 
12.13M.16.IE, in which 1nM calcitriol had no effect on Ca load in high Ca-P medium. 
There was a trend for 10nM calcitriol to reduce Ca load (NS) however it was 100nM 
calcitriol that significantly reduced Ca load from 18.73+2.21 µg/µg to 8.40+2.62 µg/µg 
(p=0.039) (Figure 5-5D). In VSMCs 14.17M.125.IE there was a trend for 10nM calcitriol 
to reduce Ca load in high Ca-P (NS). Neither 1nM nor 100nM calcitriol had an effect on 
Ca load, however both of these extreme concentrations had a significantly higher Ca load 
than VSMCs treated with 10nM calcitriol (Figure 5-5F). In dialysis VSMCs 13.15F.24.IE, 
calcitriol at 1nM, 10nM or 100nM had no effect on Ca deposition (Figure 5-5E).  
In 4 of the 6 VSMCs from different individuals, a U-shaped pattern was observed between 
the concentration of calcitriol and VSMC Ca load. Both low and high dose calcitriol were 
associated with higher Ca loads, and the physiological dose of 10nM calcitriol had the 
greatest protective effect on Ca load. In the remaining 2 VSMCs, both of which were 
dialysis, the lower dose of 1nM calcitriol was again associated with a higher Ca load than 
10nM calcitriol, however the highest dose tested of 100nM calcitriol continued to have a 
protective effect on Ca load. Overall the individual cell population data shows that 10nM 
calcitriol is the dose most consistently protective of calcification in VSMCs; it 
significantly reduced Ca load in both of the control cells and 1 of the 4 cells from dialysis 
patients. 1nM and 100nM doses of calcitriol both reduced Ca load in 2 of the cell lines, 
however the extreme doses of calcitriol did not consistently reduce Ca load.   
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Figure 5-5: Ca load in individual control and dialysis children's VSMCs treated with 
calcitriol. 
VSMCs (P9 or P10 as stated) were treated in high Ca-P medium with the vehicle, 1nM, 
10nM or 100nM calcitriol for between 4 and 6 days (as stated), until the onset of 
calcification. Experiments with insufficient calcification (Ca load < 5µg/µg in all 
treatment groups) were excluded from analysis. VSMCs used were healthy controls A) 
13.10F.108.OM B) 13.0.1F.106.OM or dialysis C) 16.16M.101.IE D) 12.13M.16.IE E) 
13.15F.24.IE F) 14.17M.125.IE. Data is shown as mean + SE and statistical significance 
was determined by an unpaired two-tailed t-test. 
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5.4.4 Paricalcitol reduced Ca load in VSMCs from some individuals. 
The mean VSMC Ca loads that are presented in Figure 5-3C and Figure 5-4C show that 
in high Ca-P, 10nM paricalcitol reduced the Ca load. There was no significant difference 
in the mean Ca load between VSMCs treated with 10nM calcitriol and 10nM paricalcitol. 
As discussed above VSMCs from individual patients may vary in their Ca deposition in 
response to different VDRA treatment conditions. This information can be lost when 
considering only mean values, which combine the data from different individual patients’ 
VSMCs. Here I compare the effect of 10nM calcitriol and 10nM paricalcitol on Ca load 
in VSMCs from each of the 6 individual patients.  
In 2 individual control patients’ VSMCs, 10nM paricalcitol significantly reduced Ca load 
in high Ca-P medium. In both of these VSMCs the Ca load was significantly higher in 
cells treated with 10nM paricalcitol compared to 10nM calcitriol (Figure 5-6A and B). 
Similarly there was a trend for 10nM paricalcitol to reduce the Ca load in high Ca-P 
medium in each of the 4 different dialysis VSMCs, which was statistically significant in 
13.16M.101.IE and 12.13M.16.IE (Figure 5-6C and D). Ca load was reduced by 10nM 
paricalcitol from 9.87+1.65 µg/µg to 3.78+0.54 µg/µg and from 18.73+2.21 µg/µg to 
3.79+0.86 µg/µg respectively. There was no significant difference in Ca load after 
treatment with 10nM calcitriol or 10nM paricalcitol in any of the dialysis VSMCs. 
The above data show that both 10nM calcitriol and 10nM paricalcitol have a protective 
effect on VSMCs from control and dialysis patients. The amplitude of this effect varies 
between VSMCs from different individuals. 
To understand the mechanism by which VDRAs affect Ca load, their effect on other 
parameters in control and dialysis VSMCs was analysed. 
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Figure 5-6: Ca load in individual control and dialysis children’s VSMCs treated with 
calcitriol and paricalcitol. 
VSMCs (P9 or P10 as stated) were treated in high Ca-P medium with the vehicle, 10nM 
calcitriol or 10nM paricalcitol for between 4 and 6 days (as stated), until the onset of 
calcification. Experiments with insufficient calcification (Ca load < 5µg/µg in all 
treatment groups) were excluded from analysis. VSMCs used were healthy controls A) 
13.10F.108.OM B) 13.0.1F.106.OM or dialysis VSMCs C) 13.16M.101.IE D) 
12.13M.16.IE E) 13.15F.24.IE F) 14.17M.125.IE. Data shown as mean + SE and 
statistical significance was determined by an unpaired two-tailed t-test. 
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5.5 By what mechanisms do VDRAs affect vascular calcification in VSMCs from 
control and dialysis children? 
5.5.1 Dialysis VSMCs upregulated CYP24A1 mRNA expression to a greater 
extent than control VSMCs. 
The dose dependent effect of calcitriol on Ca load in VSMCs formed a U-shaped curve 
with both high and low doses associated with a higher Ca load in some of the VSMCs. 
This is an atypical dose response pattern; therefore, it is of interest to consider the effect 
of the calcitriol dose on the transcriptional regulation of a gene that is well established as 
being regulated by the VDR.  
It is widely accepted that CYP24A1 is sensitive to upregulation by VDRAs. CYP24A1 
transcribes the 24 hydroxylase enzyme which converts 25(OH)D and 1,25(OH)2D to 24 
hydroxylated metabolites for degradation as discussed in the introduction, it is a key 
enzyme in the vitamin D metabolism pathway. Here I compare the mRNA expression of 
CYP24A1 in control and dialysis VSMCs treated with VDRAs, as determined by qPCR 
analysis. All data is shown as copies/1000 18s. 
CYP24A1 was expressed at low levels (0.04+0.03) in VSMCs cultured in normal Ca-P 
medium. Culture of VSMCs in high Ca-P medium with or without the vehicle did not 
affect expression of CYP24A1, as shown in Figure 5-7A. There was a trend for calcitriol 
to increase CYP24A1 expression in a dose dependent manner with from 0.02+0.01 to 
0.12+0.08 and 3.52+2.57 with 1nM and 10nM calcitriol (NS). In high Ca-P medium 
100nM calcitriol increased CYP24A1 expression to 21.72+7.06; this was significantly 
higher than the vehicle (p=0.0096, n=7) as well as 1nM and 10nM calcitriol, as shown in 
Figure 5-7C. 10nM paricalcitol also increased CYP24A1 expression in VSMCs to 
3.68+1.45 (p=0.027), as shown in Figure 5-7E.  
CYP24A1 expression was analysed in both control and dialysis VSMCs. The trend for a 
dose dependent increase in CYP24A1 expression with 1nM and 10nM calcitriol was 
evident in both control and dialysis VSMCs. In both groups CYP24A1 expression was 
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significantly greater in VSMCs treated with 100nM calcitriol than either the vehicle, 1nM 
or 10nM calcitriol (Figure 5-5 D). Similarly, there was a significant increase in CYP24A1 
expression with 10nM paricalcitol in both control and dialysis VSMCs (Figure 5-5F). 
There was a trend for the expression of CYP24A1 to be higher in dialysis than control 
VSMCs in each of the treatment conditions. In VSMCs treated with 100nM calcitriol in 
high Ca-P medium, the CYP24A1 expression was significantly greater in dialysis 
(34.5+6.9) than control VSMCs (4.76+1.38) (p=0.0156). 
  
  
168 
 
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
1mM  P & 1.8mM Ca 2mM P & 2.7mM Ca
Nill Nill Vehicle
n=7
C
Y
P
2
4
A
1
 c
o
p
ie
s/
 1
0
0
0
 1
8
S
0.0
0.1
0.2
0.3
0.4
0.5
5
10
15
20
25
30
35
40
45
Vehicle   1nM  10nM    100nM
Calcitriol
0.0261
0.0025
0.0156
P=
P=
P=
0.0322P=
0.0263P=
0.0025P=
0.0128P=
C
Y
P
2
4
A
1
 c
o
p
ie
s/
 1
0
0
0
 1
8
S
0.00
0.05
0.10
0.15
0.20
5
10
15
20
25
30
Vehicle   1nM  10nM    100nM
Calcitriol
P=
n=7
0.0096
0.0099P=
0.0322P=
C
Y
P
2
4
A
1
 c
o
p
ie
s/
 1
0
0
0
 1
8
S
0.000
0.002
0.004
0.006
0.02
0.04
0.06
0.08
0.10
0.12
1mM  P & 1.8mM Ca 2mM P & 2.7mM Ca
Nill Nill Vehicle
Control n=3
Dialysis n=4
C
Y
P
2
4
A
1
 c
o
p
ie
s/
 1
0
0
0
 1
8
S
0.00
0.02
0.04
1
2
3
4
5
6
7
Vehicle    Calcitriol  Paricalcitol
P= 0.0270
n=7
C
Y
P
2
4
A
1
 c
o
p
ie
s/
 1
0
0
0
 1
8
S
0.0
0.5
1.0
2
4
6
8
10
12
Vehicle    Calcitriol  Paricalcitol
0.0161
P= 0.0016
P=
C
Y
P
2
4
A
1
 c
o
p
ie
s/
1
0
0
0
 1
8
S
A B
C D
E F
 
Figure 5-7: CYP24A1 mRNA expression in VSMCs. 
VSMCs were cultured in A and D) normal Ca-P medium, high Ca-P or high Ca-P and the 
vehicle (3.4mM ethanol), B and E) high Ca-P medium with either the vehicle, 1nM, 10nM 
or 100nM calcitriol or C and F) high Ca-P medium with either the vehicle, 10nM calcitriol 
or 10nM paricalcitol. RNA was extracted and CYP24A1 expression determined by qPCR 
analysis and normalised to expression of 18S. A, C, E) CYP24A1 expression in control 
and dialysis VSMCs combined. B, D, F) Comparison of CYP24A1 expression in control 
and dialysis VSMCs.  Data shown as mean + SE and statistical significance was 
determined by an unpaired two-tailed t-test. 
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5.5.2 Calcitriol increased ALP expression in VSMCs explanted from control and 
dialysis children. 
ALP is normally expressed in osteoblasts but not expressed in VSMCs, as discussed in 
the introduction, it is both a marker of osteo / chondrocytic differentiation and an enzyme 
that breaks down the calcification inhibitor pyrophosphate (Villa-Bellosta and Sorribas, 
2011). Data presented in chapter 4 showed that 10nM calcitriol upregulated ALP activity 
and increased Ca load in vessel rings from CKD children, in addition ALP activity in the 
presence of calcitriol was significantly greater in vessel rings from dialysis than pre-
dialysis patients. VSMCs explanted from dialysis vessel rings represent the extreme CKD 
phenotype. Here I compare ALP expression and activity in dialysis and control VSMCs. 
I will also consider the dose dependent effect of calcitriol as well as 10nM paricalcitol on 
both ALP mRNA expression and ALP activity in VSMCs. 
ALP was expressed in VSMCs cultured in normal Ca-P medium; the level of expression 
was not affected by high Ca-P medium or the vehicle. Neither the lower doses of calcitriol 
nor 10nM Paricalcitol had an effect on ALP expression in VSMCs, as shown in Figure 
5-8B and C.  The highest concentration of calcitriol (100nM) increased ALP expression 
from 0.0008+0.0003 to 0.0022+0.0004 copies/1000 18s (p=0.011, n=7) (Figure 5-8B). 
Comparison of ALP expression in control and dialysis VSMCs showed that there was a 
trend for dialysis VSMCs to express higher levels of ALP in most of the treatment 
conditions (Figure 5-8D, E, F). In VSMCs treated with 10nM calcitriol, ALP expression 
was significantly higher (p=0.019) in dialysis VSMCs (0.0012+0.0001 copies/1000 18S) 
compared to control VSMCs (0.0005+0.0002 copies/1000 18S).  
This trend of higher ALP expression in dialysis VSMCs did not continue in VSMCs 
treated with 100nM calcitriol. In control VSMCs, 100nM calcitriol significantly increased 
ALP expression in high Ca-P medium from 0.0005+0.0002 to 0.0027+0.0007 copies/1000 
18S (p=0.035). Whereas in dialysis VSMCs, 100nM calcitriol caused a modest increase 
in ALP expression (NS) as shown in Figure 5-8E.  
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Figure 5-8: ALP mRNA expression in VSMCs. 
VSMCs were cultured in A and D) normal Ca-P medium, high Ca-P or high Ca-P and the 
vehicle (3.4mM ethanol), B and E) high Ca-P medium with either the vehicle, 1nM, 10nM 
or 100nM calcitriol or C and F) high Ca-P medium with either the vehicle, 10nM calcitriol 
or 10nM paricalcitol. RNA was extracted and ALP expression determined by qPCR 
analysis and normalised to expression of 18S. A, C, E) ALP expression in control and 
dialysis VSMCs combined. B, D, F) Comparison of ALP expression in control and 
dialysis VSMCs.  Data shown as mean + SE and statistical significance was determined 
by an unpaired two-tailed t-test. 
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5.5.3 Calcitriol increased ALP activity in VSMCs explanted from control and 
dialysis children. 
The previous section showed that only the highest dose of 100nM calcitriol increased ALP 
mRNA expression in VSMCs, and that this upregulation was significant in control but not 
dialysis VSMCs. To consider the functional importance of this, next I consider the level 
of ALP activity in control and dialysis VSMCs. 
VSMCs were treated as before and their ALP activity determined by a colorimetric assay.  
Data is shown as fold change in enzyme units relative to ALP activity in VSMCs from the 
same patient cultured in normal Ca-P medium.   
High Ca-P did not affect ALP activity in VSMCs, in addition, the vehicle, 1nM and 10nM 
calcitriol as well as 10nM paricalcitol had no effect on ALP activity in VSMCs, whereas 
100nM calcitriol significantly increased the fold change in ALP activity from 1.39+0.23 
fold in high Ca-P with the vehicle to 3.22+0.58 fold in high Ca-P with 100nM calcitriol 
(p=0.0077), as shown in Figure 5-9B. 
The trend for 100nM calcitriol to increase ALP activity was evident in both control and 
dialysis VSMCs (NS) as shown in Figure 5-9 E. There was a trend for 10nM paricalcitol 
to increase ALP activity in control but not in dialysis VSMCs (NS), consequently, in 
VSMCs treated with 10nM paricalcitol, the fold change in ALP activity was significantly 
higher in controls (2.36 0.26 fold) than in dialysis VSMCs (1.42+0.25 fold) (p=0.025).  
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Figure 5-9: Effect of VDRAs on ALP activity in VSMCs. 
VSMCs were cultured in A and D) normal Ca-P medium, high Ca-P or high Ca-P and the 
vehicle (3.4mM ethanol), B and E) high Ca-P medium with either the vehicle, 1nM, 10nM 
or 100nM calcitriol or C and F) high Ca-P medium with either the vehicle, 10nM calcitriol 
or 10nM paricalcitol. ALP activity was determined by colourimetric assay and shown as 
fold change in ALP activity after culture in treatment conditions relative to normal Ca-P 
medium.  A, B, C) All VSMCs. D, E, F) Comparison of control and dialysis VSMCs. Data 
shown as mean + SE and statistical significance was determined by an unpaired two-tailed 
t-test. 
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5.5.4 VDRAs had no effect on expression of osteoblast enzyme Runx2 in VSMCs 
from control and dialysis children. 
As shown above, the higher dose of 100nM calcitriol upregulated both ALP expression 
and activity. ALP is associated with an osteoblast like phenotype. Next I consider whether 
the osteoblast related transcription factor Runx2 was also upregulated by VDRAs. 
QPCR analysis showed that expression of osteoblast transcription factor Runx2 was not 
affected by the culture of VSMCs in any of the treatment conditions tested (high Ca-P 
medium only or with the vehicle, 1nM, 10nM or 100nM calcitriol and 10nM paricalcitol). 
This was true for VSMCs from both control and dialysis patients, as shown in Figure 5-10.  
Interestingly there was a trend for Runx2 expression to be higher in dialysis than control 
VSMCs in each of the treatment conditions. In VSMCs treated with 1nM calcitriol Runx2 
expression was significantly higher in dialysis VSMCs (0.41+0.03 copies/100 000 18S) 
than control VSMCs (0.13+0.08 copies/100 000 18S) (p=0.037). In VSMCs cultured in 
high Ca-P medium with 10nM paricalcitol Runx2 expression was also significantly higher 
in dialysis (0.50+0.12 copies/100 000 18S) than control (0.13+0.06 copies/100 000 18S) 
(p=0.047).   
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Figure 5-10: Runx2 mRNA expression in VSMCs. 
VSMCs were cultured in A and D) normal Ca-P medium, high Ca-P or high Ca-P and the 
vehicle (3.4mM ethanol), B and E) high Ca-P medium with either the vehicle, 1nM, 10nM 
or 100nM calcitriol or C and F) high Ca-P medium with either the vehicle, 10nM calcitriol 
or 10nM paricalcitol. RNA was extracted and Runx2 expression determined by qPCR 
analysis and normalised to expression of 18S. A, C, E) Runx2 expression in VSMCs. B, 
D, F) Comparison of Runx2 expression in control and dialysis VSMCs. Data shown as 
mean + SE and statistical significance was determined by an unpaired two-tailed t-test. 
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5.6 VDRAs had no effect on expression of the calcification inhibitor MGP in 
VSMCs from control and dialysis children. 
Earlier in this chapter I showed that both 10nM calcitriol and 10nM paricalcitol had a 
protective effect on Ca load in VSMCs. Physiological doses of calcitriol have been shown 
to upregulate the MGP promoter in rat VSMCs (Farzaneh-Far et al., 2001). MGP is an 
endogenously expressed inhibitor of calcification (as discussed in the introduction). Here 
I consider the effect of calcitriol and paricalcitol on MGP expression in VSMCs to 
determine if these VDRAs could have a protective effect on Ca load by regulating MGP 
expression. 
QPCR analysis showed that the culture of VSMCs in any of the treatment conditions tested 
(high Ca-P medium only, high Ca-P with 1nM, 10nM or 100nM calcitriol and 10nM 
paricalcitol) had no effect on their MGP mRNA expression VSMCs. 
In control VSMCs, MGP expression was reduced from 1.13+0.08 copies/1000 18S in 
normal Ca-P medium to 0.47+0.13 copies/1000 18S in high Ca-P medium (p=0.012). 
High Ca-P medium did not have a significant effect on MGP expression in dialysis 
VSMCs. There was a consistent trend in each of the treatment conditions for MGP 
expression to be higher in dialysis than control VSMCs (NS). All of the VDRA treatment 
conditions tested did not affect MGP expression in either the control or dialysis VSMCs. 
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Figure 5-11: MGP mRNA expression in VSMCs. 
VSMCs were cultured in A and D) normal Ca-P medium, high Ca-P or high Ca-P and the 
vehicle (3.4mM ethanol), B and E) high Ca-P medium with either the vehicle, 1nM, 10nM 
or 100nM calcitriol or C and F) high Ca-P medium with either the vehicle, 10nM calcitriol 
or 10nM paricalcitol. RNA was extracted and MGP expression determined by qPCR 
analysis and normalised to expression of 18S. A, C, E) MGP expression in VSMCs. B, D, 
F) Comparison of MGP expression in control and dialysis VSMCs. Data shown as mean 
+ SE and statistical significance was determined by an unpaired two-tailed t-test. 
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5.7 Discussion 
5.7.1 Summary 
Data in this chapter showed that the effect of calcitriol on calcification in VMSCs was 
dose dependent and the dose-response curve formed a U-shape. Both calcitriol and 
paricalcitol had a protective effect on calcification in explanted VSMCs, this effect was 
observed equally in VSMCs explanted from control and dialysis patients.  
The key findings were: 
1.  At baseline, control VSMCs expressed more SMA than dialysis VSMCs. In 
addition, some of the dialysis VSMCs had higher expression levels of the 
osteogenic markers Runx2 and BSP. 
2. The physiological doses of both 10nM calcitriol and 10nM paricalcitol were 
protective of calcification; they reduced calcification by the same extent in both 
control and dialysis VSMCs. Each of the extreme doses of 1nM and 100nM 
calcitriol were protective of calcification in only 2 of the individual VSMC 
explants.  
3. MRNA expression of CYP24A1 increased in a concentration dependent manner 
in response to 1nM, 10nM and 100nM calcitriol in both control and dialysis 
VSMCs. CYP24A1 expression in VSMCs treated with 10nM paricalcitol was 
similar to that with 10nM calcitriol. 
4. The highest dose of 100nM calcitriol increased ALP mRNA expression as well as 
fold change in ALP activity in VSMCs. The increase in ALP mRNA expression 
was significant in control but not dialysis VSMCs. 
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5. Neither mRNA expression of MGP nor Runx2 were affected by any of the VDRA 
treatments in either control or dialysis VSMCs. There was a trend for dialysis 
VSMCs to express both more MGP and Runx2 mRNA than control VSMCs. 
 
5.7.2 Baseline characteristics of control and dialysis VSMCs 
The VSMC explants utilised in this chapter all expressed SMA, SMMHC and SM22α as 
shown in Figure 5-2; expression of these multiple markers identifies these cells of VSMC 
origin. SMMHC expression is particularly important as it is considered to be explicitly 
expressed in the VSMC lineage (Madsen et al., 1998). Control and dialysis VSMCs in this 
study expressed similar levels of SMMHC confirming their VSMC lineage. 
The phenotype of VSMCs change throughout development. They do not terminally 
differentiate and are able to respond to environmental cues leading to a spectrum of VSMC 
phenotype. The extremes of this spectrum are considered to be ‘contractile’ and 
‘synthetic’, with the respective primary functions of contraction and synthesis of 
extracellular matrix proteins which are required in growth and repair (Metz et al., 2012). 
Many signalling pathways are involved in the complex regulation of VSMC 
differentiation including growth factors/inhibitors, mechanical influences, cell-cell and 
cell-matrix interactions and inflammatory mediators (Owens et al., 2004).  In culture 
VSMCs are known to switch from a contractile to a synthetic phenotype with increasing 
passage number before eventually reaching senescence (Thyberg, 1996). In this study, 
VSMCs of similar passage numbers, between passage 6 and 10, were compared in order 
to minimise the variation that changes in VSMC phenotype through extensive passaging 
may introduce. 
Many vascular calcification studies have been performed on human VSMCs, as discussed 
in the introduction, here I am able to compare the phenotype of human VSMCs from aged 
matched healthy control and CKD patients on dialysis. Dialysis VSMCs expressed less 
SMA than control VSMCs. Expression of SMA is specifically associated with a 
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contractile phenotype (Weissberg et al., 1995) therefore indicating VSMCs from dialysis 
patients had a reduction in contractile function. Despite this dialysis VSMCs were not 
predisposed to calcification relative to control VSMCs. 
As discussed in the introduction, vascular calcification is a highly regulated process that 
resembles bone formation, including osteogenic differentiation induced by Runx2 and 
characterised by the expression of bone related molecules (Kurabayashi, 2015). Control 
VSMCs and the majority of dialysis VSMCs showed low level expression of Runx2 and 
BSP, however dialysis VSMCs 05.1.5M.04.OM, 06.8F.36.IE and 15.12F.126.IE had 
noticeably higher expression of Runx2 and/or BSP as shown in Figure 5-2, which is 
suggestive of osteogenic differentiation in these dialysis VSMCs at baseline. 
For this and other qPCR analysis all expression levels were normalised to the 
housekeeping gene 18s. 18s is a ribosomal RNA that is stable and highly conserved 
between species, with only a 0.1% divergence between mice and humans (Gonzalez and 
Schmickel, 1986). It is constitutively expressed in all cells therefore widely accepted as 
an appropriate housekeeping gene to represent the relative total mRNA and normalise 
expression levels to (Goidin et al., 2001, Bas et al., 2004).  
 
5.7.3 The U-shaped curve of calcitriol concentration versus VSMC Ca load. 
The effect of different concentrations of calcitriol on Ca load in VSMCs was determined. 
The concentration range of calcitriol included the sub-physiological dose of 1nM, 
physiological dose of 10nM and supra-physiological dose of 100nM.  The mean Ca load 
of VSMCs treated with this concentration range of calcitriol formed a U-shaped curve; 
the highest and lowest dose had no effect on Ca load whereas the middle dose of 10nM 
calcitriol reduced Ca load.  
A U-shaped association between calcitriol and calcification has been observed previously 
in multiple scenarios, clinically in dialysis children (Shroff et al., 2008a) as well as in-
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vitro in human VSMCs where 1nM calcitriol had the greatest protective effect by 
upregulation of CaSR expression (Mary et al., 2015).  
Potential explanations of the U-shaped concentration to Ca load response include: 
 Theory 1: Calcitriol has a protective effect on Ca load, however at high doses it is 
rapidly converted to inactive metabolites. 
 Theory 2: Calcitriol activates counteracting protective and causative effects on 
calcification in VSMCs, the contribution of each is concentration dependent. 
 Theory 3: Calcitriol has a protective effect on calcification in VSMCs at a narrow 
concentration window only. 
 
5.7.3.1 Theory 1: Calcitriol has a protective effect on Ca load, however at high 
doses it is rapidly converted to inactive metabolites. 
CYP24A1 encodes the 24 hydroxylase enzyme which hydroxylates calcitriol to form 
metabolites for degradation. Transcription of CYP24A1 is upregulated by calcitriol to 
form a negative feedback mechanism. The transcriptional regulation of the CYP24A1 
gene is highly responsive to VDRAs. 2 VDREs were identified in its promoter region by 
cloning of the 24 hydroxylase promoter; either of the VDREs were able to direct a reporter 
gene independently however both VDREs were required to induce optimal 24 hydroxylase 
expression (Chen and DeLuca, 1995). The region up stream of the VDREs, between 
nucleotides -548 and -294 was found to have a synergistic function in expression of the 
CYP24A1 gene in human fibroblasts (Tashiro et al., 2007). Furthermore, a cluster of 
enhancers located downstream of the CYP24A1 gene were identified by Chip-sequencing 
and shown to contribute to the activation of the gene in response to VDRAs (Meyer et al., 
2010). CYP24A1 is highly inducible with 100 to 1000 fold increases in expression, 
therefore is often used as a positive control to demonstrate VDRA activity. In this study a 
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typical dose response is observed with incremental doses of calcitriol (1nM, 10nM and 
100nM) eliciting greater transcriptional upregulation of CYP24A1. Consequently, the 24 
hydroxylase expression was upregulated and the production of metabolites for the 
degradation pathway such as 1α,24,25(OH)3D3, and eventually calcitroic acid, were 
increased. The 24 hydroxylated metabolites may themselves affect calcification. In 
osteoblast cells, 1α,24,25(OH)3D3 as well as 24R,25(OH)2D3 increased ALP activity, 
increased osteocalcin production and enhanced mineralisation (van Driel et al., 2006). 
24R,25(OH)2D3 was also shown to increase ALP activity and mineralisation in human 
mesenchymal stem cells (Curtis et al., 2014).   
In future work it would be interesting to compare the significance of this greatly increased 
CYP24A1 expression on the levels of active vitamin D remaining in the system as well as 
the concentration and effect of 24 hydroxylated metabolites. Throughout these 
experiments media was replaced every 3 days, therefore prior to replenishment the 
VSMCs may have experienced peak levels of 24 hydroxylated metabolites and troths in 
levels of original VDRA concentration.  
 
5.7.3.2 Theory 2: Calcitriol activates counteracting protective and causative 
effects on calcification in VSMCs; the extent of each is concentration 
dependent. 
The lowest dose of 1nM calcitriol had no effect on Ca load in explanted human VSMCs, 
however the physiological dose of 10nM calcitriol had a protective effect; it reduced Ca 
load. Vitamin D has previously been shown to upregulate transcription of the calcification 
inhibitor MGP (Farzaneh-Far et al., 2001). QPCR analysis of MGP expression showed 
that, in this study, MGP mRNA expression was not affected by 1nM, 10nM or 100nM 
calcitriol. In other studies VDRAs have been shown to down-regulate MGP leading to an 
increased Ca load, for example in both sham operated and 5/6 nephrectomy Wistar rats, 
calcitriol increased Runx2 protein and reduced MGP protein expression, corresponding to 
an increase in calcification (Koleganova et al., 2009). In our model of children’s VSMCs 
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an alternative, as yet undefined, protective mechanism must be contributing to the reduced 
Ca load observed with 10nM calcitriol treatment.    
The supra-physiological dose of 100nM calcitriol had no effect on Ca load, however it did 
upregulate ALP mRNA expression and activity. As discussed previously ALP is an 
osteoblast marker. It also dephosphorylates and inactivates the calcification inhibitor 
pyrophosphate therefore ALP upregulation is associated with calcification. 10nM 
calcitriol did not affect ALP expression or activity but it reduced Ca load in VSMCs, this 
differed from 100nM calcitriol which upregulated ALP expression and activity, however 
it had no overall effect on Ca load. In VSMCs treated with 100nM calcitriol the causative 
effect of ALP on increasing calcification may counteract the calcification protective 
mechanisms observed with 10nM calcitriol. 
As the VDR is a transcriptional regulator it was of interest to compare the mRNA 
expression of ALP in control and dialysis VSMCs treated with VDRAs, however ALP is 
not known to be a target gene of VDRAs. Post-translational modifications or activation of 
ALP may affect its functional activity, therefore ALP mRNA expression and ALP activity 
may not be directly linked and both were studied. 
In this model of human VSMCs from both control and dialysis children, the causative and 
protective mechanisms of calcitriol are balanced at both 1nM and 100nM; at these 
concentrations there was no overall effect on Ca load. It would be of interest in future 
studies to identify the protective mechanism of calcitriol that reduced Ca load at the 10nM 
calcitriol dose and counteracted the pro-calcification effect of upregulated ALP at the 
100nM calcitriol dose that results in an overall null effect on Ca load.  
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5.7.3.3 Theory 3: Calcitriol activates a protective effect on calcification in VSMCs 
at a narrow concentration window only. 
In the explanted VSMCs in this study, calcitriol was shown to have a protective effect on 
Ca load when used at 10nM concentration only, the lower or higher dose of 1nM or 100nM 
respectively had no effect on Ca load.  This suggests that there is a narrow concentration 
window at which calcitriol is effective at reducing Ca load. This narrow effective 
concentration window was also observed in a study by the Mentaverri group. In their 
study, 1nM calcitriol had a greater protective effect on calcification than either 0.1nM or 
10nM calcitriol (Mary et al., 2015). This supports the theory that calcitriol is protective of 
calcification at a narrow concentration window only, creating a U-shaped dose response 
curve, however there is a shift in the most effective concentration in different experimental 
set ups. 
The Mentaverri group showed that 1nM calcitriol effectively increased the expression of 
CaSR hence increased Ca sensitivity of VSMCs and protected against calcification in 
human VSMCs (Mary et al., 2015). This study used an excessively high dose of 5mM Ca 
to induce calcification; 5mM Ca but not 2mM Ca reduced CaSR expression in arterial 
SMCs from adults by approximately 4 fold (Molostvov et al., 2015). This study induced 
calcification with a more modest 2.7mM Ca and 2mM P therefore any reduction in CaSR 
expression is likely to be much smaller. CaSR expression is reduced in CKD, which could 
contribute to their higher risk of vascular calcification observed in-vivo (Massy et al., 
2014). In future it would be of interest to compare the concentration of CaSR in these 
control and dialysis VSMCs and to consider the effect of calcitriol concentration on CaSR 
in my experimental setup. 
 
5.7.4 Effect of paricalcitol versus calcitriol on calcification  
The mean effect of VDRAs on Ca load was for the physiological doses of both 10nM 
paricalcitol and 10nM calcitriol to protect against Ca load by a similar extent. Individual 
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patients’ VSMCs responded to different extents to each of these VDRAs. In both of the 
control VSMCs the Ca load was significantly less in response to 10nM calcitriol than 
10nM paricalcitol. Whereas in one of the dialysis VSMCs 10nM paricalcitol, but not 
10nM calcitriol, significantly reduced Ca load, there was no significant difference 
between Ca load after treatment with 10nM calcitriol or 10nM paricalcitol in the 
remaining 3 dialysis VSMCs. This demonstrates variation in the amplitude of response to 
VDRA treatment between VSMCs from different individuals. 
 
5.7.5 Differences between control and dialysis VSMCs 
Similar mean Ca loads were observed between control and dialysis VSMCs in each of the 
VDRA treatment conditions tested as summarised in Table 5-2. Despite this, differences 
between control and dialysis VSMCs in response to VDRAs were observed in regards to 
expression of CYP24A1 as well as expression and activity of ALP.  
There was a consistent trend for CYP24A1 expression to be higher in dialysis VSMCs 
than controls both prior to VDRA treatment and in response to each of the VDRA 
treatment conditions. With 100nM calcitriol, where the greatest increase in CYP24A1 
expression was observed, it was significantly greater in dialysis than control VSMCs. 
The differential expression levels both prior to and in response to VDRA treatment in 
VSMCs explanted from control and dialysis VSMCs may be attributed to the difference 
in prescribed vitamin D in these patients. CKD patients, particularly children, are routinely 
prescribed VDRAs; in this cohort each of the patients that dialysis VSMCs were explanted 
from were on alfacalcidol supplements. VSMCs explanted from these patients have 
already been exposed to high levels of vitamin D. This may have increased their 
responsiveness to calcitriol as demonstrated by the significantly greater increase in 
CYP24A1 expression when treated with 100nM calcitriol. 
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In contrast to CYP24A1 upregulation, VDRAs upregulated ALP expression to a greater 
extent in control than dialysis VSMCs. ALP is not known to be transcriptionally regulated 
by the VDR and the mechanism for its upregulation in this system is currently not known. 
A circulating factor in uremic serum was thought to upregulate ALP activity as aortas 
from uremic rats, as well as control aortas exposed to serum from uremic rats, had 
upregulated ALP activity (Lomashvili et al., 2008). In my study, neither control nor 
dialysis VSMCs were exposed to uremic serum however there was a trend for higher ALP 
mRNA expression in dialysis VSMCs than control VSMCs in most conditions. 
Calcitriols upregulation of CYP24A1 expression was greater in dialysis VSMCs whereas 
its upregulation of ALP mRNA expression and activity was greater in control VSMCs. 
The mechanism by which VDRAs regulate ALP is not known whereas CYP24A1 is 
known to be regulated by the ligand bound VDR binding to VDRE in its promoter region. 
Difference in VDR expression between control and dialysis VSMCs will be explored in 
Chapter 4. 
Table 5-2: Summary of effects of VDRAs and the type of VSMC most affected. 
Effect of VDRAs: Cell type most affected: 
↓ Calcification Control = Dialysis 
↑ CYP24A1 mRNA Dialysis > Control 
↑ ALP mRNA Control > Dialysis 
↑ ALP activity Control > Dialysis 
 
 
5.7.6 Patient variation 
There was variation in this chapter between individual patients’ Ca load in their response 
to VDRAs with the U-shaped response shifting to either the left or the right, this suggests 
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that different concentrations of calcitriol are required to evoke the same response in 
VSMCs from different patients. Analysis of Ca load in VSMCs from individual patients 
showed that, in both of the control but none of the 4 dialysis VSMCs, 1nM calcitriol as 
well as 10nM calcitriol significantly reduced Ca load. This suggests that control VSMCs 
may be more sensitive to calcitriol treatment than dialysis VSMCs. Children on dialysis 
are routinely prescribed VDRAs, therefore the dialysis VSMCs have had prior exposure 
in-vivo to VDRAs. The effect of this is unknown but dialysis VSMCs may be desensitised 
to calcitriol treatment, therefore require a higher dose to evoke a similar protective effect 
on Ca load.  
Further individual patient variation was observed with 100nM calcitriol significantly 
reducing Ca load in one of the control and one of the dialysis VSMCs but having no effect 
in the remaining four VSMCs. Individual patient variation in the calcitriol concentration 
that elicits a protective effect on Ca load suggests that there may be differences in the 
VDR expression between VSMCs from individual patients’ VSMCs. This will be 
explored in Chapter 6. 
 
5.7.7 Limitations. 
In this chapter control and dialysis VSMCs were compared, ideally these VSMCs would 
be explanted from vessels of the same vascular bed and from patients of the same age and 
gender. As discussed in section 3.8.6, the control vessels were obtained from patients 
undergoing routine abdominal surgery and a different vascular bed was accessed, this was 
usually the mesenteric or omental arteries rather than the inferior epigastric artery obtained 
from CKD patients.   
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Chapter 6 Expression of the VDR in vessel rings and VSMCs 
6.1 Introduction 
Previous chapters have shown large variations in the response of both vessel rings and 
isolated VSMCs to VDRAs. Chapter 3 showed that there was no significant difference 
between pre-dialysis and dialysis vessel rings in their extent of calcification in response 
to VDRAs. However, there was variability within each group, particularly in response to 
10nM calcitriol with some vessel rings having increased calcification and others showing 
no response. Contrary, in the VSMCs cultured in high Ca-P 10nM calcitriol had a 
protective effect and had a lower Ca load compared to VSMCs without calcitriol. 
Interestingly the extent to which the lower and higher doses of calcitriol protected against 
calcification was hugely varied between VSMCs from different individuals. For example, 
1nM calcitriol reduced the Ca load in control but not in dialysis VSMCs. Control and 
dialysis VSMCs also differed in the extent to which VDRAs upregulated expression of 
CYP24A1 and ALP. 
It is well documented that VDRAs regulate the transcription of multiple genes via the 
VDR, ligand bound VDR forms a heterodimer with the RXR and interacts with the VDRE 
in the promoter region of target genes (as described in the introduction). Here I will focus 
on the VDRA calcitriol. This chapter investigates the expression of the VDR in vessel 
rings and VSMCs from different individuals to address whether the patient variation 
observed in response to calcitriol treatment could be attributed to a difference in the level 
of VDR expression.  
6.1.1 Aim 
1. To determine whether VDR expression in vessels varies between individuals 
giving rise to the different responses to calcitriol treatment in both arterial vessel 
rings and explanted VSMCs.  
This will be addressed with the following key questions; 
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1. Is there a difference in VDR expression at baseline and after calcitriol treatment in 
vessel rings that calcified more in response to calcitriol compared to those that did not 
respond to calcitriol?  
2. Is there a difference in VDR mRNA and protein expression between control and 
dialysis VSMCs, either at baseline and in response to calcitriol? 
3. Is there a difference in VDR isoform expression between control and dialysis VSMCs 
either at baseline or in response to calcitriol? 
4. Is there a difference between VDRE activation between control and dialysis VSMCs? 
Are any differences in VDRE activation determined by the VDR localisation in the 
cell or the ratio of VDR isoforms expressed at baseline or in response to calcitriol? 
 
6.2 Method 
Inferior epigastric arteries were harvested from children with CKD at the time of renal 
transplant, and cultured as whole vessel rings as described in Chapter 3. Vessel rings were 
fixed, embedded and sectioned for immunostaining for the VDR. Pictures were taken at 
40x magnification. The number of VDR positive nuclei were counted in 3 frames per 
vessel and the mean count compared between vessel rings whose Ca load either increased 
in response to calcitriol (Responders: 07.16F.46.IE, 07.6M.44.IE, 13.5M.110.IE) or did 
not respond to calcitriol (Non-responders: 14.8M.114.IE, 14.11M.118.IE, 
14.13M.119.IE). All patient information for each vessel ID is shown in the Methods. 
In VSMCs the expression of the VDR was analysed at baseline and after culture in sub 
physiological (1nM), physiological (10nM) or supra physiological (100nM) doses of 
calcitriol for 5 days, both in control and dialysis VSMCs. This included qPCR analysis of 
total VDR mRNA expression and western blot analysis of VDR-A and VDR-B protein 
expression, which was quantified by optical density analysis. The NCBI reference 
sequence database has identified 3 transcript variants of the human VDR gene (Pruitt et 
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al., 2014). The exons in each transcript are shown in Figure 6-1, together with the binding 
sites for the forward and reverse primers as well as the location of all ATG start codons 
to initiate translation. The primers detected all 3 transcripts therefore qPCR analysis 
represented total VDR expression. 
Control and dialysis VSMCs were transfected with a reporter construct containing the 
firefly luciferase gene under a VDRE promoter. Transfected VSMCs were cultured with 
100nM calcitriol for 24 hours and their transcriptional activation capacities compared. 
Associations between VDRE mediated luciferase activity and both VDR subcellular 
location and VDR isoform expression were analysed.  
The VSMCs used in each experiment are shown in Table 6-1 and their patient information 
is shown in Chapter 2. 
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Figure 6-1: VDR transcripts and isoforms. 
There are two VDR mRNA transcripts (transcript 1 and 2) that encode the same VDR-A isoform, both of these transcripts are translated 
from the ATG start codon in exon 2 to give the 427 amino acid VDR-A isoform. Transcript 3 encodes the VDR-B isoform which is 
translated from the ATG start codon in exon 1d to give the 477 amino acid VDR-B isoform, which has a 50 amino acid N terminal 
extension.  
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Table 6-1: Summary of VSMCs used in each experiment. 
VSMC ID: Year. 
Age and gender. 
Unique number. 
Vessel type. 
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Controls VSMC ID 
13.10F.108.OM    #   
13.0.1F.106.OM       
13.1F.28.OM*       
06.8M.20.IE**       
06.1M.39.RA**       
13.3M.31.OM*       
13.5F.32.OM*       
13.5M.33.OM*       
14.2M.123.ME       
15.2F.127.ME   # #   
35F (adult aorta)       
Dialysis VSMCs 
13.16M.101.IE       
12.13M.16.IE*       
14.13M.119.IE       
13.15F.112.IE    #   
13.15F.24.IE*       
06.8F.36.IE**       
06.9M.34.IE**       
05.1.5M.04.OM**       
14.14M.124.IE    #   
14.8F.122.IE       
14.17M.125.IE   # #   
 
*VSMCs explanted by Alex Todd. ** VSMCs explanted by Rukshana Shroff. All other 
VSMCs (except 35F) were explanted by myself, and experiments on all VSMCs were 
performed by myself, Joanne Laycock unless indicated by #. 
# Experimental repeat on this VSMC isolate performed under my supervision by Annelies 
DeMare, a master’s student that I, Joanne Laycock trained, planned experiments for and 
assisted in the lab. All data interpretation and analysis was performed by myself.  
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6.3 There was no difference in VDR expression between vessel rings that 
responded and did not respond to calcitriol with an increased Ca load. 
In Chapter 3 I showed that vessel rings could be sorted into 2 distinct groups, responders, 
whose Ca load increased in response to calcitriol and non-responders whose Ca load did 
not change. This difference was independent of dialysis status, renal diagnosis, gender, 
and age as well as vitamin D supplements at the time of transplant.  
The response to calcitriol might be affected by differences between the patients may at a 
molecular level. Therefore, immunostaining was used to determine the VDR density in 
the medial layer of patients whose Ca load responded or did not respond to calcitriol. As 
shown in Figure 6-2, VDR positive nuclei were identified in both non-responder and 
responder vessel rings at baseline and after culture in high Ca-P medium with calcitriol.  
For each condition the number of VDR positive nuclei per 10µm2 was counted, a mean 
VDR count from 3 frames per vessel was taken for 3 non-responder and 3 responder vessel 
rings. As shown in Figure 6-3, there was no difference in the number of VDR positive 
nuclei either at baseline or after culture in high Ca-P medium with calcitriol between non-
responder and responder vessel rings. 
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Figure 6-2: VDR expression in responder and non-responder vessel rings. 
Vessel rings that were harvested from children with CKD were isolated at baseline or 
cultured for 14 days in high Ca-P medium (2mM P and 2.7mM Ca) with 10nM calcitriol. 
Vessel ring sections were stained for VDR (Brown) and counter stained with 
haematoxylin. Negative control with no primary antibody. Images taken at 20x or 40x 
magnification. A- Adventitia. M – Tunica Media. L – Lumen. V – VDR positive nuclei.  
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Figure 6-3: Quantification of VDR positive nuclei in responder and non-responder 
vessel rings. 
Vessel rings harvested from children with CKD were stained for VDR. For each vessel 
ring the number of VDR positive nuclei was counted in 3 frames and a mean is shown. 
Nuclei were counted in 3 different vessel rings per condition to compare VDR expression 
in non-responders and responders at baseline and after culture in high Ca-P medium (2mM 
P and 2.7mM Ca) with 10nM calcitriol for 14 days. Mean is shown and statistical 
significance was determined by unpaired two-tailed t-test. 
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6.4 VDR expression in control and dialysis VSMCs 
6.4.1 Control and dialysis VSMCs expressed different VDR isoforms at baseline. 
The previous section showed that there was no difference in VDR protein expression 
between vessel rings whose Ca load responded and did not respond to calcitriol. This 
section will compare the VDR expression in explanted VSMCs from control and dialysis 
VSMCs. 
It was shown in Chapter 5 that there were significant differences between control and 
dialysis VSMCs in the extent of their responses to VDRAs as summarised in Table 6-2. 
For example, ALP mRNA expression was upregulated by 100nM calcitriol in all VSMCs 
but it was significantly increased in control and not dialysis VSMCs. In addition, the fold 
change in ALP activity was greater in control than dialysis VSMCs treated with VDRAs. 
CYP24A1 expression was also increased in both control and dialysis VSMCs, however a 
greater upregulation was seen in dialysis than control VSMCs.  
 
Table 6-2: Summary of effects of VDRAs on VSMCs. 
Effect of VDRAs: Cell type most affected: 
Effect statistically 
significant with: 
↓ Calcification Control = dialysis 10nM calcitriol 
↑ ALP mRNA Control 100nM calcitriol 
↑ ALP activity Control 
10nM calcitriol 
10nM paricalcitol 
↑ CYP24A1 mRNA Dialysis 100nM calcitriol 
 
Here it was considered whether there was any difference in expression of the VDR mRNA 
or protein between control and dialysis VSMCs at baseline that could contribute to these 
differences in response to VDRAs between the two groups. 
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To determine the VDR expression of VSMCs at baseline, RNA and protein were harvested 
from control and dialysis VSMCs cultured in normal Ca-P medium. QPCR and western 
blot analysis showed that here was no difference in total VDR expression between control 
and dialysis VSMCs at either the mRNA or the protein level as shown in Figure 6-4 A to 
C. 
Interestingly western blot analysis showed that some VSMC isolates expressed the larger 
VDR-B isoform as well as the standard VDR-A isoform. As shown in the example in 
Figure 6-4D controls tended to express more of the large 54kDa VDR-B, whereas dialysis 
VSMCs expressed a higher proportion of the 48 kDa VDR-A isoform. The fractional 
distribution of each isoform was quantified. The fraction of VDR-A in control VSMCs 
was 0.30+0.065, this was over doubled in dialysis VSMCs where the fraction of VDR-A 
was 0.65+0.12, as shown in Figure 6-4 E and F. 
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Figure 6-4: Expression of the VDR in control and dialysis VSMCs. 
 
MRNA and protein were harvested at baseline from control and dialysis VSMCs isolated 
from different patients. A) Total VDR mRNA normalised to 18S RNA expression. B) 
Western blot analysis of VDR-A and VDR-B isoforms, C) Relative expression of Total 
VDR quantified from the sum of VDR-B and VDR-A densities after being normalised to 
loading control (β-actin). D) Example western blot of VDR-A and VDR-B isoform 
expression in control and dialysis cell line. The fraction of VDR-A and VDR-B isoforms 
were quantified from the optical density of western blots in different control (n=8) and 
dialysis (n=7) VSMCs, shown as E) mean fraction of VDR-A and VDR-B and F) fraction 
of VDR-A. C and F data shown as mean + SE and statistical significance determined by 
unpaired two-tailed t-test. 
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6.4.2 Calcitriol increased expression of the total VDR mRNA in VSMCs. 
The previous section showed that there was no difference in total VDR mRNA or protein 
expression between control and dialysis VSMCs, however the ratio of VDR isoforms 
between the 2 groups differed. Next the effect of VDRA treatment for 5 days on 
expression of the VDR was considered.   
As shown in Figure 6-5A, high Ca-P medium with or without the vehicle did not affect 
expression of total VDR mRNA, nor did treatment of VSMCs with either 1nM calcitriol, 
10nM calcitriol or 10nM paricalcitol (Figure 6-5 B and C). The higher concentration of 
100nM calcitriol significantly increased expression of total VDR (copies/1000 18S RNA) 
from 2.6+0.5 with the vehicle in high Ca-P medium to 6.3+1.4 with 100nM calcitriol in 
high Ca-P medium (p=0.028).  
It was important to consider whether VDRAs up regulate transcription of the total VDR 
to the same extent in control and dialysis VSMCs. As shown previously in Figure 6-4A, 
there was no difference in the baseline expression of total VDR mRNA between control 
and dialysis VSMCs. Here I show that despite a trend for higher total VDR mRNA 
expression in dialysis than control VSMCs in each of the treatment conditions, as shown 
in Figure 6-5D-F there was no significant differences between total VDR expression in 
control and dialysis VSMCs. 
Next it was considered whether the increase in total VDR mRNA expression with 
calcitriol led to an increased VDR protein expression of both VDR-A and VDR-B 
isoforms.  
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Figure 6-5: Total VDR mRNA expression in VSMCs treated with VDRAs. 
VSMCs were cultured for 5 days in normal Ca-P medium, high Ca-P medium or high Ca-
P medium with vehicle (3.4mM ethanol) (A and D), high Ca-P medium with either 
vehicle, 1nM, 10nM or 100nM calcitriol (B and E) or high Ca-P medium with either 
vehicle, 10nM calcitriol or 10nM paricalcitol (C and F). RNA was extracted and VDR 
expression determined by qPCR analysis and normalised to expression of 18S RNA. A, 
C and E show VDR expression in control and dialysis VSMCs combined. B, D and F 
show the comparison of VDR expression in control and dialysis VSMCs. Data shown as 
mean + SE and statistical significance determined by unpaired two-tailed t-test. Data 
shown as mean + SE and statistical significance determined by unpaired two-tailed t-test. 
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6.5 Transcriptional activation of the VDRE. 
6.5.1 There was no difference between control and dialysis VSMCs 
transcriptional activation of the VDRE. 
Previous sections in this chapter have shown that dialysis VSMCs express a higher 
proportion of the VDR-A isoform than control VSMCs. Furthermore, 100nM calcitriol 
increased expression of the VDR-A isoform and reduced expression of the VDR-B 
isoform in both control and dialysis VSMCs. This suggests that the ratio of VDR isoforms 
expressed is functionally significant however the mechanism of this is not understood. As 
discussed in the introduction, the relative transcriptional activation capacity of the VDR-
A and VDR-B isoforms have not been consolidated in the literature.  
Here I investigate whether dialysis VSMCs, which predominantly express the VDR-A 
isoform at baseline, have a greater transactivation capacity of the VDRE than control 
VSMCs which predominantly express the VDR-B isoform at baseline. 
To compare the transactivation capacity of the VDRE in control and dialysis VSMCs, 
cells were transfected with a firefly luciferase construct with either a vitamin D-inducible 
promoter containing multiple repeats of the VDRE, a constitutively active CMV promoter 
as a positive control, or negative control without any promoter sequence. In each case a 
construct constitutively expressing Renilla luciferase was included as a transfection 
control for normalisation. Transfected VSMCs were cultured with and without 100nM 
calcitriol for 24 hours. 
In the VSMCs transfected with the vitamin D inducible construct, 100nM calcitriol was 
able to significantly increase luciferase activity in only 4 out of the 12 VSMC isolates 
tested. This was independent of the VSMC type as it included 2 out of 6 control VSMCs 
as shown in Figure 6-6 and 2 out of the 6 dialysis VSMCs as shown in Figure 6-7. 
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Figure 6-6: Activation of the VDRE-luciferase in control VSMCs. 
Control VSMCs were transfected in triplicate wells with a firefly luciferase construct 
either under a vitamin D-inducible promoter containing VDREs, or with the negative 
control non-inducible promoter or the constitutively active positive control promoter. All 
VSMCs were transfected with constitutively active Renilla luciferase as a transfection 
control. Post transfection VSMCs were treated with or without 100nM calcitriol for 24 
hours to induce the VDRE-firefly luciferase. A) Adult 35F VSMC line. B-F) Children’s 
VSMC explants from control patients. Data shown as mean + SE and statistical 
significance determined by unpaired two-tailed t-test. 
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Figure 6-7: Activation of the VDRE-luciferase in dialysis VSMCs. 
 
VSMCs were transfected in triplicate wells with the Firefly luciferase either under a 
vitamin D-inducible promoter containing VDREs, or with the negative control non-
inducible promoter or the constitutively active positive control promoter. All VSMCs 
were transfected with constitutively active Renilla luciferase as a transfection control. Post 
transfection VSMCs were treated with or without 100nM calcitriol for 24 hours to induce 
the VDRE-firefly luciferase. Data shown as mean + SE and statistical significance 
determined by unpaired two-tailed t-test. 
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Interestingly the 4 VSMC isolates that had VDRE-luciferase that was inducible by 100nM 
calcitriol also had a higher level of background luciferase activity in the VSMCs 
transfected with the VDRE-luciferase construct and treated with the vehicle only. It was 
necessary to confirm that the transfection efficiency was consistent between all 
experiments by comparing activity of the Renilla luciferase. A Renilla luciferase construct 
under a constitutively active CMV promoter was transfected alongside each of the firefly 
luciferase constructs to act as a transfection control. The firefly luciferase activity in each 
treatment condition was normalised to Renilla activity. Comparison of Renilla activity in 
each cell type, showed that transfection was successful in each of the VSMC isolates and 
there was no significant difference in transfection efficiency between experiments, data 
shown in the Appendix Figure 10-3 and Figure 10-4. 
As shown above, only 4 out of 12 VSMCs transfected with the VDRE luciferase had 
increased luciferase activity in response to 100nM calcitriol for 24 hours. An experimental 
control was required to confirm that the 100nM calcitriol used was active in each 
experiment. Non-transfected VSMCs were treated in parallel for 24 hours with 100nM 
calcitriol or vehicle, RNA was isolated and the expression of vitamin D responsive 
CYP24A1 gene was analysed by qPCR. Each VSMC isolate upregulated CYP24A1 
expression as shown in Figure 6-8A, therefore it is evident that the 100nM calcitriol used 
in each experiment was active. CYP24A1 expression was significantly upregulated by 
100nM calcitriol in VSMCs in which it also activated VDRE-luciferase as well as those 
that it did not. Furthermore, there was no significant difference in CYP24A1 expression 
after calcitriol treatment in VSMCs in which the VDRE-luciferase was activated or not 
activated (Figure 6-8B). 
Expression of the VDR in transfected VSMCs would also be essential for calcitriol to 
activate the VDRE-luciferase construct, therefor VDR mRNA expression was analysed in 
these VSMCs. There was a tendency for cell lines that activated the VDRE-luciferase to 
express higher levels of total VDR mRNA as shown in Figure 6-8 C and D, however this 
was not significantly different. In addition, 100nM calcitriol treatment for 24 hours did 
not upregulate the expression of total VDR in either VSMCs that activated or did not 
activate luciferase expression. This differs from 100nM calcitriol treatment for 5 days 
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which did increase expression of total VDR mRNA in VSMCs as shown previously in 
Figure 6-5.  
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Figure 6-8: CYP24A1 and VDR mRNA expression in VSMCs. 
Control and dialysis children’s VSMCs were cultured and treated with or without 100nM 
calcitriol in parallel to those transfected with luciferase constructs. MRNA was harvested 
and CYP24A1 (A and B) and VDR (C and D) expression quantified by qPCR. Expression 
in each VSMC type is shown in A and C. B and D compare expression levels in VSMCs 
that had VDRE-luciferase expression activated by 100nM calcitriol and those in which 
expression was not activated. Data shown as mean + SE and statistical significance 
determined by unpaired two-tailed t-test. 
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6.5.2 VDRE-dependent luciferase expression coincides with a higher fraction of 
VDR-A expression. 
As shown in the previous section, there was no difference in total VDR mRNA expression 
between VSMCs in which 100nM calcitriol treatment for 24 hours activated VDRE 
luciferase and VSMCs in which it was not activated. 
In the following section the ratio of VDR isoforms expressed was compared between 
VSMCs in which 100nM calcitriol activated the VDRE-luciferase and those VSMCs in 
which it did not. An example of the VDR protein isoforms expressed with and without 
100nM calcitriol was determined by western blot analysis as shown in Figure 6-9 A. 
Optical density of VDR-A and VDR-B was calculated and the expression of each as a 
fraction of total VDR is shown in Figure 6-9 B. Each of the 4 VSMCs that activated the 
VDRE-luciferase had a higher fractional expression of VDR-A than those that did not 
activate VDRE-luciferase. This was evident in Figure 6-9 C which showed the mean 
fraction of the VDR isoforms. In addition, Figure 6-9 D shows that the fraction of VDR-
A expressed was significantly higher in VSMCs that activated the expression of VDRE-
luciferase (0.70+0.17) than those that did not (0.07+0.02). 
Earlier in this chapter I demonstrated that treatment with 100nM calcitriol for 5 days 
caused a switch from expression of VDR-B to the VDR-A isoform in both control and 
dialysis VSMCs. Here I showed that treatment of VSMCs with 100nM calcitriol for 24 
hours did not alter the ratio of VDR isoforms expressed in either VSMCs that activated 
luciferase or those that did not activate luciferase, as shown in Figure 6-9 D. 
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Figure 6-9: VSMCs that activated the VDRE-luciferase expression, expressed a 
higher fraction of the VDR-A isoform. 
 
Control and dialysis children’s VSMCs (n=8), as well as adult VSMC line 35F were 
treated with or without 100nM calcitriol for 24 hours in parallel to those transfected with 
luciferase constructs. Protein was harvested and VDR isoform expression visualised by 
western blotting. The optical density of each isoform was quantified and calculated as a 
fraction of total VDR expression. D) Data shown as mean + SE and statistical significance 
determined by unpaired two-tailed t-test.  
  
207 
 
6.5.3 Calcitriol increased expression of the VDR-A isoform in VSMCs. 
The previous section showed that the highest tested concentration of calcitriol (100nM) 
increased expression of total VDR mRNA in VSMCs after culture for 5 days. Protein was 
also harvested from VSMCs cultured in the same treatment conditions and VDR 
expression analysed by western blot.  
It was shown in Figure 6-4 D-F that at baseline, dialysis VSMCs expressed a higher 
fraction of VDR-A, and control VSMCs expressed a higher fraction of the VDR-B 
isoform. The effect of high Ca-P and calcitriol treatment on VDR isoform expression was 
explored in both control and dialysis VSMCs. As shown in Figure 6-10, there appears to 
be no change in total VDR protein expression after treatment with 1, 10 or 100nM 
calcitriol however there was a clear shift in the VDR isoform expressed with increasing 
calcitriol dose. 
The control VSMCs predominantly expressed the VDR-B isoform at baseline and in high 
Ca-P medium only, with the vehicle and with 1nM calcitriol. Expression of VDR-A was 
increased by 10nM calcitriol, at this dose similar levels of VDR-A and VDR-B isoforms 
were expressed in the control VSMCs as shown in Figure 6-10. 100nM calcitriol further 
increased expression of the VDR-A isoform and the expression of VDR-B was drastically 
reduced to undetectable levels. 
Dialysis VSMCs expressed a higher fraction of VDR-A isoform than VDR-B at baseline. 
VDR-B was detectable in dialysis VSMCs in: normal Ca-P medium, high Ca-P medium, 
with the vehicle, 1nM or 10nM calcitriol. As with the control VSMCs, 100nM calcitriol 
reduced VDR-B expression to undetectable levels.  
In both control and dialysis VSMCs, high doses of calcitriol resulted in a shift in the 
expression of VDR isoforms from VDR-B to VDR-A. Calcitriol favoured expression of 
the VDR-A isoform.   
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Figure 6-10: Calcitriol favoured expression of the VDR-A isoform.  
VSMCs were cultured for 5 days in normal Ca-P medium, or high Ca-P medium with; no 
additives (nil), vehicle (3.4mM ethanol), 1nM, 10nM or 100nM calcitriol. Protein was 
extracted and VDR expression determined by western blot analysis, representative 
western blots from a control (13.10F.108.OM) and dialysis (13.16M.101.IE) VSMC are 
shown. 
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6.5.4 There was no difference in the subcellular localisation of the VDR in 
VSMCs that activate VDRE-luciferase expression and not. 
As discussed in the introduction, inactive VDR can be found in the cytoplasm and in order 
to regulate transcription the VDR has to translocate to the nucleus. Therefore, as well as 
the expression level, the cellular localisation of the VDR is important for its function and 
activity.  
Immunofluorescence staining of the total VDR protein was used to compare the cellular 
localisation of VDR in the control VSMC isolate 13.3M.31.OM with high VDRE-
luciferase activation and the dialysis VSMC isolate 14.14M.124.IE that did not activate 
VDRE-luciferase. Both isolates were treated with or without 100nM calcitriol. As shown 
in Figure 6-11, in each VSMC isolate and treatment condition the VDR was specifically 
located in the nucleus and there was no difference in the cellular localisation of the VDR. 
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Figure 6-11: VDR localised to the nuclei of VSMCs. 
VSMC isolates 13.3M.31.OM and 14.14M.124.IE were selected as extreme examples of 
high expression activation and no activation, respectively, of the VDRE-luciferase 
construct. VSMCs were treated with or without 100nM calcitriol, formalin-fixed and 
stained by immunofluorescence for the VDR and the nuclei counterstained with DAPI.   
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6.6 Discussion: 
6.6.1 Summary 
There was no variation in total VDR expression between individual’s vessel rings and 
VSMCs. However, differences in the ratio of VDR isoforms expressed may contribute to 
the patient variation in response to calcitriol observed in previous chapters. 
The key findings of this chapter were: 
1. Immunostaining and quantification of VDR positive nuclei showed that there was 
no difference in total VDR expression between vessel rings that either showed no 
response in their Ca load to calcitriol or responded with an increased Ca load. 
2. There was no difference in total VDR mRNA or protein expression between 
control and dialysis VSMCs either at baseline or after culture with 1nM, 10nM or 
100nM calcitriol or with 10nM paricalcitol. 
3. Control and dialysis VSMCs expressed different ratios of the VDR isoforms. 
Control VSMCs predominantly expressed the 54KDa VDR-B whereas dialysis 
VSMCs predominantly expressed the 48KDa VDR-A. In both control and dialysis 
VSMCs high doses of calcitriol decreased VDR-B and increased VDR-A 
expression.   
4. In a selection of control and dialysis VSMCs 100nM calcitriol activated the 
VDRE-dependent luciferase expression. There was no difference in VDR 
localisation between activators and non-activators however they differed in their 
VDR isoform expression. 
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6.6.2 Control VSMCs predominantly express VDR-B whereas dialysis VSMCs 
predominantly express VDR-A. 
This study for the first time compares the VDR expression in VSMCs from control and 
dialysis patients. Despite there being no difference in total VDR at either the RNA or 
protein level, there was a significant difference in the ratio of VDR isoforms expressed. 
Dialysis VSMCs predominantly expressed VDR-A whereas control VSMCs 
predominantly expressed the N-terminally extended VDR-B.  
The VDR was previously shown by western blot analysis to be expressed in human 
VSMCs, however in these VSMCs only 1 band was identified at approx. 48KDa 
corresponding to the VDR-A isoform (Mary et al., 2015). Using the same mouse anti-
VDR antibody (mAb VDR (D-6), sc-13133) I identified two VDR isoforms in the 
children’s VSMCs. There are multiple VDR antibodies available, Wang et al. tested these 
by extensive immunoassay analysis and the D-6 antibody was preferred for its high 
specificity and extreme sensitivity (Wang et al., 2010). The VDR D-6 antibody is raised 
against VDR-A amino acids 344 – 424, VDR-B has the same amino acid sequence as 
VDR-A with the addition of a 50 amino acid extension at the N-terminus, therefore both 
isoforms are detectable by this antibody as shown in Figure 6-1. 
 
6.6.3 Calcitriol increased VDR mRNA expression and shifted the ratio of VDR 
isoforms to increase VDR-A expression.  
It has been documented that VDRAs increase the expression of the VDR itself, for 
example intramuscular injections of the VDRA cholecalciferol in New Zealand white 
female rabbits increased their expression of aortic VDR (Rajasree et al., 2002). In line 
with this study my results show that, in the control and dialysis VSMCs 100nM calcitriol 
significantly increased expression of total VDR mRNA. It was not possible to accurately 
quantify the total VDR protein expression after treatment with 100nM calcitriol due to the 
shift in VDR isoform expression observed. There is a limited number of studies dedicated 
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to the expression of the different VDR isoforms; here for the first time the effects of 
different doses of calcitriol on VDR isoform expression were observed. Both in control 
and dialysis VSMCs, treatment with 100nM calcitriol reduced expression of the VDR-B 
protein and increased expression of the VDR-A protein.   
It is of interest to note that the dialysis VSMCs but not the control VSMCs were explanted 
from patients who were receiving vitamin D supplements in the form of alfacalcidol at the 
time of vessel collection. The effect of alfacalcidol treatment in-vivo on VDR isoform 
expression in VSMCs is not known. As with calcitriol treatment in-vitro, the prescribed 
alfacalcidol in-vivo may also favour the expression of the VDR-A isoform. Hence, 
alfacalcidol supplements given to dialysis patients prior to vessel collection may account 
for the higher fraction of VDR-A isoform expressed in dialysis VSMCs relative to control 
VSMCs. To test this theory, it would be necessary to investigate the effect of vitamin D 
supplementation in-vivo on VDR isoform expression, this could be examined in either 
control mice or 5/6 nephrectomised mice as a model for CKD. 
In future studies it is important to understand the functional significance of this change in 
VDR isoform composition induced by calcitriol for processes regulating calcification. As 
discussed previously, the dose-dependent effect of calcitriol on calcification forms a U 
shaped curve. Therefore, it could be speculated that the change in expression of VDR 
isoforms at different doses of calcitriol alters the pattern of downstream gene activation, 
hence the effect of calcitriol on Ca load. In particular, moderate doses of calcitriol may 
protect against calcification via activation of VDR-B, whereas higher doses of calcitriol, 
which favour the expression of VDR-A, may have causative effects on calcification. This 
hypothesis could to be tested by overexpressing VDR-A or VDR-B in cells with low 
endogenous expression of the VDR and then inducing calcification. 
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6.6.4 Activation of VDRE luciferase in some VSMCs only. 
The functional significance of the different ratios of VDR isoforms expressed in control 
and dialysis VSMCs was explored by luciferase assay. Control and dialysis VSMCs from 
children were transfected with a construct containing the firefly luciferase gene under a 
VDRE promoter and the effect of calcitriol on transcriptional activation of the luciferase 
was compared.    
100nM calcitriol was able to activate the VDRE luciferase at detectable levels in only 3 
of the 11 children’s VSMCs and one adult VSMC line. Transfection efficiency measured 
by transfection with a Renilla luciferase under a constitutively active promoter was 
comparable in cells that activated expression from VDRE and did not. In addition, the 
100nM calcitriol was evidently active as it upregulated CYP24A1 expression.  
VSMCs that activated VDRE-dependent luciferase expression included both control and 
dialysis VSMCs. Despite this, activators of luciferase expression had different fractional 
distribution of VDR isoform expression to non-activators. The VDR-A isoform was 
predominantly expressed by VSMCs that activated the VDRE luciferase promoter, 
suggesting that this isoform may be required for luciferase activation where as either VDR 
isoform is able to activate the CYP24A1 promoter in the presence of calcitriol. 
In neither activators nor non-activators did 100nM calcitriol induce a shift in isoform 
expression after 24 hours of treatment. This differs from previous data in this chapter 
where 5 days of treatment with 100nM calcitriol caused a shift in VDR expression to 
favour the VDR-A isoform. Hence, duration of calcitriol treatment is evidently important 
for its biological function. It would be interesting to determine if with a prolonged 5-day 
treatment with calcitriol these VSMCs switched to express a higher fraction of VDR-A, 
and were then able to activate the VDRE-luciferase. Unfortunately, this was not tested in 
the present study as the harsh nature of the transfection procedures limited VSMC survival 
duration post transfection.     
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Once activated, the VDR is translocated to the nucleus where it functions as a 
transcriptional regulator. The nuclear localisation of the VDR is important for its function 
as a transcriptional regulator. Immunofluorescence showed that the VDR was diffusely 
expressed in the nucleus both in VSMC isolate 13.3M.31.OM that had high expression of 
the VDR-A and activated VDRE-luciferase expression as well as in the VSMC isolate 
14.14M.124.IE that had high expression of VDR-B and did not activate VDRE-luciferase 
expression. This differed from findings by E M Gardiner’s group, which showed that the 
cellular distribution differed between VDR isoforms when transfected in COS-1 cells. 
VDR-A was diffusely expressed in the nuclei, whereas VDR-B was expressed in nuclear 
foci, that were dispersed by 10nM calcitriol, giving a diffused nuclear distribution similar 
to VDR-A (Sunn et al., 2001). It was thought that VDR-B nuclear foci represented their 
physical association with cellular cofactors in the absence of ligand, enabling a more rapid 
response to ligand activation (Flanagan et al., 2002). 
 
6.6.5 What is the functional significance of the VDR-A and VDR-B isoform? 
In chapter 5 it was shown that dialysis VSMCs were more responsive to calcitriol than 
control VSMCs in their upregulation of CYP24A1 and VDR mRNA. This chapter has 
shown that dialysis VSMCs express a higher proportion of VDR-A than control VSMCs. 
It is possible to speculate the existence of an association between higher transcriptional 
activity and higher VDR-A expression, in this scenario VDR-A has a greater 
transcriptional activation capacity than VDR-B. Original data from J A Eisman’s lab 
supports this theory, they found that VDR-B had only 60% the transcriptional activation 
capacity of VDR-A. This was determined by co transfection of the 24-hydroxylase 
promoter reporter construct with each of the VDR isoforms in Cos-1 and P19 cells that 
had low endogenous expression of the VDR (Sunn et al., 2001). However, subsequent 
data collected by the same group showed the opposite, that VDR-B had a greater 
transcriptional activation than VDR-A. Further investigation revealed that VDR-B was 
more susceptible to interference from CMV and SG5 viral promoters, which compete for 
transcriptional co-factors, and reduced the transactivation capacity of the VDR-B isoform 
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(Gardiner et al., 2004). Therefore, the relative transcriptional activation capacities of the 
two VDR isoforms may be dependent on the availability of cellular co-factors and 
transcriptional regulators in different cell types. A comparison of 7 different cell types 
confirmed that the relative VDR-A and VDR-B activity was cell type-dependent and even 
varied between different cell lines from the same tissue bed (Esteban et al., 2005). The N-
terminal extension of VDRB-1 may interact with specific cell co-factors. Pull down assays 
in COS-1 cells showed that the C terminal ligand binding domain of VDR-B had a 
stronger interaction with calcitriol than VDR-A did (Flanagan et al., 2002). As well as 
being dependent on cellular cofactors the relative activity of the two VDR isoforms varied 
between different promoters (CYP24A1 and CYP3A4) as well as different activating 
ligands (1nM calcitriol and lithocholic acid) (Esteban et al., 2005).  
In the literature many factors are reported to affect the relative activation properties of the 
two VDR isoforms. Experimental manipulation of VDR isoform expression by the viral 
promoters utilised in the experiments discussed above subsequently affected the function 
of the VDR isoforms being investigated, rendering the experiment biased. Here, with the 
control and dialysis VSMCs naturally expressing different ratios of the VDR-A and VDR-
B isoforms it is possible to compare the transcriptional regulation of naturally occurring 
downstream genes such as CYP24A1, without the need for interference from experimental 
promoters. However, this would be made challenging by the natural variation in the 
fraction of VDR isoforms expressed in VSMC explants from different patients, and the 
shift in VDR isoform expression upon calcitriol treatment.     
 
6.6.6 Limitations 
The VDR-A and VDR-B isoforms are translated from 3 different mRNA transcripts, as 
shown in Figure 6-1. The primers used in this chapter do not differentiate between the 
transcripts and the PCR product represents the quantification of total VDR mRNA. In 
future work, it would be of great interest to use isoform-specific primers in order to 
determine if the differences in VDR isoform expression arise at the transcriptional or post-
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transcriptional level. Furthermore, a VDR-B isoform-specific antibody as previously 
produced by the Gardiner group (Sunn et al., 2001), that interacted with the N-terminal 
extended region  of the VDR-B isoform would enable the comparison of isoform 
expression in vessel rings by immunohistochemistry and identification of the subcellular 
localisation of each isoform in VSMCs.  
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Chapter 7 The effects of VDRAs on vascular calcification in arterial 
rings isolated from adults with CKD. 
7.1 Introduction 
This thesis so far has focused on the effect of vitamin D on calcification in paediatric 
patients with CKD, this is of particular interest and clinical concern as children are not 
generally exposed to traditional cardiovascular risk factors and young CKD patients still 
suffer from medial calcification or Monckeberg sclerosis as discussed in the introduction. 
However, it is also important to consider the effects of VDRAs on calcification in the 
adult CKD population to determine if this mirrors the effects observed in children. In the 
adult cohort it is likely that patients have been exposed to traditional cardiovascular risk 
factors such as diabetes, smoking, dyslipidaemia and hypertension in addition to uraemia-
related cardiovascular risks. The vessels may have underlying atherosclerosis which may 
complicate the pattern of calcification observed at baseline and after treatment.  Moreover, 
adult renal patients may have a longer duration of CKD, longer time on dialysis, previous 
failed transplants and also different causes of their CKD compared to children. It was of 
particular importance to consider the general health and Ca load of the vasculature at 
baseline, as well as the patients’ past medical history with regards to cardiovascular health. 
To compensate for the patient variation, numerous rings were obtained from each patient’s 
vessel and the effects of different treatment conditions were compared against the baseline 
vessel characteristics, such that each vessel was its own internal control.  
 
7.1.1 Aim 
1. To elucidate whether VDRAs accelerate the progression of vascular calcification 
in arterial rings from adults with CKD. 
This will be addressed using the following key questions; 
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1. What effect do physiological doses of the VDRAs, calcitriol and paricalcitol, have 
on vascular calcification in vessels from adults with CKD? 
2. Are there any differences in susceptibility to vascular calcification between vessel 
rings from pre-dialysis and dialysis patients? 
3. Do any patient related factors affect the response of adult vessel rings to VDRA 
induced calcification, including gender, age, primary renal diagnosis, previous 
cardiovascular health and current vitamin D supplements? 
4. What effect do physiological doses of the VDRAs, calcitriol and paricalcitol, have 
on activity of the osteoblast enzyme ALP in vessels from adults with CKD? 
 
7.2 Method 
For this study the inferior epigastric artery was collected from patients listed in Table 7-1 
who were undergoing renal transplantation at the Royal Free Hospital. Vessel rings were 
cultured in either normal Ca-P medium (M199 tissue culture medium which contains 
1mM P and 1.8mM Ca) or high Ca-P medium (M199 with added P & Ca to a final 
concentration of 2mM P and 2.7mM Ca) for 2 weeks, with the medium changed every 3 
days. Vessels were exposed to physiological doses of either 10nM calcitriol or 10nM 
paricalcitol, or 3.4mM ethanol as the vehicle control for both VDRAs. Up to 3 vessel rings 
were cultured per condition, they were either; homogenised and their Ca content 
quantified by a colorimetric σ-cresolphthalein assay, formalin fixed and their Ca load 
visualised by von Kossa staining or homogenised and their ALP activity determined by 
colorimetric assay. Each experimental design is described in detail in the Chapter 2. All 
data shown as mean + SE. 
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Table 7-1: Patient information for adult vessels studied.  
Vessel ID format: Year. Age and gender. Unique number. Vessel type.  
IE – Inferior Epigastric artery; CAKUT – Congenital Anomalies of the Kidneys and Urinary Tract. RVD – Renovascular Disease.  
HD – Haemodialysis; PD - Peritoneal-Dialysis. Failed Tx - Prior renal transplant failed. HTN – Hypertension. IHD – Ischaemic Heart 
Disease. PVD - Peripheral Vascular Disease. 
 
Vessel ID 
Age 
Years 
Gender 
Primary renal 
Diagnosis 
Type of & time on 
dialysis (months) 
Vitamin D supplements 
HTN 
IHD / 
PVD / 
Stroke 
DM 
Alfacalcidol Cholecalciferol 
13.46M.1.IE 46 M Glomerulopathy 1 HD NO NO YES NO NO 
13.45M.2.IE 45 M Glomerulopathy Pre-dialysis Failed Tx YES NO YES NO NO 
13.57F.3.IE 57 F Unknown (Other) 48 PD YES YES YES NO NO 
13.19F.4.IE 19 F Glomerulopathy 12 PD Failed Tx YES YES NO NO NO 
13.31M.6.IE 31 M Vasculitis (Other) 12 HD NO NO NO NO NO 
13.67F.7.IE 67 F RVD (Other) 6 PD YES NO YES NO NO 
14.61M.11.IE 61 M Glomerulopathy Pre-dialysis NO YES YES YES NO 
14.45F.12.IE 45 F Glomerulopathy 6 PD NO YES YES NO NO 
14.35M.13.IE 35 M CAKUT (Other) Pre-dialysis YES YES NO NO NO 
14.27M.14.IE 27 M Fabrys (Other) Pre-dialysis YES YES NO NO NO 
14.71M.15.IE 71 M Glomerulopathy 12 HD NO NO YES YES NO 
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7.3 Adult vessel rings at baseline  
7.3.1 Vessels were in general good health at baseline. 
Adult vessels were collected from patients aged 19 to 71 years. These patients are likely 
to have been exposed to traditional cardiovascular risk factors to different extents. As 
shown in Table 7-1, 64% of patients suffered from hypertension and 18% had a previous 
cardiovascular complication. Unusually, none of the patients in this cohort were diabetic. 
Unfortunately, I do not have data on their history of smoking. In the adult cohort it was 
particularly important to observe baseline histology for general vascular health and 
atherosclerotic regions which lead to intimal calcification. The Ca load at baseline by σ-
cresolphthalein assay and observed by von Kossa were also considered. Despite the 
advancing age, vessels from each patient were generally in good health and no 
atherosclerosis was observed, examples of the vasculature at baseline are shown in Figure 
7-1. Next I looked for evidence of arteriosclerosis at baseline in the adult vessel rings. 
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Figure 7-1: Hematoxylin and Eosin at baseline: 
Inferior epigastric arteries were harvested from adults with CKD, vessel rings at baseline 
were formalin fixed, sectioned and stained with haematoxylin and eosin.  A) 13.57F.3.IE 
B) 13.31M.6.IE at 4x and 10x magnification. A: Adventitia. L: Lumen. M: Tunica Media. 
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7.3.2 Advancing age correlated with an increased Ca load at baseline. 
In this adult CKD population patient ages ranged from 19 to 71 years. Older patients have 
had more time to be exposed to traditional cardiovascular risk factors and may have lived 
for longer with CKD. In addition, age itself is considered a risk for cardiovascular disease. 
Despite vessels being free from atherosclerosis, it was important to look for any baseline 
calcification in the adult vessel rings that may represent arteriosclerosis.  
Von Kossa staining detected Ca deposition in the tunica media of 3 baseline vessels, 
indicative of arteriosclerosis; an example is shown in Figure 7-2A. The remaining 8 adult 
vessels had no von Kossa positive areas as per the example in Figure 7-2B. 
The baseline Ca load as determined from the σ-cresolphthalein assay ranged from 1.8 to 
130 µg / µg/µl. Interestingly the Ca load at baseline as determined by the σ-cresolphthalein 
assay was found to have significant positive correlation with patient age in years as shown 
in Figure 7-3.  
No other patient variables shown in Table 7-1 had an association with baseline Ca load in 
the adult vessel rings. 
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Figure 7-2: Ca deposition in baseline vessel rings: 
Inferior epigastric arteries were harvested from adults with CKD, A&B) vessel rings at 
baseline were formalin fixed, sectioned and stained with von kossa for calcium deposition 
(black) and counterstained with neutral red. A) 13.45M.2.IE B) 13.57F.3.IE B) at 4x and 
10x magnification. A: Adventitia. L: Lumen. M: Tunica Media. VK+: Von Kossa positive 
area. VK-: Von Kossa negative area. 
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Figure 7-3: Advancing age correlates with increased baseline Ca load. 
Inferior epigastric arteries were harvested from adults with CKD, a baseline vessel ring 
was homogenized and the Ca load analysed by σ-cresolphthalein assay and plotted against 
the patients’ age at time of vessel collection. The Pearson R correlation coefficient was 
calculated along with its two-tailed P value to determine the statistical significance. 
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7.4 Adult vessel rings in culture. 
7.4.1 Adult vessel rings can survive in culture ex-vivo.  
As this was the first time that vessel rings from adult patients had been cultured ex-vivo, 
it was important to consider if they could remain viable in culture. H&E staining was 
comparable at baseline and after culture in M199 for 14 days as shown in Figure 7-4, there 
was no change in VSMC nuclei density or any structural changes to the vessel rings that 
would indicate cell death.   
 
 
Figure 7-4: Adult vessel rings before and after culture for 14 days. 
Vessel rings from inferior epigastric artery (13.67F.7.IE) were formalin fixed, sectioned 
and stained with H&E. A) At baseline and B) after cultured in M199 for 14 days. (10x 
and 40x) A: Adventitia. L: Lumen. M: Tunica Media. I: Internal elastic lamella. N: 
VSMC Nuclei. 
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7.4.2 High Ca-P medium induced calcification in vessel rings isolated from adults. 
The previous section has shown that adult vessel rings were in good general health and 
able to survive in culture for 14 days, therefore it was possible to study the effect of 
VDRAs on vascular calcification in ex-vivo adult vessel rings. As with the children’s 
vessel rings, the Ca load was studied both in normal Ca-P medium and in high Ca-P 
medium to mimic the mineral disturbances observed in CKD.  
Culture of adult vessel rings in normal Ca-P medium did not affect Ca load in the vessel 
wall relative to baseline. As shown in Figure 7-5. The Ca load was significantly increased 
by the raised mineral content from 57.8+14.2 µg/ µg/µl in normal Ca-P medium to 
1077+390.8 µg/ µg/µl in high Ca-P medium (P<0.05).  
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Figure 7-5: High Ca-P medium increased Ca load in vessel rings from adults with 
CKD. 
Vessel rings harvested from adults with CKD were isolated at baseline or cultured for 14 
days in either normal Ca-P medium (1mM P and 1.8mM Ca M199) or high Ca-P medium 
(2mM P and 2.7mM Ca) to induce calcification. Both were in the presence of 3.4mM 
ethanol, which will be used as the vehicle in this project. Ca load in the vessel wall 
analysed by σ-cresolphthalein assay. D'Agostino & Pearson omnibus normality test was 
performed as a guide to analyse the distribution and statistical significance was determined 
unpaired two-tailed t-test. 
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7.4.3 VDRAs had no effect on vascular calcification in vessel rings isolated from 
adults with CKD. 
High Ca-P increased the Ca load in adult vessel rings. Next the effect of 10nM calcitriol 
and 10nM paricalcitol on Ca load were assessed using this ex-vivo adult vessel ring model 
in both normal Ca-P and high Ca-P medium. 
In the presence of each of the VDRAs, high Ca-P medium significantly increased the Ca 
load in the vessel wall as shown in Figure 7-6. However, neither calcitriol nor paricalcitol 
had an effect on Ca load in the vessel wall in normal Ca-P or high Ca-P medium. 
As with the baseline vessel rings the localisation of the Ca deposition was determined by 
von Kossa staining. In each vessel ring the Ca deposition was specifically in the tunica 
media. The von Kossa staining was semi-quantitatively scored (0, +, ++, +++, ++++) and 
assigned a colour dependent on the estimated percentage of tunica media positive for von 
Kossa, and therefore Ca deposition. This gives rise to the key in Figure 7-7. The Ca load 
determined by σ-cresolphthalein assay, and its corresponding colour for von Kossa 
positive areas were represented graphically in Figure 7-7 and summarised in Table 7-2. 
After culture in normal Ca-P medium, 4 of the 11 vessel rings had small areas of von 
Kossa positivity. Culture in high Ca-P medium increased this to 8/10 vessels showing 
some von Kossa positive area with 4 of those having very dense von Kossa staining in the 
tunica media (Figure 7-7). The rings with a higher Ca load quantified by σ-cresolphthalein 
assay tended to be grouped as +++ or ++++ for on Kossa representing the highest density 
of von Kossa.  
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Figure 7-6: Ca load in vessel rings from CKD adults cultured with VDRAs. 
Vessel rings isolated from adults with CKD were cultured in both normal Ca-P medium 
(1mM P and 1.8mM Ca) or high Ca-P medium (2mM P and 2.7mM Ca), as well as 
either the vehicle of 3.4mM ethanol or A) 10nM calcitriol, and B) 10nM paricalcitol. 
The different y-axis each graph accommodates the different calcification potentials of 
the two VDRAs. D'Agostino & Pearson omnibus normality test was performed as a 
guide to analyse the distribution and statistical significance was determined by A) Two-
tailed Mann Whitney test and B unpaired two-tailed t-test. 
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Figure 7-7: Ca load and von Kossa density in vessel rings. 
Vessel rings isolated from adults with CKD were cultured for 14 days with 3.4mM ethanol 
or 10nM calcitriol, rings were harvested and their Ca load analysed by σ-cresolphthalein 
assay and Ca deposition visualised by von Kossa stain. Rings were colour coded 
dependent on their von Kossa positive area (black), a representative key is shown above. 
D'Agostino & Pearson omnibus normality test was performed as a guide to analyse the 
distribution of Ca load scores and statistical significance was determined by two-tailed 
Mann Whitney test (NS). 
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Table 7-2: Summary of pre-dialysis and dialysis adult’s vessels Ca load. 
Vessel IDs and their corresponding von Kossa score and Ca load determined by the σ-cresolphthalein assay. Data for each vessel shown 
at baseline and after treatment for 14 days in each condition. 
 
 
Vessel ID Method 
 1mM P and 1.8mM Ca 2mM P and 2.7mM Ca 
Baseline Ethanol Calcitriol Paricalcitol Ethanol Calcitriol Paricalcitol 
P
re
 -
 D
ia
ly
si
s 
13.45M.2.IE 
Von Kossa ++ ++   ++++ +++ +++ 
Ca load 26.7 64.9   115.6 85.9 130.0 
14.61M.11.IE 
Von Kossa + 0 + + +++ +++ ++ 
Ca load 18.2 25.9 42.3 24.3 735.9 2346.6 624.6 
14.35M.13.IE 
Von Kossa 0 0 0 0    
Ca load 34.4 95.1 78.3 105.1    
14.27M.14.IE 
Von Kossa 0 0  0 ++++ ++++ ++++ 
Ca load 15.6   46 4073.4 3361.4  
D
ia
ly
si
s 
13.46M.1.IE 
Von Kossa ++ ++   ++++ +++ +++ 
Ca load 69.8 40.7   1399.2 735.4 483.0 
13.57F.3.IE 
Von kossa 0 +   + + 0 
Ca load  30.9   249.5 365.9  
13.19F.4.IE 
Von Kossa 0 0   0 0 0 
Ca load 1.8 73.1   1257.8 1953.5 5067.5 
13.31M.6.IE 
Von Kossa 0 0   + + + 
Ca load 31.2 91.9   169.5 132.5 582.4 
13.67F.7.IE 
Von Kossa 0 0 0  0 0 0 
Ca load 130.0 140.7 187.3  221.8 218.7 180.1 
14.45F.12.IE 
Von Kossa 0    ++++ ++++ ++++ 
Ca load 11.5    5980.0 1954.9 523.8 
14.71M.15.IE 
Von Kossa  + + + ++++ ++++ ++++ 
Ca load  155.5  84.7 473.4 508.6 437.3 
 232 
 
7.4.4 VDRAs had no effect on ALP activity in adult vessel rings. 
This chapter so far has shown that neither calcitriol nor paricalcitol had any significant 
effect on Ca load in adult vessel rings. Next I considered whether the VDRAs had an 
effect on ALP activity, indicative of osteogenic transformation in the vessel rings. The 
osteogenic enzyme ALP is normally expressed in bone and is a marker of increased 
osteoblast activity.  
As shown in Figure 7-8 culture of vessel rings in high Ca-P medium did not increase 
ALP activity relative to that observed in normal Ca-P medium. Furthermore, neither 
calcitriol nor paricalcitol had an effect on ALP activity in adult vessel rings. 
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Figure 7-8: ALP activity in adult vessel rings. 
Vessel rings were isolated from adults with CKD. Rings were cultured for 14 days in 
either normal Ca-P medium with 1mM P and 1.8mM Ca or high Ca-P medium with 
2mM P and 2.7mM Ca to induce calcification. Rings were cultured with A) calcitriol 
or B) paricalcitol. Vessel rings were homogenised and the ALP activity in the vessel 
wall was determined by a colorimetric assay. Statistical significance was analysed by 
unpaired two-tailed t-test (NS). 
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7.5 The effect of patient related variables on Ca load in adult vessels. 
The previous section showed that neither 10nM calcitriol or 10nM paricalcitol had an 
effect on mean Ca load in adult vessel rings.  As discussed previously there are many 
patient variables to be considered when analysing this data. The following section will 
take into consideration whether patients are pre-dialysis or dialysis, their prescribed 
vitamin D supplements, age, gender, primary renal diagnosis and history of 
hypertension or other cardiovascular events. 
 
7.5.1 There was no difference in Ca load in adult vessel rings from pre-dialysis 
and dialysis patients. 
The Ca load as determined by σ-cresolphthalein assay was compared between pre-
dialysis (n=4) and dialysis (n=7) vessel rings. No difference in Ca load was found 
either at baseline, in normal Ca-P medium or in high Ca-P medium. The effect of 
VDRAs on Ca load in pre-dialysis and dialysis vessels was also considered and no 
difference was found between them after either calcitriol or paricalcitol treatment. 
The duration which dialysis patients had been receiving their renal replacement 
therapy was between 1 and 48 months, this was taken into consideration and no 
correlation was found between time on dialysis and Ca load at baseline or after any 
treatment condition. Further variation arises in the mode of dialysis given, patients 
were either receiving haemodialysis (n=3) or peritoneal dialysis (n=4). No significant 
difference in Ca load was found between the two modalities at baseline or after 
treatment of vessel rings. 
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7.5.2 Prior cholecalciferol supplements increased Ca load in response to 
calcitriol. 
CKD patients are often deficient in vitamin D and are prescribed supplements to 
compensate for this. In this study it was important to consider if vitamin D supplements 
in-vivo altered the response of ex-vivo vessel rings to VDRAs in culture. Two different 
vitamin D supplements were prescribed in this cohort, cholecalciferol and alfacalcidol 
as shown in Table 7-1. 
Cholecalciferol supplements had no effect on baseline Ca load in the adult vessels or 
on Ca load after culture in normal Ca-P medium. There was a trend (NS) for patients 
on cholecalciferol supplements to have a higher Ca load in their vessel rings cultured 
in high Ca-P medium alone or with paricalcitol. As shown in Figure 7-9B 
cholecalciferol supplements prescribed in-vivo did significantly increase the Ca load 
in CKD vessel rings cultured in high Ca-P medium with calcitriol (p=0.0103). Vessel 
rings from patients not given cholecalciferol (n=5) had a Ca load of 336.2 + 123.9 µg 
/ µg/µl after culture in high Ca-P with calcitriol, while those treated with 
cholecalciferol (n=6) had vessel Ca loads of 1996 + 482.1 µg / µg/µl ex-vivo.  
Some patients were prescribed alfacalcidol either instead of or as well as 25OHD. The 
Ca load in patients that were prescribed alfacalcidol (n=6) or not (n=5) was compared. 
Alfacalcidol prescribed in-vivo had no effect on Ca load either at baseline or after 
culture in normal Ca-P or high Ca-P medium with or without calcitriol or paricalcitol 
(data not shown). 
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Figure 7-9: Comparison of Ca load in vessel rings from patients receiving 25OHD 
supplements or not.  
Vessel rings were isolated from adults with CKD, some who were receiving 
cholecalciferol supplements as part of their routine treatment and others who were not. 
Ca load in the vessel walls were analysed by σ-cresolphthalein assay. A) At baseline 
and after culture for 14 days in either normal Ca-P medium (M199 with 1mM P and 
1.8mM Ca) or high Ca-P medium (M199 with 2mM P and 2.7mM Ca) to induce 
calcification. B) Rings cultured in high Ca-P medium with calcitriol or paricalcitol. 
Statistical significance was determined by unpaired two-tailed t-test. Chole – 
cholecalciferol supplements. 
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7.5.3 No other patient variables had an effect on Ca load in adult vessels. 
Other patient variables that were considered and found to have no significant effect on 
Ca load either after culture in normal Ca-P or high Ca-P medium only or with calcitriol 
or paricalcitol included: 
Age: Despite the positive correlation between age and Ca load at baseline, there was 
no relationship between age and Ca load after culture in any of the treatment 
conditions. 
Primary renal diagnosis: There was no difference in Ca load between patients that were 
diagnosed with glomerulopathy (n=6) compared to patients with other diagnosis (n=5). 
Hypertension: There was no difference in Ca load between patients who had a history 
of hypertension (n=7) compared to those that had not (n=4) 
Other cardiovascular events: No statistical analysis was performed as only 2 patients 
had suffered a cardiovascular event such as stroke, ischaemic heart disease or 
peripheral vascular disease.  
Gender: There was no difference in Ca load between males (n=7) and females (n=4). 
 
 
7.5.4 Low VDR expression in adult vessel rings. 
Earlier in this chapter it was shown that neither calcitriol nor paricalcitol had an effect 
on the mean Ca load in adult VSMCs. This differs from results in Chapter 3 where a 
subgroup of children’s vessel rings responded to calcitriol in high Ca-P medium and 
an increase in Ca load was observed. As discussed in the introduction and in chapter 
6, VDRAs such as calcitriol act via the nuclear VDR to elicit a response. In the 
following section, expression of the VDR was analysed in adult vessel rings. 
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Immunohistochemistry staining for the VDR in adult vessel rings was not able to 
detect any VDR positive nuclei in any vessel rings either at baseline or after culture in 
any of the treatment conditions. Therefore, expression of the VDR in adult vessel rings 
was below detectable levels by immunostaining, an example is shown in Figure 7-10A. 
A positive control of VDR immunostaining in children’s vessel rings is shown in 
Figure 7-10B. A further positive control in Figure 7-10D shows that adult vessel rings 
were successfully immuno-stained with other antibodies, here the tunica media but not 
the adventitia is positive for SMA.  
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Figure 7-10: VDR not expressed at detectable levels in adult vessel rings. 
Vessel rings from inferior epigastric arteries were formalin fixed, sectioned and 
immune-stained with A,B,C) VDR. A) Adult vessel 14.45F.12.IE at baseline (20x and 
40x). B) Positive control: Children’s vessel 07.6M.44.IE at baseline (40x). C) 
Negative control, no primary antibody: Adult vessel 14.45F.12.IE at baseline (40x). 
D) SMA immune-stain of 14.45F.12.IE (20x) and E) negative control for SMA (no 
primary antibody) 14.45.12.IE (20x) A: Adventitia. L: Lumen. M: Tunica Media. 
VDR+: VDR positive nuclei. VDR-: VDR negative nuclei. 
 240 
 
7.6 Discussion 
7.6.1 Summary 
The VDRAs calcitriol and paricalcitol had no overall effect on Ca load in the adult 
vessel rings, they did not accelerate the progression of vascular calcification in these 
vessels.  
The key findings were: 
1. Physiological doses of calcitriol and paricalcitol had no effect on vascular 
calcification in vessels from adults with CKD.  
2. Vessel rings from pre-dialysis and dialysis patients were equally susceptible to 
vascular calcification. 
3. Variability in patient gender, age, primary renal diagnosis and previous 
cardiovascular health had no effect on calcification in response to VDRA 
treatment. Vessel rings from patients receiving cholecalciferol supplements 
had a higher Ca load after treatment in high Ca-P with calcitriol than patients 
not prescribed cholecalciferol.  
4. Calcitriol and paricalcitol had no effect on activity of the osteoblast enzyme 
ALP in vessels from adults with CKD. 
 
7.6.2 Baseline vessel characteristics and survival in culture. 
This was the first time that vessel rings from adult patients have been cultured ex-vivo. 
Histological analysis of the vessel rings at baseline showed that each patient’s 
vasculature was in general good health and no atherosclerotic regions were observed 
in the 11 vessels studied.  This was unexpected as adults are at increased risk of 
atherosclerosis due to their prolonged exposure to traditional cardiovascular risk 
factors. Age itself also predisposes patients to atherosclerosis, which is supported by 
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CT studies on ancient human mummies. These mummies while never exposed to 
modern cardiovascular risk factors, and presumably without CKD, their odds of 
increased severity of atherosclerosis still increased by 70% every decade lived 
(Thompson et al., 2013). The incidence of atherosclerosis observed in this study of ex-
vivo vessel rings from a section of inferior epigastric artery was 0% (n=11) compared 
to (Thompson et al., 2013) who found 34% of mummies had atherosclerosis. They did 
not analyse atherosclerosis in the inferior epigastric artery, instead they examined 5 
different vascular beds per mummy which may account for the higher incidence of 
atherosclerosis recorded. The inferior epigastric artery may be less prone to 
atherosclerosis than other vascular beds. 
Despite the lack of calcified atherosclerotic regions in patient’s vessels, there was 
varying levels of Ca deposition in the tunica media at baseline identified by von Kossa 
positive regions and semi quantitatively analysed as ranging from 0 to ++. Medial 
calcification is characteristic of Monckeberg sclerosis and is associated with CKD.  
A modern, cross sectional study of 150 patients that used radiography to measure 
intimal and medial calcification (Gelev et al., 2008) found that males and patients over 
55 years had a higher frequency of arterial calcification. Although I found no 
difference between genders, a positive correlation between age and Ca load at baseline 
was observed in the adult vessel rings. 
After 2 weeks in culture in normal Ca-P medium, adult vessel rings showed no 
apoptotic or necrotic regions, and continued to express SMA demonstrating for the 
first time that it is possible to study vessel rings from adult patients of all ages in culture 
for 2 weeks. 
7.6.3 Physiological doses of the VDRAs, calcitriol and paricalcitol, have no 
effect on vascular calcification in vessels from adults with CKD. 
In adult vessel rings neither paricalcitol nor calcitriol had a significant effect on 
calcification, there was no change in either mean Ca load or ALP activity. For 
paricalcitol this reflects the effect observed in children’s vessel rings however the 
effect of calcitriol in adults differs from children’s vessel rings. In adult vessel rings, 
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calcitriol had no effect on the mean Ca load whereas it increased Ca load in children’s 
vessel rings. Calcitriol had no effect or a minor protective effect in some adult vessels 
and slightly increased calcification in others, leading to either low or high Ca loads in 
the calcitriol treated vessels. There may be a set of vessel ring responders and non-
responders to calcitriol as observed in the children’s vessel rings, however in this case 
it is less defined. 
Interestingly the VDR expression in all adult vessels was either undetectable or sparse 
as shown by immunohistochemistry, this differed from the children’s vessel rings 
where the VDR was detected by the same method. It has been shown previously that 
the VDR expression was reduced with advancing age in human skeletal muscle 
biopsies (Bischoff-Ferrari et al., 2004). A reduced expression of VDR in adult VSMCs 
could prevent the VDRAs having an effect on calcification. 
 
7.6.4 Patient related factors and their effect on calcification of cultured adult 
vessel rings. 
At baseline and after each treatment condition there was a wide range of Ca loads 
observed, this may be explained by the high degree of patient variation. The effect of 
patient variation was minimised by comparing vessel rings from the same patients in 
each treatment condition, therefore each vessel acts as its own control. In addition, the 
implication of patient related factors on response to treatment was taken into 
consideration. 
Adult patients varied in the vitamin D supplements prescribed, some were given 
cholecalciferol either alone or in combination with alfacalcidol. Cholecalciferol is 
easily absorbed from the small intestine lowering the risk of hypercalcaemia (Brandi 
and Minisola, 2013).  At baseline there was no difference in Ca load between vessels 
from patients prescribed cholecalciferol and those that were not. This agrees with 
findings from a randomised trial in Germany on 105 adults that found no difference in 
cardiovascular risk including markers of vascular calcification (Runx 2, osteocalcin 
and osteopontin) between groups given either 20µg cholecalciferol per day or a 
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placebo (Seibert et al., 2015). In addition, (Gelev et al., 2008) found no association 
between vitamin D supplementation and presence of calcification in their cross 
sectional study of 150 patients. Interestingly after culture in high Ca-P medium with 
calcitriol the Ca load was significantly higher in patients that were prescribed 25OHD 
relative to those who were not. This suggests that although 25OHD does not affect 
baseline Ca load it may prime the adult vessels to be more susceptible to calcitriol 
induced calcification.  
As discussed in Chapter 3 it has previously been documented that patients on dialysis 
are more prone to vascular calcification than pre-dialysis CKD patients, in this study 
of adult vessel rings no difference was found between pre-dialysis and dialysis vessels 
in any treatment conditions. 
The correlation between age and Ca load did not persist after culture in either normal 
Ca-P or high Ca-P medium, this suggests that any effect of culture must strongly 
outweigh the effects of aging on Ca load.    
 
7.6.5 Limitations 
This chapter focuses on vascular calcification in whole vessel rings from adult patients 
with CKD. As with the children’s vessels and any human tissue, it is a scarce resource 
but incredibly valuable in providing a clinically relevant model for translational 
research.  This creates its own challenges and data in this chapter are collected from 
very few vessels (11 in total) with high patient variability. Vessels were collected from 
both male and female patients with a wide age range of 19-71 years, some patients had 
a past medical history of hypertension or other cardiovascular events. Patients had 
different primary renal diagnosis and were either pre-dialysis or had a dialysis vintage 
of between 1 and 48 months. In addition, patients were on different combinations of 
vitamin D supplements at the time of vessel collection. Unfortunately, I was unable to 
collect data on patients’ smoking history therefore could not take into consideration its 
impact on vascular health. 
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In this adult cohort no patients had co-morbidity with diabetes, this is atypical of the 
general adult CKD population, as diabetes is the leading cause of CKD in adults and 
40% of people with diabetes also have CKD (Van Huffel et al., 2014). 
The length of inferior epigastric artery that could be dissected during renal transplant 
determined how many 1mm vessel rings were obtained for ex-vivo culture, this was 
the limiting factor in determining the number of ex-vivo treatment conditions. 
Unfortunately, there was insufficient tissue to test the effects of the 3 different VDRAs 
used in the treatment of children’s vessels. Calcitriol treatment was prioritised as this 
is the natural active form of vitamin D therefore an important reference point for 
comparing other VDRAs. For clinical use it is important to identify a VDRA that does 
not cause calcification in vessels. Alfacalcidol increased Ca load in the children’s 
vessels where as paricalcitol did not, based on this data paricalcitol would be favoured 
for clinical use therefore testing its effect on calcification in adult vessels was 
prioritised over alfacalcidol.     
It can be assumed that calcitriol and paricalcitol were biologically active as they 
provoked the responses observed in the previous chapters. It would be of interest to 
confirm that the VDRAs were able to evoke a response in adult vessel rings, CYP24A1 
is well documented as being upregulated in response to vitamin D therefore an 
upregulation of CYP24A1 protein shown by immunohistochemistry would confirm 
their activity in the adult vessel rings.  
Here for the first time adult vessel rings were cultured ex-vivo, histological analysis 
suggests that they remained viable for 2 weeks in culture. In future it would be of 
interest to quantify VSMC viability in the vessel rings by β-glucuronidase assay. 
Unfortunately, I was unable to obtain vessels from non-renal controls. As with the 
children’s vessels, VSMCs were explanted from the vessel rings however only 2 of 
the vessels successfully established VSMC cultures. Therefore, further molecular 
analysis on VSMCs explanted from adults with CKD was not performed.  
  
 245 
 
Chapter 8 Final Discussion 
The effects of VDRAs on vascular calcification in CKD has emerged as a controversial 
topic in the literature, with different models and experimental designs showing 
opposing effects of VDRAs on calcification. This thesis focussed on a clinically 
relevant, ex-vivo model of intact vessel rings obtained from children or adults with 
CKD, as well as the in-vitro study of VSMCs explanted from the children’s vessels. 
Calcification was induced with high Ca-P medium to mimic the dysregulated mineral 
metabolism observed in CKD and vessel rings were treated with the VDRAs, calcitriol, 
alfacalcidol or paricalcitol which are routinely used in clinical practice.  
In the children’s vessel rings, alfacalcidol and to a greater extent calcitriol increased 
Ca load whereas paricalcitol had no effect on Ca load. 25-hydroxylase, required for 
the activation of alfacalcidol was expressed in VSMCs, therefore it was assumed that 
alfacalcidol was functioning in its active, di-hydroxylated form. Despite calcitriol 
naturally being in its active di-hydroxylated form, there was no correlation between 
the Ca load in vessel rings cultured in high Ca-P medium with calcitriol and 
alfacalcidol suggesting that they were acting via different mechanisms. This was also 
evident as calcitriol but not alfacalcidol promoted vascular calcification in the vessel 
rings through increased ALP activity and reduced cell viability.  
The VDR is a transcriptional regulator, therefore to further understand the mechanisms 
of action of VDRAs on vascular calcification I examined the expression of VDR 
downstream genes in the explanted VSMCs. Physiological doses of both calcitriol and 
paricalcitol had a protective effect on Ca load in the VSMCs, however neither of them 
had an effect on expression of the calcification inhibitor MGP. Nor did physiological 
doses of calcitriol or paricalcitol affect expression of osteoblast markers Runx2 or 
ALP. Both VDRAs increased expression of CYP24A1 mRNA, required for their own 
inactivation. Further work is required to understand the mechanism by which 10nM 
calcitriol and paricalcitol had a protective effect on Ca load in this model of explanted 
VSMCs. A potential mechanism is that VDRAs upregulate expression of the CaSR 
and increased sensitivity to Ca therefore protecting against calcification, this was 
recently observed in human VSMCs at a narrow concentration range (Mary et al., 
2015).   
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My data showed that the effects of VDRAs on calcification was not comparable 
between the different experimental models of ex-vivo children’s vessel rings and 
explanted VSMCs, despite the fact that they were both harvested from the same cohort 
of paediatric patients. This is most notable with 10nM calcitriol which reduced Ca load 
in explanted VSMCs but increased Ca load in vessel rings. Furthermore, 10nM 
calcitriol increased ALP activity in the vessel rings but had no effect on ALP in 
VSMCs in which 100nM calcitriol was required to increase ALP activity. I also 
observed that the effect of paricalcitol was different between the 2 experimental 
models, it had no effect on Ca load in the vessel rings, whereas it was protective of 
calcification and reduced Ca load in VSMCs. The different characteristics of the 2 
models may give rise to the different responses observed in response to VDRAs. 
Explanted VSMCs lose their contractility in culture and develop a synthetic phenotype 
similar to that observed in dialysis VSMCs. In contrast, VSMCs in the vessel rings 
maintain their contractile phenotype in culture and have their adventitia and internal 
lamella intact therefore closely resemble in-vivo vessels. 
In both the children’s vessel ring and the VSMC model variation was observed 
between individual patients in their response to VDRAs. Despite there being no 
difference between vessel rings from pre-dialysis and dialysis patients in their Ca load 
in response to calcitriol, paricalcitol or alfacalcidol, there was patient variation within 
the whole CKD cohort. Children’s vessel rings naturally segregated into those that 
responded to 10nM calcitriol treatment with an increased Ca load and those that did 
not respond showing no change in Ca load. There was no difference in SMA, ALP or 
total VDR expression between responders and non-responders however they did differ 
in their expression profile of 24 hydroxylase which is highly regulated by the VDRE.  
The dose dependent effect of calcitriol was studied in control and dialysis VSMCs, the 
physiological dose of 10nM calcitriol was protective of calcification. In addition 1nM 
and/or 100nM calcitriol also reduced Ca load in VSMCs from some individuals. These 
doses were less effective than 10nM calcitriol at reducing Ca load and the Ca load to 
calcitriol dose response curve produced a U-shaped. Individual patient variation was 
observed within both control and dialysis VSMCs and the U-shaped dose response 
curve shifted to either the left or the right in some patients. 
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Control and dialysis VSMCs differed in their baseline mRNA expression profiles with 
dialysis VSMCs having a higher expression of osteoblast markers ALP, BSP and 
Runx2 than control VSMCs, along with a lower expression of SMA and other smooth 
muscle cell markers. Despite this indication of osteogenic conversion in the dialysis 
VSMCs, there was no difference between control and dialysis VSMCs’ Ca load in 
response to high Ca-P, calcitriol or paricalcitol. There was no difference between 
control and dialysis VSMCs in the expression of total VDR mRNA or total VDR 
protein. However, 2 isoforms of the VDR protein were expressed in the VSMCs. 
Control and dialysis VSMCs differed in the ratio of the VDR-A and the N terminally 
extended VDR-B isoforms expressed at baseline, with dialysis VSMCs expressing a 
higher proportion of the VDR-A isoform. Calcitriol dose dependently increased 
expression of the total VDR mRNA and caused a shift in the ratio of VDR protein 
isoforms expressed. More specifically, it reduced the expression of the VDR-B 
isoform and increased expression of the VDR-A isoform in both control and dialysis 
VSMCs. I speculate that the administration of VDRAs in-vivo may cause a similar 
shift in the ratio of the VDR isoforms expressed, this would account for the higher 
ratio of VDR-A expressed in dialysis VSMCs relative to control VSMCs as CKD 
patients on dialysis were all prescribed the VDRA alfacalcidol.  
There is still much to learn in order to understand the functional significance of the 
VDR-A and VDR-B isoforms, current literature suggests that the relative 
transcriptional activation capacity of the VDR-A and the VDR-B isoform is dependent 
on the cell type and cellular cofactors available (Esteban et al., 2005, Gardiner et al., 
2004). Control and dialysis VSMCs differed in the extent of their upregulation of 
downstream genes in response to calcitriol: there was a greater upregulation of both 
ALP mRNA expression and activity in control VSMCs, whereas there was a greater 
upregulation of CYP24A1 mRNA expression in dialysis VSMCs.  CYP24A1 is well 
documented as being highly regulated by VDRAs, it encodes the 24-hydroxylase 
enzyme for the inactivation of VDRAs. The increased responsiveness of dialysis 
VSMCs to upregulate CYP24A1 could suggest that they are primed to respond to 
VDRA treatment, including the shift in expression of VDR isoforms and being more 
efficient at inactivating VDRAs. This leads to the relatively limited response in the 
upregulation of ALP in comparison to control VSMCs. Despite these differences in 
control and dialysis VSMCs, there is much overlap between the 2 groups in terms of 
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the ratio of their VDR isoform expression as well as their responses to calcitriol. The 
VDRE luciferase assay showed that an equal number of control and dialysis VSMCs 
were able to activate the VDRE in this system. Those that activated the VDRE 
luciferase expressed a higher fraction of the VDR-A isoform, supporting the theory 
that the ratio of VDR isoforms expressed is functionally significant and this hypothesis 
should be explored further. 
The patient variation in the ratio of VDR isoforms expressed, suggests that there is not 
a single solution for the optimal vitamin D treatment regime for all patients. 
Individualised treatments based on the patients VDR expression profile may be 
required, this would be complex and require continuous monitoring as once VDRAs 
are prescribed, a shift to favour expression of the VDR-A isoform may be observed. 
For now, the differential expression of VDR isoforms has only been observed in-vitro, 
therefore is far from being translated directly into patients.  
Due to the limited tissue availability it was outside the scope of this thesis to explore 
the ratio of VDR isoforms expressed in the CKD vessel rings. In future work it would 
be of great interest to compare the VDR isoform expression profile in children’s vessel 
rings that either responded or did not respond to calcitriol. Sufficient tissue would be 
required to extract protein for western blot analysis. As the VDR-B isoform is a 50 
amino acid N-terminal extension of the shorter VDR-A isoform, it would also be of 
interest to produce a VDR-B specific antibody for both western blot analysis and 
immunohistochemistry comparison of responder and non-responder vessel rings. 
Furthermore, if sufficient tissue could be acquired for RNA extraction, the mRNA 
expression profile of the different VDR isoforms could be investigated using primers 
specific to their unique first exons. This would be of great interest in both the VSMCs 
and the vessel rings to determine if the different VDR isoform expression profiles 
observed, were a consequence of a transcriptional or a post transcriptional 
modification.   
A third model of vessel rings from adult CKD patients was studied in this thesis. 
Despite the adult vessel rings surviving in culture and having an increased Ca load 
when exposed to high Ca-P medium, their Ca load did not respond to calcitriol 
treatment. This differs from analysis of Ca load in the children’s vessel rings where a 
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group of non-responders and responders emerged, where responders to calcitriol had 
an increased Ca load. Immunohistochemistry analysis of total VDR expression showed 
that the VDR was not expressed at detectable levels in the adult vessel rings, whereas 
the VDR was detected in the majority of VSMC nuclei in the children’s vessel rings. 
Advancing age and a decline in VDR expression may play a key role in the lack of 
response to calcitriol observed in the adult vessel rings. We must bear in mind that this 
is a small cohort of only 11 adult vessels, this may represent a group of non-responders. 
With a larger cohort a group of responders may also emerge, as was observed in the 
children’s vessel ring model. The paediatric patients with CKD were all prescribed 
alfacalcidol whereas the adults were prescribed either alfacalcidol, cholecalciferol or 
a combination of both. Vessel rings from those patients given cholecalciferol alone or 
in combination had a higher Ca load in high Ca-P with calcitriol than patients not 
receiving cholecalciferol, this is further evidence that prior in-vivo administration of 
VDRAs may alter the response of these vessels to subsequent treatment. CKD is a 
chronic disorder and patients are currently prescribed VDRAs on a long term basis to 
help maintain homeostatic levels of PTH and mineral metabolism. It is therefore 
important that future work considers not only the short term but also the long term 
effects of VDRAs on the susceptibility of vessels to calcification. 
This thesis addressed the hypothesis that VDRAs play a key role in driving vascular 
calcification in vessels from CKD patients and the differential expression pattern of 
the VDR can determine the extent of mineralisation in an in vitro and ex vivo model. 
The 2 main conclusions from this thesis are; 
1. VDRAs can have either a protective, causative or null effect on vascular 
calcification in CKD, this response is highly complex and is dependent on the 
model studied (children’s vessel rings, adult vessel rings or explanted 
VSMCs), as well as the type of VDRA (calcitriol, paricalcitol or alfacalcidol), 
and the VDRA concentration (as demonstrated with 1nM, 10nM and 100nM 
calcitriol). 
2. VSMCs were shown to express 2 different isoforms of the VDR, VDR-A and 
VDR-B. The ratio of these expressed isoforms differed between control and 
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dialysis VSMCs, was altered by exposure to calcitriol and was functionally 
important for the activation of the VDRE in the luciferase promoter. 
There is a vast collection of previous literature that use different models and show 
contradictory results in the study of the effects of VDRAs on vascular calcification in 
CKD. This thesis focused on the clinically relevant model of intact vessel rings from 
CKD patients as well as VSMCs explanted from them. Within each of these models a 
high degree of patient variation was observed that could not be accounted for by any 
of the patient characteristics analysed. This patient variation in the effect of VDRAs 
on calcification may arise from differences in the ratio of VDR isoforms expressed in 
each patient. I have demonstrated that the ratio of VDR isoform expression is 
functionally important for activation of the VDRE luciferase. It would be of great 
interest in future studies to compare the effects of VDR-A and VDR-B activation on 
vascular calcification. This could determine if the ratio of these isoforms expressed in 
a patients’ vessels is a predictor of whether VDRAs will have a protective or causative 
effect on calcification, and patients’ individual treatment courses could be adapted 
appropriately.     
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Figure-10-1: Is there an age difference between the CKD children’s male and 
female cohorts? 
Vessel rings were isolated from both male and female children with CKD, the age 
distribution for each gender was compared. Statistical significance was determined by 
two-tailed unpaired t-test. 
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Figure -10-2: Effect of primary renal diagnosis on Ca load. 
Vessel rings were isolated from CKD children with different primary renal diagnosis, 
grouped as CAKUT (congenital anomalies of the kidneys and urinary tract), 
glomerulopathy or other. A ring was taken at A) baseline or cultured for 14 days in 
high Ca-P medium (M199 with 2mM P and 2.7mM Ca) to induce calcification and 
cultured with B) calcitriol, C) alfacalcidol or D) paricalcitol. Ca load in the vessel wall 
analysed by cresolphthalein assay. D'Agostino & Pearson omnibus normality test was 
performed as a guide to analyse the distribution and statistical significance was 
determined by A, B, C) Kruskal Wallis test with Dunn’s multiple comparison post hoc 
test. No statistical significance. D) n numbers too small for statistical analysis. 
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Figure 10-3: Transfection control: Renilla activity in control VSMCs 
VSMCs were transfected in triplicate wells with the constitutively active Renilla 
luciferase under a cmv promoter as a transfection control for Firefly luciferase (either 
VDRE, negative control or positive control constructs).  Post transfection VSMCs 
were treated with or without 100nM calcitriol to induce the VDRE- Firefly luciferase. 
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Figure 10-4: Transfection control: Renilla activity in dialysis VSMCs. 
VSMCs were transfected in triplicate wells with the constitutively active Renilla 
luciferase under a cmv promoter as a transfection control for Firefly luciferase (either 
VDRE, negative control or positive control constructs).  Post transfection VSMCs 
were treated with or without 100nM calcitriol to induce the VDRE- Firefly luciferase. 
 
 
